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Abstract
In the week of February 2nd (21 days into gestation) my parents Ali, and Aicha heard
my first heart beat. This shouldn’t be a surprise as the heart is the first organ to form
and function during the developmental stages of the fetus. In the embryo, newly formed
blood vessels provide the growing organs with the vital oxygen and nutrients required for
them to flourish. During adulthood, angiogenesis—the process by which new blood vessels
form—remains largely quiescent until the delicate balance between pro- and anti-angiogenic
factors is disrupted, either through injury or disease.
Cardiovascular complications are among the leading causes of morbidity and mortality
in diabetic patients, and account for over 80% of diabetes-associated deaths. One of the
most serious is peripheral arterial disease (PAD), which is defined as a narowing of the
peripheral vasculature. In this thesis, I will employ a range of imaging modalities to study
PAD, investigating methods that may one day enable earlier detection of the disease, and
exploring the therapeutic potential of stem cells to treat vascular complications associated
with diabetes.
This document is divided into four main chapters. The first chapter describes the
biological characterization of two different imaging probes targeted, respectively, at hypoxia
and αV β3 activity, as well as a new power Doppler ultrasound imaging technique capable
of detecting small spatiotemporal changes in blood perfusion within muscle. The second
chapters applies the 64Cu-NOTA-PEG4-cRGD2 peptide targeted at αV β3, to establish an
optimal preclinical model of PAD. The third chapter builds on the first and second, by
developing a multimodal approach for vascular imaging that enables simultaneous evaluation
ii
of molecular and physiological changes during angiogenesis. Finally, the fourth chapter turns
its attention toward the mitigation of diabetes-associated PAD. In it, we show that a targeted
stem cell-based therapy can exert far reaching effects on the ischemic tissue microenvironment,
and may provide clinical improvement for PAD patients in the future.
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Chapter 1
Introduction
I joined the Dobrucki lab in the Fall of 2013, and over the course of the following five years
I have co-authored some seventeen articles, of which seven are published [1–7], four are in
revisions, and six are still in preparation. The research spans multiple areas microbiology,
cancer biology, chemistry, biochemistry, molecular biology, and bioengineering. I have had the
opportunity to collaborate with many talented scientists, and have learned so much from them.
My work has earned me a number of accolades and recognitions, including my selection as an
Illinois Innovation Prize Finalist, and a Jay D. Coffman Early Career Investigator Award
Finalist (AHA), as well as several awards including a T32 NIH Tissue Microenvironment
Training Program Fellowship, a Summer Research Trainee Program - Massachusetts General
Hospital fellowship, a PVD Travel Award (AHA), a Britta L. and Charles J. Wolfe Award
for Diabetes Research, a Beckman Institute Graduate Fellowship, and a Beckman-Brown
Post-Doctoral Fellowship. But as I reflect back on my time as a graduate student, there
are only a few works that stand out to me as milestones in my growth as a scientist. This
document includes four of them, each in their entirety, as Chapters 2–5.
1.1 Problem statement and objectives
Diabetes represents a major world-wide health concern. Hung et al. projects that between
2009 and 2034 the number of people with diabetes will increase from 23.7 million to 44.1
million, resulting in a significant strain to the global health care system with a projected
increase in relative cost of almost 4-fold [8]. The Centers for Disease Control (CDC) in a 2014
diabetes report card estimated that about 1.7 million new cases of diabetes are diagnosed
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each year, and predicted a sharp rise in the next couple of years, during which an estimated
1 in 3 adults will be diagnosed [9].
Cardiovascular complications are among the leading causes of morbidity and mortality
in diabetic patients, and account for over 80% of diabetes-associated deaths. One of the
most serious is peripheral arterial disease (PAD), which involves the gradual narrowing of the
arteries to the extremities. Very often patients with PAD can be asymptomatic, making the
condition difficult to recognize and treat. As a result, the blood flow can become progressively
impaired, and ischemia can occur. When ineffectively treated, peripheral ischemia can
result in debilitating injury; in the United States alone roughly 50,000 cases each year lead
to amputation [8]. The deleterious nature of PAD coupled with its often underdiagnosed
and undertreated status necessitates a reexamination of the existing methodologies used to
diagnose and manage the disease.
Understanding both the progression of PAD, and the bodily response to the disease,
requires the simultaneous evaluation of several interrelated molecular, anatomical, and
functional parameters, all within a living subject. The overarching goal of this disseration is
to provide a better understanding of the progression of PAD, and to develop new methods to
help detect it earlier and treat it more effectively. My efforts will bring to bear a number of
leading-edge imaging modalities, and will ultimately lead to an exciting new stem cell-based
therapy with the potential for clinical translation.
1.2 Peripheral Arterial Disease (PAD)
1.2.1 Historical perspective
It is difficult to pinpoint exactly when cardiovascular diseases were first discovered. Somewhere
between 1504 and 1506 Leonardo da Vinci met an elderly man who describing experiencing
weakness with no bodily ailment, and who died shortly thereafter. Without any medical
training, Leonard performed an autopsy on the man in an attempt to understand the reason
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of his “peaceful death” [10]. What resulted was the first drawings and description of what
would come to be known as coronary artery disease. This achievement however, is often
overlooked in the history of medicine due to Leonardo’s notoriously fragmented notes and
lack of publications. It would take almost 100 years for the circulatory system to begin to
be properly described with a 72 page book written by William Harvey in 1628 [11]. Harvey,
through experimentation, correctly distinguished between arteries and veins, and provided
the first evidence of blood circulation.
This achievement would be followed by many milestones. In 1893 Holland Willem
Einthoven constructed the first electrocardiograph and recorded one of the first ECGs ever
via a 1.5 km telephone cable connecting the hospital to his laboratory [12]. He was awarded
the noble prize in physiology and medicine in 1924. Many other discoveries followed; the
X-ray by Wilhem Konrad Roentgen in 1895 [13], the first defibrillation of a human heart
during cardiac surgery by Claude Beck (1947) [14], and the first battery-powered external
pacemaker in 1957 [15].
PAD, described as the narrowing and eventual blockage of arteries that supply blood to
the lower extremities, has a long history and remains highly prevalent, with an estimated 200
million people afflicted worldwide despite a steady decline in overall morbidity and mortality
from cardiovascular diseases.
Histological evaluation of the Egyptian mummies gastrocnemius and soleus muscles
indicate changes indistinguishable from the effects of PAD [16]. The first manifestation of the
disease to be recognized in modern times was gangrene (tissue death caused by lack of blood
supply) in 1771 by the french physician Quesnay [16]. He further associated the obstruction
of distal arteries to be the cause of distal gangrene. Before World War II, the syndrome
of intermittent claudication in the periphery was well characterized but the mechanism
underlying the disease remained poorly understood.
One of the earliest methods to diagnose PAD was tonoscillography, which detects the
amplitudes of the pressure waves in the arteries at different levels in the leg. Developed
3
in 1940, the instrument allowed Ejrup Bo¨rje, through experimentation, to confirm that
arterial pulsation diminished after exercise in patients with PAD [17]. A more invasive
technique emerged from the work of Kety Seymour in 1948, who measured blood flow in the
gastrocnemius by way of the clearance rates of injected radioactive isotopes [18].
Various forms of plethysmography were developed—gravimetric, capacitance, and strain
gauge—and while they provide quantitative measures, they did not lead to any actionable
information regarding the occlusion site. For the Last 90 years the method of choice for the
anatomical determination of PAD has been arteriography. In 1929 Dos Santos performed the
first translumbar aortogram by the direct injection of contrast medium percutaneously into
the aorta. This marks a major milestone in the imaging of PAD [19]. Indeed, arteriography
remains an important diagnostic tool and has even come to be used during reconstructive
surgery.
The second major milestone in PAD imaging involved Doppler Ultrasound. In 1959
Shigeo Satomura was the first to describe the application of Doppler ultrasound to investigate
PAD [20]. Even today, the pocket Doppler probe remains one of the most widely used pieces
of equipment among vascular surgeons. Duplex scanning, a more recent innovation, combines
real time ultrasonic imaging with Doppler flow measurements that have undergone sound
spectrum analysis for visual display.
1.2.2 Molecular physiology of PAD
Angiogenesis, the formation of new blood vessels from pre-existing microvasculature, represents
an important and complex biological process. Blood vessels are the first organ to form in
the embryo, and constitute the largest network in our body [21–23]. When the delicate
balance between pro- and anti-angiogenic factors is disrupted, numerous physiological and
pathological processes, including PAD and cancer, can be affected [24,25]. The most influential
stimulator of angiogenesis is hypoxia-inducible factor-1 (HIF-1), the expression of which
is normally enhanced under hypoxic conditions. HIF-1 in turn regulates the expression of
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many key angiogenic factors, including vascular endothelial growth factor (VEGF), and
platelet-derived growth factor (PDGF) [25]. VEGF binds its receptor VEGFR which, through
a cascade of biochemical interactions, elicits cellular responses that include endothelial cell
proliferation, migration, and survival. Activated endothelial cells upregulate transmembrane
cell adhesion molecules such as the integrins that assist in cell-cell signaling. In particular,
αV β3 facilitates interactions between endothelial cells and the extracellular matrix (ECM),
which ic critical during migration. Under normal circumstances, all of this biochemistry
results in the formation and elongation of new vascular networks that increase blood flow
to the hypoxic tissue. Unfortunately, a number of conditions are known to dysregulate
these pathways, which can lead to chronic hypoxia, and ultimately debilitating injury or
death. Among the most prevalent world-wide is diabetes mellitus (DM), which when poorly
treated results in hyperglycemia that inhibits HIF-1 transcription [26], and in turn, the entire
angiogenic response. This is particularly problematic in the extremities, which gives rise to a
strong association between DM and PAD.
1.2.3 Current state-of-the-art methods to diagnose PAD
Current clinical options for the preoperative assessment of PAD patients include two main
methodologies: the ankle-brachial pluse index (ABI); and contrast angiography. The mea-
surement of ABI is widely used by surgeons in assessing the disease state, but is highly
unreliable in individuals with long-standing diabetes who develop noncompressible arteries
due to medial calcification [27]. Contrast angiography, the “gold standard”, on the other
hand, is an invasive imaging technique often employed during reconstructive surgery in PAD
patients [28]. It carries the inherent risks of bleeding, infection, and vessel disruption, with
rates of major complications ranging from 1.9 to 2.9% [29].
Recent advances in non-invasive angiography, including magnetic resonance angiography
(MRA), can enable the diagnosis of the location and degree of stenosis in PAD patients.
However, MRA tends to overestimate the degree of stenosis because of turbulence. Moreover,
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it cannot be used to scan patients with pacemakers or defibrillators [30].
1.3 Research overview
The recent history of PAD research has been punctuated by milestones in visualizing the
disease. This remains true even today. But slowly, researchers are starting to expand
their focus to include the effects of vascular occlusion on the tissue microenvironment,
and ways to modulate the web of chemical and cellular interactions that underlie vascular
healing. The main focus of this thesis comes in two parts: first, I will study the ischemic
microenvironment of PAD by integrating a range of non-invasive imaging modalities; and
second, I will demonstrate the use of muscle-derived mesenchymal stem cells as a promising
approach to speed vascular recovery following arterial occlusion Figure 4.1.
PAD Research Ladder
Potential Therapies
Ischemia
Hypoxia
Angiogenesis
Perfusion 
Laser Doppler 
Flowmetry
Doppler 
Ultrasound
Protein and gene expression
Microarray 
Analysis
HistologyMolecular
Pathways
Non-invasive Methods
Invasive Methods
Physiological changes
Molecular changes
Molecular changes
Molecular changes
Figure 1.1: Schematic Diagram of the proposed research plan.
Chapter 2 focuses on the development of two novel probes designed to image key
biomarkers associated with angiogenesis. It begins with Hypoxia Probe 1 (HyP-1), a hypoxia-
responsive imaging agent designed for photoacoustic imaging, which we demonstrate its
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applicability in a murine model of hindlimb ischemia [4]. We then move on to develop a
Dimeric-cRGD probe targeted at αV β3. This probe, radiolabeled for PET imaging, will be
characterized across multiple scales—receptor, cell, and whole body—in order to describe its
binding kinetics, specificity, and clearance route. αV β3 is a key player in angiogenisis, and by
targeting its activated form, we can image where and when the body in actively growing new
blood vessels.
While targeted radio-labeled probes like ours are becoming increasingly important in
diagnostics and prognostication, they come with some inherent drawbacks. First, the short
lives of the isotopes commonly used necessitate that they be manufactured, delivered, and
chelated to the probes shortly before administration. Second, both PET and SPECT devices
are relatively expensive in and of themselves. These issues render nuclear imaging technologies
less attractive as tools for prescreening large numbers of patients who may or may not suffer
from a disease. In the third part of Chapter 2, we introduce a new Power Doppler ultrasound
(US) technology that, without any exogenous contrast enhancement or specialized equipment,
is sensitive enough to detect spatiotemporal changes in blood perfusion within muscle.
Developed by the Insana lab, this new US methodology uses conventional instrumentation,
but samples and filters echo signals in new ways. This can enable general practitioners, who
are usually the first point of contact with a patient, to recognize and diagnose the disease
early, and at a low cost, ultimately leading to more effective treatment and better patient
outcomes [3].
Chapter 3, “Evaluation of a dimeric-cRGD peptide for targeted PET-CT imaging of
peripheral angiogenesis in diabetic mice,” [1] picks up where Chapter 2 leaves off. With
our imaging technologies already in hand, this next chapter seeks to establish a suitable
animal model of PAD. The major risk factors for PAD include smoking, diabetes, high blood
pressure, and obesity [31]—factors whose effects can build up over years or decades in humans,
and whose full impact can be difficult to reproduce in weeks-old laboratory mice. Focusing
on diabetes, we developed protocols for inducing DM in mice via streptozotocin injection,
7
and then surgically ligating the right femoral arteries of the mice in order to model PAD.
Subsequent imaging using our PET-CT probe showed a significant reduction in the αV β3
activation in DM mice when compared to non-DM control mice. This was confirmed by
immunofluorescence staining of excised ischemic tissues, which showed a three-fold reduction
in CD31 (endothelium cell marker) and a four-fold reduction in the αV β3 expression in DM
vs. non-DM animals.
Much of the work described thusfar has focused on imaging a single observable in ischemic
tissue (e.g. hypoxia, αV β3 activation, or blood perfusion), but the biological processes
involved in vascular recovery involve complex signalling cascades and the interplay of multiple
different cell types within a shared microenvironment. Chapter 4, which reproduces “A
Multimodal Lens into Vascular Recovery in a Preclinical Model of Peripheral Arterial Disease,”
expands our view by serially evaluating a number of different biochemical and physiological
indicators of angiogenic process. Specifically, we employ an integrated multimodal approach
to study PAD using: 1) SPECT imaging of probes targeted at HIF-1α and αV β3—the former
being one of the originators of the hypoxia-induced proangiogenic signalling cascade, and
the later being one of its many downstream products; 2) high resolution Power Doppler US
to directly detect tissue perfusion; 3) photoacoustic imaging (PA) designed to detect tissue
oxygenation; and 4) laser speckle contrast imaging (LSCI) for label-free perfusion and blood
oxygenation imaging in the shallow tissue. When viewed together, this multimodal imaging
approach paints a holistic picture of the peripheral limb response to vascular occlusion at
the anatomical, functional, and molecular levels. We observe that the effects of ligation are
almost immediate, with perfusion and oxygenation levels dropping substantially just minutes
after the operation. From there, we noticed that in the deep tissue, the angiogenic response
can take approximately three days or more to be fully elicited, beginning with a rapid rise in
HIF-1α expression followed by a slower rise in αV β3 expression. The effects of angiogenesis,
viv-a-vis blood perfusion, do not manifest until approximately a week after ligation. We also
see that the surface tissue undergoes a very different mode of recovery than does the deep
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tissue, beginning to reestablish normal blood perfusion within just two days, likely through
arteriogenesis rather than angiogenesis. It is hoped that this type of multimodal imaging
approach will help to better understand a number of complex biological systems, and aid in
the development and evaluation of new therapies for human disease.
Chapter 5, the final chapter of this document, reproduces “Multimodal Assessment
of Mesenchymal Stem Cell Therapy for Diabetic Vascular Complications” [2]. Building on
what we have learned about the different microenvironmental cues that support angiogenesis,
this project brings to bear both imaging and gene expression profiling technologies in order
to investigate the use of mesenchymal stem cells as a therapy for diabetic patients with
PAD. I enjoyed this project immensely, and remain extremely proud of it. Current clinical
management of PAD focuses largely on surgical interventions and lifestyle changes including
exercise. Unfortunately, over 30% patients are not considered suitable for surgery [32],
and exercise can be difficult and painful for diabetic patients who are already experiencing
noticeable symptoms of lower limb ischemia. A new generation of therapies intended to
promote angiogenesis and arteriogenesis is sorely needed. Here, we consider the use of
muscle-derived mesenchymal stem cells (mMSCs) injected into the ischemic tissue of our
diabetic mice as a method of altering the microenviroment and rendering it more conducive
for angiogenesis. We employed several minimally invasive in vivo imaging and diagnostic
approaches (nuclear, laser Doppler perfusion, muscle function and microarray transcriptomics)
in order to construct an accurate picture of the effects of our transplanted mMSCs, as well as
the response of our mice to treatment, and their long-term prognosis. We find that mMSCs
lead to greatly enhanced neovascularization roughly one week after treatment. We also find
that at the two-week timepoint, the transcriptional profile of our stem-cell treated mice
resembles that of healthy mice while a control group treated with saline continue to express
anti-angiogenic factors, indicating a relative lack of healing. The translational nature and
timeliness of this work is significant, and our results have potentially important clinical
implications for the evaluation and management of diabetic patients with PAD.
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Chapter 2
Development of the methodology for
non-invasive multimodal assessment
of PAD †
2.1 Hypoxia detection using a Bioreducible
N-oxide-based Probe
2.1.1 Introduction
Hypoxia refers to a physiological state in which tissue oxy-gen supply is restricted. Diminished
oxygen levels can be in-duced by a variety of diseased states; including coronary artery disease
peripheral arterial disease and gastrointestinal inflammatory conditions [33,34]. With respect
to cancer, an estimated 50-60% of solid tumors contain hypoxic regions, which is noteworthy
considering that hypoxic tumors are commonly associated with high metastatic potential,
aggressive phenotypes and treatment resistance [35]. Detection of hypoxia in vivo is therefore
an area of significant research interest because of the potential to predict treatment responses
and provide patient-specific therapies [36,37]. The current gold standard of hypoxia detection
involves the use of oxygen-sensitive electrodes, which must be inserted into the tissue of
interest. Although this technique provides a direct measurement of oxygen partial pressure
(pO2) it is highly invasive and only applicable when tissue is accessible, such as in superficial
tumors of the head and neck [38]. As such, significant effort has been put forth to develop
alternative methods for non-invasive hypoxia detection. For instance, optical imaging with
†Work includes previously published material incorporating contributions from Hedhli Jamila, Czerwinski
Andrzej, MinWoo Kim, Hailey J. Knox and others [3–5].
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hypoxia-responsive fluorescent probes has enabled visualization of hypoxia in living cells with
excellent subcellular resolution. However, due to high scattering and limited penetra-tion
of light in biological tissue, fluorescent probes afford poor resolution beyond an imaging
depth of 1 mm in animal models [39]. In contrast, positron emission tomography (PET) is
not constrained by depth, and has been utilized for hypoxia detection in vivo using various
fluorine-18 18F-labeled radio-tracers [40]. However, imaging hypoxia using this modality also
faces major obstacles including high background due to non-specific uptake of radiotracers
in tissue and limited spatial resolution, hampering its ability to accurately discern specific
hypoxic regions. Moreover, owing to the relatively short half-life of 18F ( 110 mins), imaging
sessions must be performed immediately following probe synthesis. Photoacoustic (PA)
imaging is an emerging imaging modality that enables ultrasonic detection of absorbed
light in deep tissue. PA imaging is based on the phenomenon known as the PA effect, first
described by Bell in 1880 [41,42]. Excitation of chromophores in tissue with near-infrared
(NIR) light results in vibrational relaxation, which stimulates a local temperature increase.
The heat produced causes thermoelastic expansion of the surrounding tissue, stimulating a
change in pressure. Because imaging is performed using a pulsed laser sequence, expansion
and contraction cycles are induced, creating repeated pressure fluctuations and thereby
propagating ultrasound waves through the tissue. These ultrasound waves are detected by
transducers, and the signal can be reconstructed to produce a 3D image of the area of interest.
The limited scattering of sound in tissue enables PA imaging to produce high resolution
images at depths in the centimeter range [41]. Moreover, the non-ionizing radiation used
for PA imaging is a potentially safer alternative to high-energy radiation used for other
imaging modalities [43]. Herein, I present the development of Hypoxia Probe 1 (HyP-1),
a hypoxia-responsive acoustogenic probe designed for PA imaging. HyP-1 utilizes a novel
bioreducibile N-oxide trigger that is selectively reduced by CYP450 enzymes in the absence of
oxygen. This design was inspired by AQ4N, a hypoxia-responsive cancer prodrug containing
two N-oxide moieties that mask its cytotoxic effects prior to reduction in hypoxic tissue. Of
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note, N-oxides have also been employed for fluorescence sensing of Fe(II) and biorthogonal
conjugation reactions; however,This work represents the first application of this functionality
for selective hypoxia detection [44]. The PA response of HyP-1 is based on the ability of
the N-oxide to modulate its optical properties. Specifically, conversion of the N-oxide to the
corresponding aniline (red-HyP-1) elicits a dramatic bathochromic shift in the absorbance
from 670 to 760 nm (Figure 2.1). Because HyP-1 does not absorb at this wavelength, the PA
signal produced upon excitation at 760 nm corresponds exclusively to red-HyP-1. Therefore,
hypoxia detection is made possible by determining the signal enhancement observed at this
wavelength. Additionally, because HyP-1 and red-HyP-1 are highly fluorescent, HyP-1 can be
used for ratiometric quantification. To demonstrate the imaging capabilities of HyP-1, I first
evaluated its hypoxia-mediated response and selectivity in vitro. I then moved to verify that
HyP-1 shows a selective response in cancer cells cultured under hypoxic conditions. Finally, I
demonstrated the rapid response of HyP-1 in a hindlimb ischemia model of peripheral arterial
disease (PAD).
Figure 2.1: Chemical structure of HyP-1 and red-HyP-1. HyP-1 undergoes hypoxia-selective
reduction by CYP450 enzymes
2.1.2 Methods
A detailed description of the chemical and the in vitro characterization of HyP-1 is highlighted
in [4]. But briefly, HyP-1 features an N-oxide-based trigger that can undergo facile bioreduction
in the absence of oxygen. This design was inspired by AQ4N, a hypoxia-responsive cancer
prodrug containing two N- oxide moieties that mask its cytotoxic effects prior to reduction
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in hypoxic tissue. The responsiveness of HyP-1 to hypoxia was first evaluated in vitro via
fluorescence by incubating HyP-1 with CYP450-rich rat liver microsomes under atmospheric
(normoxic) and oxygen-deprived (hypoxic) conditions. After establishing excellent selectivity
and responsiveness to hypoxic conditions in vitro, I sought to evaluate the performance of
HyP-1 in living cells before moving to in vivo studies. 4T1 murine mammary carcinoma cells
were treated with a 5 µM solution of HyP-1 and incubated at 37 ◦C either in a standard
atmosphere containing 20% oxygen (normoxic conditions), or in an airtight chamber containing
<0.1% oxygen (hypoxic conditions). Imaging was performed at 2, 4, and 6 h using an epi-
fluorescence microscope equipped with Cy5 and Cy7 filter sets to visualize HyP-1 and red-
HyP-1, respectively.
Murine ischemia model
All in vivo imaging experiments were performed with the approval of the Institutional Animal
Care and Use Committee of the University of Illinois at Urbana-Champaign, following the
principles outlined by the American Physiological Society on research animal use. Female
mice (5–6 weeks old) were acquired from The Jackson Laboratory. Mice were anesthetized
with isoflurane, and unilateral hindlimb ischemia was surgically induced by femoral artery
ligation following previously published approaches. Animals that underwent unsuccessful
surgery as determined by laser Doppler perfusion imaging were excluded from analysis.
Fluorescence imaging In vivo Images were obtained using epi-fluorescence with excita-
tion filters of 675 and 745 and corresponding emission filters of 720 and 800, respectively.
Data was processed using Living Image software (Version 4.1). ROIs of equal area were drawn
around signals, and the total radiant efficiency in each ROI was determined. Ratiometric
signal was calculated by determining the ratio of radiant efficiency corresponding to 800 and
720 nm emissions.
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PA imaging In vivo. Prior to imaging, hair was removed from the lower body half by
shaving and treating with a topical hair removal cream. Mice were positioned on their sides
such that the area to be imaged was directly above the light source. Images were acquired
using the Step and Shoot mode with 120 angles and 30 pulses per angle. Data were analyzed
using OsiriX software. Thick slab processing was used to visualize accumulated signal over
12 mm. ROIs of equal area were drawn to include all visible signal in the image, and mean
PA signal in each ROI was recorded. Change in PA signal was calculated by subtracting
signal from images taken prior to injection from those at given time points.
2.1.3 Results and Discussion
In vivo imaging of hypoxia in a murine model of peripheral arterial disease
Due to the rapid oxygen depletion that results from PAD model, I envisioned it could be
used to demonstrate the response of HyP-1 to hypoxic conditions in vivo independent of
changes in gene and protein expression levels that can result from other models (i.e. cancer).
In these studies, ischemia was induced in the right hindlimb of BALB/c mice via ligation
of the femoral artery. To confirm that the ligation had successfully limited blood perfusion
through the limb, laser Doppler perfusion imaging was performed immediately following the
surgery, and a drastic decrease in blood flow was observed in the right hindlimb (Figure 2.2).
Figure 2.2: Laser Doppler perfusion images acquired (a) before and (b) 15 minutes after
surgical ligation of the femoral artery in the right hindlimb
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After a 1 hour recovery period, HyP-1 (50 µL, 50 µM) was administered via intramuscular
injection into both hindlimbs of the mouse. To visualize the time-dependent response of HyP-1
in the ischemic and non-ischemic tissue, ratiometric fluorescence imaging was performed over
the course of 1 hour immediately following injection. A rapid increase in the ratiometric
fluorescence intensity corresponding to conversion of HyP-1 to red-HyP-1 was observed in
the ischemic tissue. Overall, the average ratiometric signal increase was 1.7-fold greater in
the ischemic tissue compared to the control, indicating oxygen-dependent inhibition of HyP-1
activation (Figure 2.3a,b).
Moreover, I confirmed that the activation of HyP-1 under ischemic conditions does not
involve Fe(II) by co-administering HyP-1 with BIPY (5 mM) to chelate free Fe(II). The
ratiometric fluorescence enhancement was statistically indistinguishable from that of when
HyP-1 was administered alone Figure 2.4.
After observing the hypoxia-mediated response of HyP-1 in the hindlimb ischemia model,
I turned my attention to detecting this response using PA imaging. As described above,
ligation of the surgical ligation was employed to induce ischemia, and HyP-1 (50 µL, 50 µM)
was administered via intramuscular injection. PA images were acquired 1h following injection,
and a robust signal enhancement 3.1-fold greater on average than that of the control leg was
observed in the ischemic tissue see (Figure 2.3b,d). These results demonstrate that HyP-1
can be applied to hypoxia detection in multiple disease models. In addition, the limited
time frame between induction of ischemia and imaging suggests that HyP-1 does not rely
significantly on upregulation of heme-based redox proteins, but rather can undergo rapid
conversion to red-HyP-1 under hypoxic conditions at constitutive enzyme expression levels.
2.1.4 Conclusion
PAD is characterized by restricted arterial circulation to the limbs, most commonly the
legs, resulting from plaque deposition and arterial hardening. The murine hindlimb ischemia
model is widely accepted for the study of PAD and has been used in the evaluation of
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potential treatment options. In the following study, I have demonstrated that HyP-1 exhibits
a rapid turn-on response in murine hindlimb ischemia just 1h following surgical ligation of
the femoral artery. These results show the excellent sensitivity of HyP-1 to oxygen-deficient
conditions resulting from ischemia. Thus, detection of hypoxia can guide treatment planning
and serve as a predictor of PAD patient prognosis. Prior to this work, hypoxia detection
using optical methods has relied extensively on fluorogenic probes that provide minimal
resolution and depth penetration. Through the development of HyP-1, I have established
criteria for employing optical-based probe designs for translation into powerful PA imaging
agents. Probes, such as HyP-1, that undergo reaction-based activation to elicit a PA turn-on
response can provide a target-specific readout in deep tissue, a direction that was previously
exploited only for cell-based fluorescence imaging. While impressive, the advances in PA
techniques and instrumentation have been constrained by a shortage of PA probes that can
demonstrate target-specific detection. As such, the importance of HyP-1 extends beyond
hypoxia detection; rather, I anticipate this work will stimulate further investigations in this
rapidly growing arena.
2.2 Perfusion imaging using Ultrasonic Power
Doppler
2.2.1 Introduction
The goal of ultrasonic Power Doppler (PD) imaging is to display the magnitude of blood
perfusion in tissue at each point in a scan plane. PD methods are sensitive to red-blood-cell
(RBC) movements, making them useful for assessing ischemia and flow in tortuous vessels.
Nonetheless, quantifying slow and weakly-scattering intrinsic perfusion signals remains a
formidable challenge. The principal challenge is to increase the signal-to-noise+clutter ratio
(SNCR), which is addressed by either suppressing noise and clutter components [45–47] or
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augmenting the blood-flow component with contrast agents [48–50]. The work focuses on
non-contrast-enhanced approaches to improving PD imaging.
I provide an initial demonstration of a simple echo-acquisition and data filtering strategy
that appears to substantially improve SNCR and Doppler-frequency resolution. With some
tuning of the filters, I clearly see regions of slower perfusion that are not visible using
established PD techniques. The acquired data at each spatial location are arranged to have
two temporal dimensions: slow-time sampled on the order of kHz and frame time sampled
on the order of Hz. Temporal sampling is adjusted to increase the density of independent
samples in the low-frequency Doppler spectrum where the weak perfusion signal is strongest.
I then increase the dimension of the clutter filter to fully exploit the expanded dimensionality
of the data, and employ high-frequency pulses to further increase SNCR.
The recorded data array initially has two spatial dimensions (axial and lateral) and two
temporal dimensions (slow-time and frame-time). These data are reordered to combine the
two spatial axes into one, resulting in a 3-D data array with one spatial and two temporal
axes. I describe the information contained within this 3-D data array and a 3-D clutter filter
that separates blood components from clutter and noise.
Traditional filters have been employed in the slow-time domain to reduce power at low
temporal frequencies where clutter dominates [51]. The resulting perfusion estimates are
often averaged over a few spatial locations and/or multiple frames to reduce variance in the
estimates. However, under conditions of slow flow, a significant portion of the perfusion
signal may fall into the attenuated frequency channels of the clutter filter. This issue is also
present for more general eigenfilters that operate on slow-time echo signals [52, 53].
An alternative to 1-D slow-time filters has been to expand the filter dimension to use
information from both space and time to isolate the blood signal [45]. Two-dimensional
filters are derived from the echo data using singular-value decomposition (SVD). They exploit
the spatial coherence of clutter echoes as distinct from the more incoherent flow patterns
of perfusion when separating clutter and blood signals. Today, estimation of SVD-filtered
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data often takes place along the spatial and slow-time axes. If frame-time data are recorded,
they are averaged to stabilize the SVD filter. Higher sampling rates along the slow-time axis
can be achieved with plane-wave imaging techniques [47] that facilitate noise averaging when
forming SVD filters from the data.
We propose here to extend SVD filters to 3-D data arrays described above using a higher-
order SVD (HOSVD) technique [54,55]. I will show data that suggests this filter facilitates
isolation of echo power from slowly-moving and spatially disorganized RBC movement.
HOSVD filter construction yields one set of basis vectors for each of the three data dimensions
within a region of interest. Retaining all three data dimensions enables the adaptive HOSVD
filter to effectively separately signal components. I hypothesize that by analyzing data
along the frame-time axis, I can enhance the sensitivity of PD imaging to blood perfusion
echo signals. The challenge for users is to find a subspace in the HOSVD core array that
isolates perfusing blood signals. Projecting the recorded echo data onto that subspace before
computing the signal power at each pixel dramatically increases PD sensitivity to perfusion.
The process of filter formation includes signal averaging that improves filter stability. However,
I must take care to select spatial regions that include only wide-sense stationary echo data.
To test the feasibility of the approach, these measurement methods are applied to muscle-
perfusion imaging of healthy and ischemic mouse hindlimbs. Perfusion in this model of
surgically-induced ischemia generates spatial patterns of perfusion/ischemia [56] that I track
to observe and compare with alternative approaches.
2.2.2 Methods
Implementation
A detailed description of the PD methodology is presented in [3]. Briefly, three eigenanalyses
are performed on X via Eq. (2.1).
RN = [X ]1[X ]
†
1 = UΛNU
† ∈ CN×N
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RS = [X ]2[X ]
†
2 = VΛSV
† ∈ CS×S (2.1)
RK = [X ]3[X ]
†
3 =WΛKW
† ∈ CK×K .
From the three sets of eigenvectors generated, the core tensor is formed via Eq. (2.2).
G = X ×1 U
† ×2 V
† ×3 W
† . (2.2)
Components of G are orthogonal in that the dot product between planes in the array,
< Gin=α,Gin=β >= 0, α 6= β, ∀n, ∀α, ∀β , (2.3)
We then select a region within the core tensor that contains information about perfusion and
zero the other elements via Eq. (2.5). This process yields the perfusion subspace whose
elements are squared and summed in Eq. (2.4) to estimate the signal power mapped into PD
images.
pj[i2] =
1
NK˙
N∑
i1=1
K˙∑
i3=1
|B˜j[i1, i2, i3]|
2 , (2.4)
where pj ∈ R
S˙. In vivo experiments below show that the perfusion subspace is confined to a
small region within G. Therefore I find it is fast and easy to exhaustively search for values of
cn and bn in Eq. (2.5) that yield the “best” perfusion maps shown in the results below.
Bˆ =
c1+b1∑
i1=c1+1
c2+b2∑
i2=c2+1
c3+b3∑
i3=c3+1
gi1,i2,i3ui1 × vi2 ×wi3
=
c1+b1∑
i1=c1+1
c2+b2∑
i2=c2+1
c3+b3∑
i3=c3+1
X ×1 ui1ui1
†
×2vi2vi2
† ×3 wi3wi3
† . (2.5)
Echo data were recorded using a VevoR 2100 system and a MS400 linear array (FUJIFILM
VisualSonics Inc. Toronto, Ontario, Canada). The transducer transmits 2-cycle pulses with a
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24 MHz center frequency. All processing was implemented in Matlab 2013b on an Intel
processor i5-4300U CPU, 2.50 GHz. The highest computational burden is filter construction,
which was performed using a truncation technique [57] to minimize running time. The average
time to compute the 1600 windows for one PD image frame is 19.1 s.
In Vivo Perfusion Imaging
A murine model of partial hindlimb ischemia was used [58] to study the feasibility of the
methods for in vivo perfusion imaging (Fig. 2.5). Each mouse was anesthetized with 1.5%
isofluorane vaporized in O2 at a rate of 1 L/min via nose cone. Each animal underwent
hindlimb occlusion of the right femoral artery, following the procedure described previously
in [56, 58] without disturbing non-femoral peripheral flow to the right leg or any blood flow
to the left leg. Briefly, the anesthetized mouse was placed on a 37◦C heating pad, a small
incision was made on the right leg to expose the femoral vasculature, and dual ligation of the
femoral artery was performed distal to the profundus branch to induce unilateral hindlimb
ischemia. To confirm the occlusion and the reduction of blood flow in ischemic hindlimb,
animals were imaged with a Laser Doppler Imager (moorLDI, Moor Instruments, UK) before,
and immediately after ligation. For US scanning at 24 hrs post-surgery, the anesthetized
animal was placed in a supine position with hindlimbs extended, and the transducer scanned
the shaved inner hindlimb along a longitudinal cross section that included muscle, bone and,
vasculature. Fig. 2.5b displays a B-mode view of the anatomy. Although measurements were
made on three mice, I will show results of scanning contralateral limbs of two mice specifically
to compare methods. All experiments were performed with the approval of the Institutional
Animal Care and Use Committee of the University of Illinois at Urbana-Champaign following
the principles outlined by the American Physiological Society on research animal use.
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2.2.3 Results
n order filter
In Fig. 2.6, I compare results of first, second, and third-order clutter filters for displaying the
slow-time arterial flow (first three rows of images) and frame-time perfusion (last three rows
of images). All results are obtained from the same echo-data array, viz., X ∈ C17×200·240×17.
For the first and second-order filters, 17 post-filtered images are averaged over either the
slow-time or the frame-time axes to take full advantage of all echo data. The third-order filter
first decomposes the entire data array before projecting onto the appropriate subspace. The
entire echo-data array influences each image displayed in Fig. 2.6. In each case, I selected
filter parameters that provided the clearest visualization of RBC movement. From one set
of recorded echo data, I can see the effects of filter order and data-array axis (eigen-basis)
on the ability to visualize fast or slow-flow patterns in normal and ischemic hindlimbs. In
particular, compare the noise levels in the third-order filter results with first and second-order
results. A noticeable contrast improvement is observed.
The full impact of using 3-D data may be appreciated when I threshold and color code
the power signals before overlaying them on the B-mode image (Fig. 2.7) as is traditionally
displayed for clinical applications. I use a blue color map to display the slow-time-axis power
(arterial flows) seen in Figs. 2.6 (E) and (F) and a red color map to display the frame-time-axis
power (blood perfusion) from Figs. 2.6 (K) and (L). Colored PD images are displayed in the
third row of Fig. 2.7. The inset shows 160 µm-dia vessels are clearly resolved.
The first and second rows of Fig. 2.7 display FIR-filtered PD images, and the third row
shows HOSVD-filtered images. All are computed from the same echo-data array. I applied a
fixed 25 Hz high-pass FIR filter in (A) and (B) and a 150 Hz high-pass FIR filter in (C) and
(D). While surface vessels and bone artifacts can be seen in the 25 Hz FIR-filtered and the
HOSVD images of Fig. 2.7, only HOSVD images show slow flow within interior vessels of
the ischemic hindlimb and uniformly perfused muscle in proximal regions of healthy controls.
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Sensitivity is reduced in distal muscle regions of all images as sound attenuation reduces
SNCR.
2.2.4 Discussion
These preliminary data suggest the proposed changes in acquisition and filtering can greatly
increase the sensitivity of ultrasonic power-Doppler perfusion imaging without contrast
enhancement. The HOSVD filter allows us to separate fast and slow flows that I indicate
with blue and red color maps in Fig. 2.7 (arrows in top row of Fig. 2.8 also indicate arterial
flows). I was fortunate to capture a portion of the femoral artery in the ischemic image.
This ligated vessel appears prominently in the perfusion image because it is weakly fed from
collateral vessels. Also, at 24 MHz, the ischemic hindlimb perfusion image inset in Fig. 2.7
(E) clearly displays vessels with diameter smaller than 200 µm. These small vessels are less
visible in the control hindlimb (F) where surrounding capillary perfusion reduces small-vessel
contrast (not shown).
Baseline perfusion, which is 17 ml/min/100g in the normal hindlimb [59], falls to 60-70%
of that value following femoral ligation [58]. Consequently, a 5-10 g hindlimb muscle has
normal capillary flow in the range of 1-3 ml/min. A key element of successful HOSVD
filtering is selection of the clutter and blood subspaces within core tensor, G. The standard
selection method is based on eigenvalue information and echogenic properties of the sources
as mentioned in Section ??. Since there are only a few prominent elements in G, I now
just try various filter ranges and inspect the resulting PD images to determine the “best”
filter parameters. The following techniques using eigenvector information could guide a more
objective and automated partitioning of G.
The top left PD image in Fig. 2.8 represents a different normal mouse hindlimb. Here I
see two segments of arterial flow as indicated by arrows and the blue-green color. On the
right, I reproduce the ischemic hindlimb image from Fig. 2.7 that displays no fast blood flow
patterns. In both images, I box a region of interest that includes directed vascular flows away
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from the transducer; on the left, flow velocity is in the range 2-15 mm/s and on the right the
flow velocity is in the range ±0.2 mm/s.
In the second row of Fig. 2.8, I display the first nine odd spatial eigenvectors as gray scale
images. These are taken from data in the boxed regions in the figures above. The absolute
values of elements in each spatial eigenvector are reshaped back into the shapes of the 2-D
image patches. Looking closely, I see the linear shape of the vessel within each eigenvector
that is similar to that in the boxed image region above, except for the first eigenvector. The
uniformity of spatial eigenvector 1 suggests it is dominated by clutter, while the appearance
of a vessel-like structure in the other eigenvectors suggest they are influenced by directional
blood flow in the vessel. For this reason, I eliminate at least the first spatial eigenmode
through HOSVD filtering.
Images of the slow-time eigenvector spectra (third row in Fig. 2.8) and frame-time
eigenvector spectra (fourth row) further reveal information about blood flow. In the first
eigenvector spectrum (left-most column of the spectral images) the only nonzero value is at
zero-frequency; consequently the first eigenvector offers no information about movement and
should be discarded. The linear spectral pattern in the normal hindlimb slow-time spectral
image between eigenvectors 5-10 (third row, left in Fig. 2.8) suggests a strong signal is present
for fast directed blood flow. Because this flow is away from the transducer, the linear pattern
appears along the negative-frequency axis, which shows there is directional flow information
available. Notice the spectrum shows evidence of aliasing as the linear structure wraps from
negative to positive frequencies at eigenvector 13. There is no linear spectral pattern for
the normal hindlimb image in the corresponding frame-time spectrum (fourth row, left in
Fig. 2.8) as expected for the slow, disorganized RBC movement associated with capillary
perfusion. The red arrows along the abscissa indicate the upper and lower bounds on the
eigenvector pass band set for HOSVD filtering.
There is also an asymmetric linear spectral pattern in the ischemic hindlimb image between
eigenvectors 3-9 in the frame-time spectrum (fourth row, right in Fig. 2.8). This corresponds
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to the relatively-slow but downward-directed flow within the large vessel in the ischemic
tissue. I know it is slow flow because it is found in the frame-time spectrum and the linear
pattern indicates the flow is directed. Conversely, the slow-time eigenvector spectrum for the
ischemic leg (third row, right in Fig. 2.8) is symmetric and diffuse, indicating no directed fast
flow in this region.
Future work includes imaging at lower transmission frequencies and higher frame-time
rates to assess clinical utility in human subjects. The low frame rate used for the murine
model is unlikely to span the wider range of perfusion velocities found in human tissue.
2.2.5 Conclusion
In this preliminary study, I found that expanding the dimension of the acquired echo-data
array and then strategically reducing the data dimension using adaptive HOSVD filters leads
to images that suggest improved perfusion sensitivity. At this point in development, the
method offers images of signal power that describes relative flow and perfusion patterns.
HOSVD filtering appears to enhance the distinct information provided by each axis of the
3-D data array, enabling visualization of blood components of the echo signal while effectively
suppressing clutter and noise components. The addition of frame-time data as a separate
array dimension appears to allow increased sensitivity to slower flows through a longer
acquisition period without discarding fast blood flow echoes offered by the slow-time array
axis. One 3-D acquisition processed via HOSVD effectively displays both blood components.
Although I apply power-Doppler processing here, I note that the eigenvector spectra seen
in Fig. 2.8 contain information about the direction and spatial coherence of RBC movement.
In principle, color-flow imaging is possible. I applied 24 MHz ultrasonic pulses to couple the
method to the small mouse model which enabled sub-millimeter vessel diameter flows to be
imaged with 5-mm tissue penetration.
The price paid for adding the frame-time axis in the echo-power estimator is that each PD
frame requires more than 1 s worth of data acquisition. Since perfusion is normally steady or
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slowly varying, the long acquisition could be inconsequential depending on the application.
The added sensitivity and lower noise justify the extra time and effort, especially when
imaging stationary echo data that describe steady RBC movements, as for the application
described in this report. Little effort has been made thus far to minimize the time required
to compute one PD image frame, which now stands at 19.1 s.
2.3 Molecular imaging of αV β3 integrin with dimeric
cRGD probes
2.3.1 Introduction
The development of capillaries from preexisting vessels to form new vasculature, termed as
angiogenesis, is tightly controlled by a delicate balance of pro- and anti-angiogenic factors.
The main stimulators of blood vessel formation are vascular endothelial growth factor
(VEGF) and basic fibroblast growth factor (bFGF), while endogenous inhibitors include
thrombospondin, and angiostatin [25]. The process of creating new blood vessels is necessary
for physiological function, but is also a hallmark of many pathological disorders such as
inflammation, ischemic heart disease, and cancer. Over the last two decades, significant
research efforts have been directed at developing novel targeted imaging techniques for the
non-invasive assessment of angiogenesis as a tool for early diagnosis, prognostication, and
monitoring of novel individualized therapeutic interventions focused on the modulation of the
angiogenic process [60]. These efforts resulted in the discovery of numerous potential imaging
targets including integrins, which play an important role in the regulation of angiogenesis [23].
Found in species ranging from sponges to mammals, integrins are heterodimer transmembrane
glycoproteins consisting of α (150-180kD) and β (90kD) subunits. The cell surface receptor
is composed of three parts: a large ectodomain, a single transmembrane domain, and a short
cytoplasmic tail. Integrins, when activated by an intracellular ligand (e.g. talin or kindlin),
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become capable of binding specific extracellular molecules in a unique combination of “inside-
out” and “outside-in” signaling. In response, the integrins elicit a cascade of biochemical
events that modulate gene expression, and regulate cytoskeleton organization [61–63].
Significant effort has been expended exploring the clinical utility of imaging αV β3 [64, 65]
expression associated with tumor angiogenesis and metastatic dissemination [66, 67]. For
example, radiolabeled integrin peptide ligands with a pentapeptide motif Arg-Gly-Asp-Phe-
Lys (RGDfK) have been used as tools in research aimed at developing radiotracers for clinical
applications [68, 69]. Numerous linear and cyclic RGD peptides based (to a greater or lesser
extent) on the RGDfK motif, in combination with a variety of pharmacokinetic modifiers,
prosthetic groups or bifunctional chelators and radionuclides have been reported and used as
diagnostic probes in animal studies and clinical investigations in the areas of oncology [70–80]
and cardiology [81–84].
Multivalent interactions have been shown to play a key role in many biological processes [85].
This phenomenon was behind the rationale for the design of multimeric cRGD ligands. A
series of such peptides labeled with 18F, 64Cu and 68Ga for PET or 99mTc for SPECT
imaging have been reported [86–90]. They demonstrated higher receptor binding affinity in
vitro and better tumor retention in vivo when compared to their corresponding monomeric
counterparts. PEG and other types of linkers have been employed as pharmacokinetic
modifiers, resulting in significantly increased tumor uptake and enhanced clearance from
noncancerous organs [91–95].
Comparisons of different RGD-based tracers have demonstrated that increasing the peptide
multiplicity can greatly improve affinity, but above a certain threshold, highly multimeric
compounds exhibit non-specific organ uptake that can limit their applicability as imaging
agents. This led to the conclusion that the dimeric subclass of the RGD peptides is an optimal
choice for the development of imaging agents for clinical applications [72,80,96]. The SPECT
tracer 99mTc-3PRGD2 [91, 97–100] as well as several RGD-based PET radiotracers [101–105],
have already entered the clinical investigation stage [69]. In the design of the new αV β3
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targeted probe related to the previously reported 3PRGD2, I integrated several structural
elements known for their positive impact on pharmacokinetic properties including PEG
moieties and 1,2,3-triazole residues [106].
Here I report the synthesis and chemical characterization of αV β3 integrin targeted
64Cu-labeled dimeric-cRGD probe (designed for in vivo PET imaging) and its FITC-labeled
fluorescent analogue (designed for in vitro imaging with single-cell resolution). Using estab-
lished in vitro and in vivo models I evaluated its efficacy as an imaging agent at the receptor,
single cell, organ, and whole-body levels with the emphasis on quantitative assessment of
αV β3 integrin expression in diabetic and non-diabetic rats following myocardial infarction
(MI).
2.3.2 Methods
Synthesis and Chemical Characterization
The chemical characterization (NMR and HR-MS) of both 64Cu-NOTA-PEG4-cRGD2 and
FITC-PEG4-cRGD2 have been described in Supporting Information (Figures 2.9 - 2.23).
Reagents Diphenylphosphoryl azide (DPPA), N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide
hydrochloride (EDC), N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), copper(II)
sulfate pentahydrate (CuSO4 × 5H2O), sodium L-ascorbate, triisopropylsilane (TIPS) were
purchased from Aldrich (St. Louis, MO). Boc-PEG4-OH and isothiocyanatobenzyl-1,4,7-
triazacyclononane- 1,4,7-triacetic acid (p-SCN-Bn-NOTA) were obtained from Quanta BioDe-
sign (Plain City, OH) and Macrocyclics (Dallas, TX), respectively. Fluorescein isothiocyanate
(5-FITC) was obtained from AnaSpec (Fremont, CA). 8-Azido-3,6-dioxaoctanoic acid (N3-
PEG2-OH) and Boc-L-glutamic acid bis-propargyl amide were the products of Peptides
International (Louisville, KY). Cyclo [Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys] was prepared
according to the literature method [107].
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Synthesis The synthesis of both 64Cu-NOTA-PEG4-cRGD2 and FITC-PEG4-cRGD2 has
been described in detail below:
(1) cyclo[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys(PEG2-N3)
To a solution of cyclo[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys] hydrochloride (1.71 g, 1.80 mmol)
and N3-PEG2-OH (0.43 g, 2.27 mmol) in DMF (10 mL) was added DPPA (0.59 mL, 2.72
mmol), followed by the addition of Et3N (0.50 mL, 3.59 mmol). The reaction mixture was
kept at 0 ◦C for 5 h, with occasional adjustments of the pH value (7-8) with Et3N. Then, the
mixture was diluted with THF (100 mL), EtOAc (300 mL), and 0.4 N HCl (100 mL). The
organic layer was washed with saturated NaHCO3 (2 × 100 mL), brine (100 mL), dried over
Na2SO4, and evaporated. The residue was triturated with isopropyl ether, and the product
was collected by filtration, washed with the ether and dried under vacuum to afford 1.80 g of
(1) in 92.3% yield as a colorless solid. ESI-MS: m/z = 1105.56 [M+Na]+; 1083.51 [M+H]+.
(2) Boc-Glucyclo[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys(PEG2-(1,2,3-triazole)
-1-yl-4-methylamide)]2
To a stirred solution of (1) (1.765 g, 1.63 mmol) and Boc-L-glutamic acid bis-propargyl
amide (0.253 g, 0.79 mmol) in a mixture of DMF (20 mL), t-BuOH (32 mL), and H2O (11
mL) were added 0.2 M CuSO4 x 5H2O (2.6 mL) and 0.5 M sodium ascorbate solution (1 mL)
at room temperature. After 1 h the reaction mixture was diluted with 1-BuOH (300 mL) and
H2O (200 mL). The organic layer was washed with H2O (2 × 100 mL), and concentrated
under reduced pressure. Addition of Et2O resulted in a precipitate, which was collected by
filtration, washed with Et2O, and dried to give 1.95 g of (2) (99.6%).
(3) H-Glucyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4
-methylamide)]2 × 3 TFA
The protected peptide (2) (1.94 g, 0.78 mmol) was dissolved in 20 mL of a solution
TFA/TIPS/H2O (95/2.5/2.5, v/v/v) at room temperature. After 2 h, the reaction mixture
was concentrated under reduced pressure and the deprotected crude product was precipitated
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with cold Et2O. It was collected by filtration, washed with Et2O, and dried to give (3) in
quantitative yield. ESI-MS: m/z = 591.07 [M+3H]3+.
(4) Boc-PEG4-Glucyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4
-methylamide)]2
A solution of Boc-PEG4-OH (0.38 g, 1.04 mmol), N-hydroxysuccinimide (0.13 g, 1.13 mmol),
and EDC hydrochloride (0.21 g, 1.10 mmol) in DMF (2 mL) was stirred at 0 ◦C. After 1
h, the ice bath was removed, and the reaction was allowed to proceed for 20 h at room
temperature. The reaction mixture was then added to a stirred solution of (3) (1.65 g, 0.78
mmol) and DIPEA (0.73 mL, to adjust pH to 6) in DMF (15 mL). The reaction was allowed
to proceed at room temperature for 6 h, with occasional adjustments of the pH value (7-8)
with DIPEA. The reaction mixture was evaporated and the residue triturated with a mixture
of acetonitrile and Et2O. Precipitated peptide was collected by filtration, washed with Et2O,
and dried to yield (4) (1.85 g) as a crude product.
(5) H-PEG4-Glucyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4
-methylamide)]2 × 3 TFA
Boc-protected peptide (4) (1.85 g) was dissolved in 20 mL of TFA/H2O (90/10, v/v) solution,
and the mixture was stirred at room temperature for 30 min. After evaporation of solvent, the
residue was triturated with EtOAc and cold Et2O. The crude product (1.50 g) was purified
using preparative RP-HPLC to yield 735 mg of (5) as a white powder. The identity of
the peptide was confirmed using HR-MS, monoisotopic mass calculated for C88H136N28O27:
2017.0128 m/z, [M+H]+: 2018.0202; found: [M+3H]+3 673.3440 m/z, corresponding to
molecular mass 2017.0079, accuracy 2.4 ppm.
(6) NOTA-PEG4-cRGD2 × 2TFA
Compound (6) was prepared in the reaction of peptide (5) (200 mg, 0.085 mmol) with p-SCN-
Bn-NOTA × 3 HCl (50 mg, 0.089 mmol) in DMF (5.7 mL) in a presence of DIPEA used for
adjustment of pH to 8 (room temperature, 20 h). The product was precipitated with EtOAc
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and purified using preparative RP-HPLC to yield the title compound as a trifluoroacetate
salt (57 mg, 24.9%) with a purity of 95.5% (Figure 2.9). The peptide was characterized
by NMR (Tables 2.3 and 2.4) and HR-MS, m/z calculated for C108H162N32O33S average
mass: 2468.7361, monoisotopic mass: 2467.1702, [M+H]+ 2468.1775; found: [M+4H]+4
617.7966 m/z, and monoisotopic [M+3H]+3 823.4048 m/z, which corresponds to molecular
mass 2467.1724, accuracy 0.9 ppm.
(7) 64Cu-NOTA-PEG4-cRGD2
Compound (6) was dissolved in 0.5 mL ammonium acetate buffer (100 mmol, pH 5.5) at
room temperature. To the solution, about 37 MBq of Copper-64 (64Cu) acetate in 0.02 mL
ammonium acetate buffer (100 mmol, pH 5.5) was added. Radiolabeling was completed at
room temperature after 30 min incubation and was confirmed by RP-HPLC (Agilent C18
column, flow 1 ml/min, CH3OH/H2O, 5/95, v/v) and thin-layer chromatography (Scan-RAM,
LabLogic). For all experiments, radiochemical purity (% RCP) was at least 95%.
(8) Synthesis of FITC-PEG4-cRGD2
Compound (8) was prepared in the reaction of peptide (5) (300 mg, 0.127 mmol) with
fluorescein-5-isothiocyanate (54.4 mg, 0.140 mmol) in DMF (4 mL) in a presence of DIPEA
used for adjustment of pH to 8 (room temperature, 4 h). The peptide was precipitated with
Et2O and purified using preparative RP-HPLC to give 241 mg (71.9%) of the desired product
as a trifluoroacetate salt with a purity of 97.7%. The structure of the peptide FITC derivative
was verified using HR-MS, m/z calculated for C109H147N29O32S average mass: 2407.6084,
monoisotopic mass: 2406.0486, [M+H]+ : 2407.0559; found: [M+4H]+4 602.5226 m/z, and
monoisotopic [M+3H]+3 803.0215 m/z, which corresponds to molecular mass 2406.0495,
accuracy 0.4 ppm.
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Ligand-Receptor Binding Kinetics Studies
All surface plasmon resonance (SPR) studies were performed with the BIAcore 3000 instrument
(Biacore International AB, Uppsala, Sweden) at 25 ◦C on dextran-coated gold sensor chips
(CM5, Research grade, GE Healthcare Bio-sciences AB, Uppsala) divided into four separate
flow cells (three containing immobilized αV β3 integrin receptor and one control). HBS-EP
pH 7.4 (10 mmol HEPES, 3 mmol EDTA, 150 mmol NaCl, 0.002% TWEEN-20) was used as
a running buffer.
Pre-concentration studies were performed to determine optimal pH conditions for receptor
immobilization (see, Table 2.1).
Protein pI Optimal pH
Anti-hCD34 8.7 6.0
αV β3 5.6 4.0
Table 2.1: Isoelectric points (pI) and optimal immobilization pHs for immobilized proteins.
Protein immobilization Pre-concentration studies were performed to determine optimal
pH conditions for protein immobilization. This helped to ensure that the target levels of
immobilized protein could be achieved precisely while also enabling us to conserve materials.
Receptor solutions were prepared at 20 µg/mL with acetate buffer (10 mmol, pH ranging
from 0.5 to 3.5, at -1.0 below the protein’s isoelectric point, Table 2.1). Each receptor
solution (20 µL) was injected at a flow rate of 5 µL/min, followed by a 5 µL injection of
ethanolamine-HCL (GE Healthcare AB, Uppsala, Sweden) to clear out the binding surface of
the receptor. The optimal pH of acetate buffer for each protein was selected according to the
maximum level of protein immobilization reached in the pre-concentration study sensograms.
Integrin αV β3 receptor (R&D Systems, USA) was irreversibly immobilized to a single flow
cell via amine coupling with the dextran matrix. A recombinant human CD-34 (R&D Systems,
USA), a protein with no known interaction with peptides based on cRGD structure, was
31
immobilized to a flow cell as a reference signal protein to account for non-specific interactions.
Briefly, the surface was activated by injecting 35 µL of 50 mM N-hydroxysuccinimide (NHS,
GE Healthcare AB) and 200 mM EDC (GE Healthcare AB) at 1:1 ratio (v/v) and a flow
rate of 5 µL/min. Integrin αV β3 receptor was dissolved at 20 µg/mL in 10 mM acetate buffer
at its optimal pH and injected at 5 µL/min until the target surface immobilization level was
reached (approximately 200-500 R.U. of immobilized receptor). After sufficient amount of
protein was coupled, the surface was deactivated by injecting 35 µL ethanolamine. Kinetic
studies with dimeric and monomeric cRGD ligands were performed on the target flow cell
containing the immobilized integrin αV β3 receptor and the reference flow cell simultaneously.
120 µL of each ligand (10, 20, and 40 nmol in HBP-EP running buffer) was injected at
30 µL/min through both flow cells, followed by a 10 minute running buffer injection to
observe ligand-receptor dissociation. After recording SPR sensograms, a series of 5 µL HCl
(5 mM) and 5 µL NaOH (10 mM) at 5 µL/min was injected to remove any remaining bound
ligand residues. This cycle was repeated twice for each concentration of the ligand. The
kinetic rate constants (association kon and dissociation koff constants), the goodness-of-fit
parameter (χ2) and the peak magnitude of the signal response (Rmax) were determined
by performing global kinetic analysis on the binding curves for each ligand-receptor pair
(Supporting Information) [108–110].
Ligand-receptor kinetics measurements The kinetic rate constants were determined
by performing global kinetic analysis on the binding curves for each ligand-receptor pair
with the BIAevaluation software (Version 4.1.1, GE Healthcare). In global kinetic analysis,
nonlinear least squares was used to determine the association and dissociation constants
that produced the best fit for multiple response curves, simultaneously. Global analysis is
considered to produce the most accurate results in comparison to fitting of a single response
curve [111]. Raw sensogram were processed for a given ligand-receptor pair. Briefly, each
raw response curve was aligned and subtracted from the reference cell signal of each receptor
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signal to remove the effects of non-specific interactions. Once processed, a 1:1 Langmuir
binding model (Equation 2.6) was fit to the data, and the association (kon) and dissociation
(koff ) kinetic constants, as well as the goodness-of-fit parameter (χ
2) and the peak magnitude
of the signal response (Rmax) were determined. This analysis was applied to each set of
kinetic studies, except where the subtracted association phase was negative. A negative
association curve occurs when the non-specific binding events on the reference cell exceed
the binding events observed for the actual ligand-receptor pair; hence, it is indicative of a
non-interaction.
L+R
kon−−⇀↽−
koff
LR (2.6)
Next, the χ2-to-Rmax ratios were calculated which provide a well-established heuristic to
determine the validity of obtained parameters for each ligand-receptor kinetic study. Previous
studies have suggested that (χ2) value obtained by fitting kinetic constants globally should
be at least 10% of, or lower than, the signal’s Rmax (the change in signal from the highest
level to the baseline) [108,112].
Cell Culture
Human Umbilical Vein Endothelial Cells (HUVEC) were acquired from American Type
Culture Collection (ATCC, USA) and grown to confluence in K-12 medium containing 10%
heat-inactivated FBS (Invitrogen), 100 U/mL penicillin G, 100 µg/mL streptomycin, 0.25
µg/mL amphotericin B (HyClone) and were maintained in a humidified incubator at 37 ◦C
with 5% CO2.
Cellular Binding Studies
To investigate various cellular binding characteristics of radiolabeled 64Cu-NOTA-PEG4-
cRGD2 and its FITC-analogue, both gamma well counting and flow cytometry/fluorescence
microscopy were used, respectively. HUVEC were incubated with 64Cu-NOTA-PEG4-cRGD2
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(0-100 nM) for 1 h at room temperature, filtered with 0.22 µm centrifuge filters (Corning
Incorporated, USA), washed twice with PBS (pH 7.4) and radioactivity measured with gamma
well counter (Wizard2, Perkin-Elmer, USA). HUVEC were also incubated in FITC-PEG4-
cRGD2 (0-200 nM) for 1 h at room temperature. Cells were centrifuged, washed twice, and
analyzed with a BD LSR II flow cytometer (BD Biosciences, USA) using gates set for FITC
and corrected for auto-fluorescence. All experiments were performed in technical triplicates.
Integrin activation and deactivation To study the effect of αV β3 integrin activa-
tion/deactivation on cellular binding, HUVEC were pretreated with of Mn2+ or EDTA
(20 µM) for 10 min, washed with ice-cold PBS, and incubated with 64Cu-NOTA-PEG4-cRGD2
(0-100 nM) or FITC-PEG4-cRGD2 (0-200 nM) for 1 h at room temperature. Cells were
centrifuged, washed twice with PBS (pH 7.4), and analyzed with gamma well counter or flow
cytometry using gates set for FITC and corrected for auto-fluorescence.
Competitive binding HUVEC were pretreated with 50 µM of unlabeled H-PEG4-cRGD2
for 30 min, and then incubated with 64Cu-NOTA-PEG4-cRGD2 (0-100 nM) or FITC-PEG4-
cRGD2 (0-200 nM) for 1 h at room temperature. Cells were centrifuged, filtered with 0.22
µm centrifuge filters (Corning incorporated, USA), washed twice with PBS (pH 7.4), and
analyzed with gamma well counter or flow cytometry using gates set for FITC and corrected
for auto-fluorescence.
Competitive inhibition (IC50 determination) HUVEC were incubated with 50 nM of
64Cu-NOTA-PEG4-cRGD2 and increasing concentrations of H-PEG4-cRGD2 (0-1 µM) for 1
h at room temperature, filtered, and washed twice with PBS (pH 7.4), and transferred to
counting tubes for gamma well counting.
Specificity In order to determine the specificity to αV β3 integrin, HUVEC were incubated
with FITC-PEG4-cRGD2 (0.34 µM) and co-incubated with phycoerythrin (PE) conjugated
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anti-αV β3 integrin antibody PE-LM609 (11.12 µg/ml) (R&D Systems, USA) for 1 h at room
temperature. Cells were centrifuged at 5000 rpm for 10 min and washed twice with ice-cold
PBS (pH 7.4). Gates were set for PE, FITC, and corrected for auto-fluorescence and potential
overlap between the PE and FITC channels.
Dual-fluorescence staining HUVEC were grown to confluence on coverslips and fixed
with 4% paraformaldehyde for dual-fluorescence staining with FITC-PEG4-cRGD2 (1 µM) and
anti-αV β3 PE-LM609 antibody (1:100, R&D Systems, USA). The coverslips were incubated
with each stain separately for 1 h at room temperature, with washing buffer (PBS, pH 7.4)
rinses before and after each incubation for a duration of 5 min. Coverslips were mounted to
slides with DAPI Fluoromount (Southern Biotech, USA), imaged with a confocal fluorescence
inverted microscope (Zeiss LSM 700 Confocal, Germany) equipped with 63x oil objective,
preprocessed with commercial software package (ZEN 2012, Zeiss, USA), and colocalization
analyzed with Fiji software [113].
In vivo Evaluation
Animal preparation All in vivo imaging experiments were performed with the approval
of the Institutional Animal Care and Use Committee of the University of Illinois at Urbana-
Champaign, following the principles outlined by the American Physiological Society on
research animal use.
Blood clearance, metabolism and biodistribution To assess blood clearance and
organ uptake dynamic in vivo PET-CT imaging was performed followed by image processing
and analysis. Lewis rats (n = 6, Harlan Inc.) were anesthetized with 2% isoflurane, the
neck area was shaved and a jugular vein cut-down procedure was performed to insert a
PE-50 polyurethane catheter for radiotracer injection. Animals were then placed in supine
position on the polyacrylic imaging bed of a small animal dedicated PET-CT scanner (Inveon,
Siemens Healthcare, USA). At the time of PET acquisition, animals were injected with ∼22.2
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MBq of 64Cu-NOTA-PEG4-cRGD2 via the jugular vein catheter over 30 s followed by bolus
infusion of 0.2 mL sterile saline. Animals underwent 60 min dynamic PET imaging (15%
energy window centered at 511 keV) followed by anatomical X-ray CT imaging (80 keV, 500
µA, 100 µm spatial resolution). Following dynamic PET-CT imaging, both urine and feces
samples were collected to assess radiotracer’s metabolism and excretion route. The urine
samples were collected at 90 min post injection by manual void, mixed at 1:1 ratio (v/v)
with 50% CH3CN and centrifuged at 5000 rpm. The supernatant was collected, analyzed by
HPLC (C18 column, flow 1 mL/min, CH3OH/H2O, 5/95, v/v), and chromatograms compared
to reference samples of 64Cu-NOTA-PEG4-cRGD2 and
64Cu-acetate. Feces samples were
collected at 90 min post injection, suspended in 50% CH3CN, homogenized and centrifuged
at 5000 rpm. The supernatant was filtered and analyzed by RP-HPLC. For biodistribution
studies, all animals were euthanized at 90 min post-injection and selected organ samples
were collected for gamma well counting analysis. All collected sections were weighed and the
tissue radioactivity was measured with Wizard2 gamma well counter (Perkin-Elmer, USA).
Measured 64Cu activity was corrected for background, decay time, and tissue weight.
In vivo imaging of myocardial angiogenesis To evaluate the feasibility of 64Cu-NOTA-
PEG4-cRGD2 imaging in rodent model of myocardial ischemia, male diabetic and non-diabetic
Lewis rats (n = 5 in each group) were subjected to surgical permanent ligation of left anterior
descending (LAD) artery to induce anteriolateral myocardial infarction (MI) resulting in
angiogenic response [114]. Type-1 diabetes was induced by bolus injection of 50 mg/kg
streptozotocin (STZ), which resulted in hyperglycemia (> 200mg/dl glucose) and glucosuria
at 6 weeks post STZ injection. To induce MI, animals were anesthetized with 1-3% isoflurane,
and the respiration was controlled using an animal ventilator (Kent Scientific, USA) for
a thoracotomy incision. Myocardial infarction was induced by ligating the proximal LAD
coronary artery with 8-0 silk suture. One week after the surgery, all animals were anesthetized
with 1-3% isoflurane, neck area shaved, and the left jugular vein was isolated for placement
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of a PE-50 polyurethane catheter to facilitate injection of the radiotracer. All animals
were injected with ∼29.6 MBq of 64Cu-NOTA-PEG4-cRGD2. Imaging was performed using
hybrid small animal microPET-CT scanner (Inveon, Siemens Healthcare, USA). Animals were
placed on animal bed and ∼60 min after radiotracer injection, a 15 min microPET imaging
was performed. This was followed by a high-resolution anatomical microCT imaging (360
projections, 80 keV/500 µA energy) during continuous (0.8 mL/min) intravenous infusion of
an X-ray CT contrast agent (Omnipaque, GE Healthcare, USA) using programmable syringe
pump (Kent Scientific, USA).
Image analysis and tissue processing The microPET and microCT images were recon-
structed using OSEM/3D iterative algorithm (Siemens Healthcare, USA) and cone-beam
technique (Cobra Exim), respectively. Both microPET and microCT images were fused,
reoriented and visualized as short (SA), vertical- (VLA) and horizontal-long (HLA) axis
slices using Inveon Research Workplace (Siemens Healthcare, USA). Immediately after last
imaging session, all animals were euthanized with intravenous injection of KCl (1 mol/L),
hearts excised and washed in ice-cold buffered saline. Both right and left ventricles were
filled with dental molding material to facilitate uniform cutting into 2 mm slices. All slices
were then divided into four sections; anterior, lateral, posterior and septal. Collected sections
were weighed and tissue radioactivity was measured with Wizard2 gamma well counter
(Perkin-Elmer, USA). Measured 64Cu activity was corrected for background, decay time, and
tissue weight, and expressed as percent injected dose per gram tissue (%I.D./g).
2.3.3 Results
Synthesis and Chemical Characterization
The synthesis (Figure 2.9) began with coupling of N3-PEG2-OH to a selectively protected
cyclopentapeptide, yielding azidopegylated protected peptide (1). An important aspect of the
design was related to the dimerization method. Dimeric peptides have usually been prepared
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by an acylation reaction using cRGD monomers and N-protected glutamic acid active esters,
e.g. Boc-Glu(OSu)2 as the substrates [87, 88, 115, 116]. In this case, the dimerization was
achieved by employing Boc-glutamic acid bis-propargyl amide as an alkyne substrate to bridge
two RGD pegylated cyclopentapeptides via the copper (I)-catalyzed 1,3-dipolar Huisgen
cycloaddition, yielding the protected product (2). This is only the second synthesis of the
cRGD dimer, after galacto-RGD2, based on the aforementioned click reaction protocol [95].
Total deprotection of (2), followed by the PEGylation reaction using Boc-PEG4-OSu, and
Boc-group removal yielded compound (5). After RP-HPLC preparative purification, product
(5) was used as the substrate for the synthesis of both tracers, 64Cu-NOTA-PEG4-cRGD2
(7) and fluorescent analogue FITC-PEG4-cRGD2 (8). Briefly, product (7) was prepared in
the reaction of (5) with p-SCN-Bn-NOTA, followed by the radiolabeling of NOTA-chelated
compound (6). Reaction of (5) with fluorescein-5- isothiocyanate yielded the fluorescent
product (8). Based on the 1H, 13C, DQF-COSY, TOCSY, NOESY NMR and H/C correlation
spectra (gHSQC and gHMBC, Supporting Information, Figures 2.17-2.23), a full structural
analysis of NOTA-PEG4-cRGD2 (6) was performed, including assignment of all proton and
carbon resonances (Supporting Information, Table 2.3 and 2.4). To confirm the successful
synthesis and measure masses of NOTA-PEG4-cRGD2 (6) and FITC-PEG4-cRGD2 (8),
high-resolution MS spectra for pure products were registered in direct infusion mode. For
product (6) the three- and four-fold charged molecular ions were identified on ESI spectrum
(Supporting Information, Figure 2.23).
Dimeric cRGD Probe Binds Preferentially to the αV β3 Integrin Receptor
Receptor binding kinetics We investigated the receptor binding kinetics of both the
FITC- and 64Cu-labeled tracers using surface plasmon resonance (SPR). As described in
Methods and Supporting Information sections, initial pre-concentration studies were focused
on adjusting the pH to optimize protein immobilization. I then evaluated the association
and dissociation rates of the probes to the immobilized αV β3 receptors and compared these
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values with those of a commercially available monomeric probe, cRGDyK.
The SPR sensograms associated with each probe demonstrated significant accumulation
upon initial injection (Figure 2.11). Their association phases were characterized by a sharp
signal increase at the start of the injection, followed by a slow decrease following the injection.
I observed that unlabeled dimeric probe bound αV β3 with an affinity (Kd) approximately
50 times greater than the monomeric cRGD (Table 2.2), which was paralleled by a larger
magnitude response Rmax = 10 R.U. (Figure 2.11B) compared to ∼ 5 R.U. (Figure 2.11A).
Both labeled versions of the probe showed only marginally reduced binding affinity for αV β3
relative to the unlabeled version, but they both outperformed the monomeric cRGD-based
probe.
Probe Kon (M
−1 s−1) Koff (s
−1) χ2/Rmax
NOTA-cRGD 2.7× 105 2.6× 10−6 0.26
NOTA-PEG4-cRGD2 1.1× 10
7 2.1× 10−6 0.22
FITC-PEG4-cRGD2 7.6× 10
5 6.6× 10−6 0.19
64Cu-NOTA-PEG4-cRGD2 7.1× 10
5 1.1× 10−6 0.14
Table 2.2: Summary of binding affinity and kinetic rates measured between cRGD-based
monomeric and dimeric probes and immobilized integrin αV β3 receptor using a surface
plasmon resonance-based approach. Kinetic constants were obtained by performing global
kinetic analysis using the BIAevaluation software across several kinetic binding sensograms
for each ligand-receptor pair.
Interestingly, although both labeled versions of the probe (Cu2+ and FITC) showed
superior binding affinities for αV β3 relative to the monomeric cRGD probe, neither performed
as well as the the unlabeled version (Table 3). The diminished affinities were found to be
mainly due to decreased association rates.
Binding affinity in HUVECs We next studied the cellular binding properties of both
FITC-PEG4-cRGD2 and
64Cu-NOTA-PEG4-cRGD2. HUVECs were first treated with FITC-
PEG4-cRGD2 and co-incubated with the anti-αV β3 antibody. Subsequent two-channel
confocal fluorescent microscopic images (Figure 2.12 A-C) demonstrated a significant degree
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of overlap between the fluorescein and phycoerythrin signals (Pearson’s coefficient ρ = 0.87),
which indicates a strong co-localization of FITC-PEG4-cRGD2 with αV β3 integrin receptor.
The specificity of FITC-PEG4-cRGD2 was further assessed on a single cell level using flow
cytometry. Figure 2.12D shows a quadrant plot of HUVECs treated with FITC-PEG4-cRGD2
and co-incubated with the anti-αV β3 antibody, which showed that FITC-PEG4-cRGD2
successfully bound over 99% of HUVECs expressing αV β3 integrin.
To quantitatively evaluate binding parameters, cultured HUVECs were incubated with
various concentrations of 64Cu-NOTA-PEG4-cRGD2 and FITC-PEG4-cRGD2 followed by
cellular binding assay with gamma well counting and flow cytometry. The observed radioac-
tivity and fluorescence intensity was found to increase with probe concentration and fit well
to a Hill-type function (Figure 2.13A and 2.13B). This allowed us to estimate the dissociation
constant (Kd) at 38.27 nM and 33.85 nM for the FITC-PEG4-cRGD2 and
64Cu-NOTA-PEG4-
cRGD2, respectively. Both
64Cu-NOTA-PEG4-cRGD2 and FITC-PEG4-cRGD2 also showed
strong correlation (R2 = 0.95) over the range of concentrations used in the cellular binding
experiments (Figure 2.13C).
Binding affinity in the presence of metal ions We incubated HUVECs with either 20
µM of Mn2+ or EDTA and measured the Bmax and Kd with flow cytometry and gamma well
counting. The maximum fraction of bound receptors was found to decrease in the presence
of EDTA (Figure 2.13) for both probes. Interestingly, the 64Cu-labeled probe showed a
significantly more pronounced decrease in Bmax, which I attribute to the scavenging of
64Cu
by EDTA. The dissociation constants for both the 64Cu- and FITC-labeled probes in the
presence of EDTA were measured to be approximately 55 nM, indicating a similar effect on
the binding kinetics.
In the presence of Mn2+ the probes’ binding was found to increase by 78% when compared
to HUVECs incubated without Mn2+ (Figure 2.13D). Likewise, the dissociation constant in
the presence of Mn2+ was considerably lower reaching 13.8 nM.
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Competitive binding Finally, I studied competitive αV β3 integrin binding properties
for the dimeric-cRGD probes. HUVECs were pre-treated with an excess of unlabeled
NOTA-PEG4-cRGD2 (50 µM) followed by incubation with various concentrations of
64Cu-
NOTA-PEG4-cRGD2 or FITC-PEG4-cRGD2. This resulted in a noticeable decrease in
Bmax and an increase in the Kd (188 nM) compared to untreated cells (Figure 2.13AB). To
determine IC50 values, HUVEC were treated with a fixed concentration of the probe (50 nM)
and incubated with a range of unlabeled NOTA-PEG4-cRGD2 concentrations. The results of
these experiments were fit to a model of homologous inhibition and yielded an approximate
IC50 of 5.1 nM (Figure 2.13E) [117].
Pharmacokinetics, Biodistribution, and PET Imaging
Dynamic in vivo PET-CT imaging of αV β3 integrin activity (Figure 2.14A) demonstrated
favorable initial biodistribution and clearance kinetics for 64Cu-NOTA-PEG4-cRGD2. Clear-
ance kinetics from critical organs during the first 60 min after injection was quantified by
placing volumes of interest (VOIs) on the dynamic co-registered PET-CT image sets. The
radioactivity within these VOIs was expressed as percent injected dose per gram tissue
(%I.D./g). The representative blood and tissue activity curves are shown in (Figures 2.14B
and 2.14C). After intravascular injection, 64Cu-NOTA-PEG4-cRGD2 cleared rapidly from
the blood, accumulated primarily in the kidneys, and was excreted in the urine, which was
retained in the bladder as early as 15 min after injection.
Figure 2.14D shows the biodistribution data of 64Cu-NOTA-PEG4-cRGD2 at 90 min
after intravascular injection into control rats and animals subjected to the LAD ligation.
As expected, the highest uptake was observed in the kidneys due to renal filtration being
the dominate excretion route (11.08± 2.20 and 3.66± 0.40 %I.D./g for cortex and medulla,
respectively). Relatively high uptake was also observed in the intestines (4.62 ± 0.24),
lungs (2.95 ± 0.43), and the spleen (2.25 ± 0.33). To assess in vivo stability of 64Cu-
NOTA-PEG4-cRGD2 I performed metabolism studies at the end of the dynamic PET-CT
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acquisitions. Figure 2.15AB shows representative HPLC radiochromatograms of 64Cu-NOTA-
PEG4-cRGD2 prepared immediately before injection into the animal, and non-targeted
64Cu-acetate in ammonium acetate buffer, respectively. These studies allowed us to determine
the retention times for 64Cu-NOTA-PEG4-cRGD2 and unbound
64Cu, which were further
used to demonstrate that more than 90% of 64Cu-NOTA-PEG4-cRGD2 remained intact in
the urine (Figure 2.15C) while there was no detectable activity in the feces (Figure 2.15D).
To explore the feasibility of in vivo imaging and quantification of αV β3 integrin activation
in the myocardium, static in vivo PET-CT images were performed at 90 min after injection
of 64Cu-NOTA-PEG4-cRGD2 in both diabetic and non-diabetic control rats one week after
myocardial infarction. To better define the right ventricular (RV) and left ventricular (LV)
myocardium I administered the iodine-based X-ray contrast agent Omnipaque (GE Healthcare,
USA) during CT acquisition. Representative co-registered PET-CT images are shown in
Figure 2.16A.
PET images of 64Cu-NOTA-PEG4-cRGD2 demonstrated strong focal uptake of the tracer
in the infarcted area (dashed arrows), as well as in the chest wall at the site of the thoracotomy
(solid arrows). The significant increase in 64Cu-NOTA-PEG4-cRGD2 activity within infarcted
myocardium that was observed by PET-CT imaging was confirmed by quantitative gamma
well counting of myocardial sections. The retention of the radiotracer was expressed as
%I.D./g tissue and graphed as circumferential Bull’s eye plots for myocardial slices spanning
from the apex to the base, and divided into anterior, septal, posterior and lateral sections
(Figure 2.16B). LAD ligation resulted in anterior-lateral infarct, which was characterized by
an increased 64Cu-NOTA-PEG4-cRGD2 uptake. Radioactivity within the infarcted anterior
sections was approximately 4-fold higher than in non-infarcted septal regions at one week after
myocardial infarction (Figure 2.16C). I have also demonstrated that diabetic animals had
significantly reduced (∼ 40%, *P < 0.05) myocardial uptake of 64Cu-NOTA-PEG4-cRGD2
within the infarct, whereas there was no significant difference in both border and remote
sections of diabetic and non-diabetic rats.
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Figure 2.3: (a) IVIS Spectrum images acquired of hindlimb ischemia mouse model (right leg)
1 h following intramuscular injection (50 µL, 50 µM) of HyP-1 in both legs. Acquired using
675/720 nm (left) and 745/800 nm (right) filter sets. Mouse imaged in supine position. (b)
PA images (770 nm) of the ischemic and control leg before and 1 h following injection of
HyP-1 (50 µL, 50 µM). (c) Time-dependent ratiometric fluores-cence increase of ischemic
and control limbs. (d) Time-dependent increase of PA signal of ischemic and control limbs.
Results with error bars are represented by mean SD. *p < 0.05, **p <0.01
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Figure 2.4: Normalized ratiometric fluorescence of ischemic hindlimbs following intramuscular
injection of HyP-1 (50 µL, 50 µM) or HyP-1 + BIPY (5 mM). Surgical ligation of the femoral
artery was performed on both hindlimbs of female BALB/c mice (6 weeks old). HyP-1 was
injected intramuscularly into one of the hindlimbs, while a HyP-1 solution containing BIPY
was injected into the other hindlimb. Images were acquired using 675/720 nm and 745/800
nm filter sets. Ratiometric fluorescence of the BIPY-treated hindlimb was normalized with
respect to the control. Results are presented as mean SD (n = 3).
Figure 2.5: (a) An anesthetized mouse placed on a heated surface in a supine position is
scanned with a linear array. (b) A longitudinal cross-section of the hindlimb is displayed as a
B-mode image.
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Figure 2.6: Comparisons of the visually clearest examples of first, second, and third-order
filters applied to the slow-time data axis (A-F) to display arterial flow and to the frame-time
data axis (G-L) to display perfusion. Each image is based on same 17 frames of echo data.
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Figure 2.7: PD images are compared using standard FIR clutter filtering (first row: 25
Hz high-pass, second row: 150 Hz high-pass) and adaptive HOSVD filtering (third row)
applied to the same data array. Notice that perfusion in the control limb is fairly uniform,
except in distal regions where the SNCR is low. Conversely, the ischemic limb shows patchy
perfusion throughout. The inset shows an enlargement of microvessels. Given that the PD
pixel dimensions are 32 µm axially and 60 µm laterally, I are resolving 160 µm-dia vessels
axially and 300 µm-dia vessels laterally. Axial resolution for 24 MHz pulses with 12 MHz
bandwidth is ∼ 128 µm. The blue and red colorbars indicate, respectively, color maps related
to slow-time power (dB) and frame-time power (dB).
46
Figure 2.8: The two columns illustrate analyses of data within local regions of three images.
Top row shows adaptive HOSVD images of normal and ischemic hindlimbs. White arrows
indicate arterial flows, and boxes indicate analysis regions that include a vessel. The second
row shows 9 of the first 18 spatial eigenvectors, some showing linear shapes similar to vessels
seen in top row images. Third and fourth rows depict the power spectrum of slow-time and
frame-time eigenvectors, respectively. The vertical axis is temporal frequency with the origin
at the center, and the horizontal axis indicates eigenvectors along the corresponding axes, of
which there are 17. Each column of the four spectral images is the absolute-square Fourier
transform of the corresponding eigenvector. Eigenvectors between the red arrows were passed
by the HOSVD filter for the images displayed in this report. Eigenvectors outside these
ranges were removed by the filter.
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N3-PEG2-OH + cyclo[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys] x HCl
cyclo[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys(PEG2-N3)]
Boc-Glu{cyclo[Arg(Pbf)-Gly-Asp(OtBu)-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4-methylamide)]}2
H-Glu{cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4-methylamide)]}2
Boc-PEG4-Glu{cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4-methylamide)]}2
H-PEG4-Glu{cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4-methylamide)]}2
NOTA-PEG4-Glu{cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4-methylamide)]}2
64Cu-NOTA-PEG4-Glu{cyclo[Arg-Gly-Asp-D-Phe-Lys(PEG2-(1,2,3-triazole)-1-yl-4-methylamide)]}2
DPPA/DMF/TEA
Boc-L-glutamic acid bis-propargyl amide
CuSO4 x 5H2O, sodium L-ascorbate
DMF/t-BuOH/H2O
TFA/TIPS/H2O
Boc-PEG4-OSu
DMF/DIPEA
TFA/H2O
p-SCN-Bn-NOTA
DMF/DIPEA
64CuCl2
ammonium acetate buffer pH5 
(1)
(2)
(3)
(4)
(5)
(6)
(7)
Figure 2.9: Detailed synthesis of 64Cu-NOTA-PEG4-cRGD2.
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Figure 2.10: Chemical structures of (A) NOTA-PEG4-cRGD2 and (B) FITC-PEG4-cRGD2.
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Figure 2.11: SPR sensograms depicting binding between cRGD ligands and αV β3 integrin
receptor. BIAcore 3000 kinetics studies of interactions between immobilized integrin αV β3
receptor and (A) monomeric cyclic RGD probe (NOTA-cRGD), (B) dimeric cyclic RGD
(NOTA-PEG4-cRGD2) probe, (C) cRGD2 conjugated with FITC (FITC-PEG4-cRGD2), and
(D) NOTA-PEG4-cRGD2 labeled with non-radioactive Cu
2+. Kinetic studies were performed
at a 30 µL/min flow rate, with a 4 min association followed by a 10 min dissociation period.
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Figure 2.12: Colocalization between phycoerythrin-labeled anti-αV β3 integrin primary anti-
body (PE-LM609) and FITC-labeled PEG4-cRGD2 probe. Human umbilical vein endothe-
lial cells (HUVEC) were grown to confluency and incubated with both PE-LM609 and
FITC-PEG4-cRGD2. Fluorescence microscopy images were acquired in DAPI/PE (A) and
DAPI/FITC (B) channels and were superimposed to create colocalized pixel map (C) to
calculate Pearson’s coefficient. Flow cytometric analysis of HUVEC co-incubated with PE-
LM609 and FITC-PEG4-cRGD2 demonstrated a very high degree of colocalization between
integrin αV β3 and FITC-PEG4-cRGD2 probe (D).
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Figure 2.13: Binding kinetics of FITC and Cu64 labeled cRGD2 probes. (A) Radioactivity
of confluent HUVEC cells incubated with varying concentrations of 64Cu-NOTA-PEG4-
cRGD2 (green) and with either 20 µM EDTA (red) or 50 µM of H-PEG4-cRGD2 (blue).
(B) Fluorescence of the FITC-PEG4-cRGD2 (green) with either 20 µM EDTA (red) or 50
µM of H-PEG4-cRGD2 (blue). (C) Correlation between FITC and Cu
64 labeled cRGD2
probes bound to HUVECs. (D) The fluorescence of HUVEC cells incubated with varying
concentrations of FITC-PEG4-cRGD2 (green) and co-incubated with 20 µM of Mn
2+ (pur-
ple). (E) Competition binding between 64Cu-NOTA-PEG4-cRGD2 (50 nM) and increasing
concentrations of unlabeled H-PEG4-cRGD2 in HUVEC cells.
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Figure 2.14: Dynamic PET-CT images (A) were used to plot the blood clearance (B)
and time activity curves (TAC) of 64Cu-NOTA-PEG4-cRGD2 in selected organs (C). (D)
Biodistribution of 64Cu-NOTA-PEG4-cRGD2 in selected organs at 90 min post- injection in
Lewis rats subjected to myocardial infarction induced by surgical ligation of LAD. Results
are expressed in percentage of injected dose per gram tissue (%I.D./g). These results suggest
a rapid blood clearance through renal filtration and very low non-specific uptake in other
critical organs.
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Figure 2.15: Representative radio-HPLC chromatograms for (A) 64Cu-NOTA-PEG4-cRGD2
in acetate buffer 30 min after radiolabeling and immediately before injection, (B) 64Cu-acetate
used for radiolabeling, (C) 64Cu-NOTA-PEG4-cRGD2 in urine at 90 min post-injection, and
(D) 64Cu-NOTA-PEG4-cRGD2 in feces at 90 min post-injection.
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Figure 2.16: Representative in vivo hybrid PET-CT reconstructed short-axis (SA), vertical-
(VLA) and horizontal long-axis (HLA) images acquired with iodinated contrast agent (Omni-
paque) at 90 min post-injection of 64Cu-NOTA-PEG4-cRGD2 (A). The iodinated blood pool
contrast agent permitted better definition of right (RV) and left ventricle (LV) within the
myocardium which is contoured with solid white line. Focal uptake of 64Cu-NOTA-PEG4-
cRGD2 was seen within anteriolateral LV regions (dashed yellow arrow) although significant
uptake was seen in chest wall (CH) at the thoracotomy site (solid yellow arrows) indicating
active wound healing associated αV β3 receptor expression. Bull’s eye myocardial plots of
64Cu-NOTA-PEG4-cRGD2 activity in diabetic and non-diabetic Lewis rats subjected to sur-
gical ligation of LAD to induce myocardial infarction (arrow) (B). Hearts were immediately
excised at 120 min post-injection, cleaned and filled with inert dental molding material and
cut in four 2-mm thick slices from apex to base. After removing right ventricle (RV), each
left ventricular (LV) slice was cut in four segments (anterior, septal, posterior, lateral), and
64Cu radioactivity was measured in each segment with gamma well counting. Data for each
slice were expressed as percentage of injected dose per gram tissue (%I.D./g) and categorized
as infarct, border and remote areas (C).
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2.3.4 Discussion
Dimers constitute a valuable subclass of RGD cyclopeptides, characterized by better tar-
geting capability and higher integrin-specific uptake, when compared to their monocyclic
counterparts. In the past, a variety of linkers connecting two monomeric cyclic RGDs have
been evaluated to modify radiotracer receptor binding affinity, organ uptake, biodistribution,
and excretion kinetics from non-cancerous organs.
In this work, I describe the synthesis and chemical characterization of a novel dimeric
cyclic-RGD probe for quantitative non-invasive imaging of αV β3 activity followed by a
multiscale biological analysis of probe’s receptor binding and its pharmacokinetics. In a series
of experiments I explored probe’s in vitro binding affinity using surface plasmon resonance
(SPR) with immobilized αV β3 receptor and live endothelial cells expressing αV β3. Finally, I
evaluated the behavior of 64Cu-NOTA-PEG4-cRGD2 in vivo and investigated its feasibility for
non-invasive PET-CT imaging of αV β3 expression following myocardial infarction in diabetic
and non-diabetic animals.
We began the investigations by studying direct interactions between dimeric- and monomeric-
cRGD probes and αV β3 at the receptor level using surface plasmon resonance technique.
SPR provides a powerful tool for the analysis of protein-protein and protein-ligand kinetics,
including the determination of affinity, association and dissociation rates, and activation
energies. SPR can be applicable even for low affinity systems which are often notoriously
difficult to study using other techniques.
We demonstrated that the dimeric-cRGD construct is characterized by a very fast asso-
ciation to αV β3 receptor (kon = 1.1× 10
7 M−1 s−1) which is approximately 40-fold greater
than that of previously characterized monomeric cRGDfK (kon = 2.7 × 10
5 M−1 s−1) see
Table 2.2. In contrast, the receptor-bound dimeric-cRGD probe dissociated from the αV β3
receptor at a much slower rate (koff = 2.1× 10
−6 s−1) than classical adhesive proteins like
fibrinogen and vibronectin (koff = 9.8× 10
−4 s−1 and 2.1× 10−4 s−1, respectively) [118]. All
these results suggest that both dimerization and use of certain structural elements such as
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PEG linkers and 1,2,3-triazole moieties, contributed to improved association to αV β3 integrin
(hence longer bound lifetime), while leaving dissociation properties essentially unchanged.
To study probe-receptor interactions at the cellular level in a biologically relevant model I
used human umbilical vein endothelial cells (HUVEC), which are known to constitutively
express αV β3 integrin. The binding affinity (Kd) of fluorescein (38.27 nM) and
64Cu-labeled
(33.85 nM) dimeric cRGD probes were comparable to those of fibrinogen and vibronectin (27
nM and 64 nM, respectively). More importantly, the dissociation constant of the dimeric
cRGD probes were approximately 20-fold smaller than most monomeric cRGD peptides, and
similar to tetrameric cRGD probes reported in the literature [81]. Moreover, the dimeric-
cRGD peptides have approximately only 2.5-fold lower affinity than αV β3 integrin antibody
(LM609, Kd = 14.4 nM), which suggests feasibility of
64Cu-NOTA-PEG4-cRGD2 and FITC-
PEG4-cRGD2 for high-sensitive targeted imaging of angiogenic activity. In addition, the
tracer exhibits a nearly identical IC50 value (5.1 nM, see Figure 2.13E) as that reported for
18F-Galacto-RGD (5 nM) [119]. While I have used endothelial cells in the own assay, I note
that IC50 values can vary considerably from one cell-type to another [80]. This difference
should be accounted for when comparing IC50 across cell lines.
Certain metal ions, when bound to the β3 subunit of αV β3, are known to induce a
conformational change that can affect the binding of cRGD ligands [120]. Manganese (II)
ions, for example, activate the αV β3 integrin, while calcium ions or strong chelators like
EDTA lead to its deactivation. To study this phenomenon, I incubated HUVECs with Mn2+
or EDTA. The addition of manganese led to a dissociation constant that was considerably
lower (13.8 nM) in comparison to excess EDTA (Figure 4AB). These results support the
notion that metal ions like Mn2+ play an important role in mediating the interactions between
αV β3 integrin and cRGD, and illustrate the important role of environmental conditions when
assessing the binding characteristics and potential of cRGD-based probes as imaging agents.
Angiogenesis is a key factor in the process of cardiac healing after myocardial ischemia.
Much work was focused at targeting angiogenesis for both diagnosis and therapy. For
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this reason non-invasive methods for visualizing αV β3 after myocardial infarction using
both SPECT and PET have been reported in the literature. Noteworthy examples of
radio-labeled αV β3 probes include the
111In-labelled SPECT tracer 111In–RP748, Technetium-
labeled SPECT tracers like 99mTc-RAFT-RGD, 99mTc-IDA-D-[c(RGDfK)]2, and
99mTc-
NC100692, as well as PET tracers such as 18F-Galacto-RGD, 68Ga-NODAGA-RGD, and the
trimeric 68Ga-TRAP(RGD)3, all of which have been studied in animal models of myocardial
infarction [121–125]. PET affords higher count numbers and sensitivity than SPECT (in part
because PET does not use an extrinsic collimator), and as such the probe can be used to give
more sensitive images with fewer artifacts than the available SPECT tracers. Moreover, the
probe utilizes 64Cu because of its favorable decay characteristics (half life 12.7h), which allow
imaging at later time points than several other commonly used PET and SPECT isotopes
like 18F, 68Ga and 99mTc (half life 110min, 68 min, and 6 hours, respectively). While the
rapid pharmacokinetics of the radiotracer may speak to using a short half-life radionuclide, I
chose to employ a longer half-life radioisotope which enabled the 64Cu-NOTA-PEG4-cRGD2
to be more broadly applicable: the required 64Cu can be produced at a nearby cyclotron
facility and then used hours to a day later without requiring the type of on-site isotope
production facilities that shorter-lived isotopes do. Moreover, the NOTA chelating moiety
on the probe enabled fast single step labeling (∼ 60 min) at room temperature. Other
imaging probes can require higher temperatures and much long preparation times. The
preparation of 18F-Galacto-RGD, for example, requires temperatures as high as 70 ◦C and
takes approximately 200 minutes—significantly longer than the halflife of the 18F radionuclide
itself [107].
While several multimeric cRGD-based probes have been described in that past, it has been
found that little sensitivity or specificity is gained by increasing the cRGD multiplicity past
two cRGD units [122,125]; as such, I have focused here on enhancing the pharmacokinetic
properties of a dimeric cRDG probe. In designing the structure of the dimer I decided to
employ two PEG linkers, and 1,2,3-triazole moieties. Combining both of these structural
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elements as pharmacokinetic modifiers was expected to improve the biodistribution and
elimination of the tracer [106]. Additionally, I used NOTA when labeling with 64Cu, which
has been shown to exhibit lower accumulation in the liver than other available bifunctional
chelators such as DOTA [126].
The favorable effects of these structural modifications on both pharmacokinetics and
organ retention were verified with dynamic PET imaging followed by biodistribution studies,
which provided vital insight into the in vivo behavior of 64Cu-NOTA-PEG4-cRGD2. Within
minutes after injection, I observed a rapid blood clearance of 64Cu-NOTA-PEG4-cRGD2
with paralleled retention within kidney medulla and cortex. I also observed almost complete
clearance after one hour with little gastrointestinal activity (Figure 2.14), which I attributed
to the hydrophilicity of 64Cu-NOTA-PEG4-cRGD2. I found high kidney and bladder retention,
but essentially no detectable radioactivity in feces (Figure 2.15), indicating the main excretion
route is through kidney filtration and urine (which has also been observed in other cRGD-based
radiotracers [88, 125]).
While many of the previous studies of myocardial infarction employed healthy animals,
here I focused specifically on imaging myocardial infarction in diabetic rats. High resolution
microPET-CT imaging using 64Cu-NOTA-PEG4-cRGD2 in diabetic and non-diabetic rats
subjected to LAD ligation and subsequent myocardial infarction demonstrated both discrete
and focal myocardial distributions (Figure 2.16). the probe was found to localize to the
infarcted tissue within the anterio-lateral region of the heart, and this in vivo imaging pattern
was obtained consistently for different rats (both diabetic and non-diabetic) at 1 week after
surgical induction of myocardial infarction. Importantly, I found that the ratio of probe uptake
in the infarcted region of the heart compared to a normal region was significantly higher in
non-DM rats than in DM rats (3.85±0.51 versus 2.44±0.35, respectively), indicating decreased
αV β3 activity and, in turn, decreased capacity for neovascularization in rats with diabetes.
Similar infarcted vs. normal myocardial segments for healthy rats have been reported in
prior studies (4.7± 0.8 using 18F-Galacto-RGD, 5.2± 0.8 using 68Ga-NODAGA-RGD, and
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4.1± 0.7 using 68Ga-TRAP(RGD)3 [121,125]).
We found that the greatest αV β3 activity occurred 1 week after induction of myocardial
infarction in both healthy and diabetic rats, a finding in good agreement with previous
studies using other RGD-based tracers in non-DM rats [124, 125]. This delayed αV β3 uptake
is a critical point to consider when designing potential stem-cell-based therapies for patients
with myocardial infarction, especially those with other pathologies like diabetes that may
limit their innate capacity for neovascularization. In particular, in diabetic patients, early
detection and treatment could prove extremely important to myocardial infarction recovery,
and to that end, rapid non-invasive imaging strategies like ours could play an important role
in the clinical setting.
We demonstrated that in vivo targeted αV β3 integrin imaging can be performed in
combination with contrast CT imaging. The administration of X-ray contrast agent did
improve definition of the myocardial edges and the blood pool. These in vivo PET-CT
images with contrast provided better localization of 64Cu-NOTA-PEG4-cRGD2 to the site
of the myocardial infarction within the anterior-lateral wall and allowed for differentiation
between the myocardial wall and thoracotomy site, which was characterized by active wound
healing associated αV β3 integrin expression. Moreover, the use of the X-ray contrast agent
permitted reconstruction of the αV β3 images without the need for a reference perfusion
image. Reconstruction and orientation of the PET images was extremely difficult without
the reference CT images. The image properties of 64Cu-NOTA-PEG4-cRGD2 are superior
due to the low background activity.
This combination of both anatomical and molecular targeted imaging with dimeric-cRGD-
based agents holds great promise for non-invasive quantitative assessment of different uptake
patterns observed within the myocardium of diabetic and non-diabetic animals post-MI. The
results strongly suggest reduced αV β3 integrin activation in the onset of diabetes. While the
observed regional fluctuations in the radiotracer’s retention remain in general agreement with
previously reported observations with monomeric cRGD based SPECT and PET imaging
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agents or more invasive non-imaging techniques [60, 81], targeted molecular imaging with
64Cu-NOTA-PEG4-cRGD2 demonstrated excellent quality images, higher or comparable
specific uptake within infarcted tissue, and relatively low non-specific uptake in critical
organs. All told, these imaging results clearly indicate that the dimeric-cRGD probe has
a potential for quantitative mapping of spatial and temporal changes in αV β3 activation
in small animal models of myocardial injury in the onset of diabetes as well as potentially
expanding these studies to larger animals and humans.
2.3.5 Conclusion
During the last decade, much effort has been expended on the chemical modification of RGD
peptides to increase affinity for αV β3 integrin. Recent studies suggested that cyclic RGD
dimers have high affinity due to bivalency and have relatively low non-specific uptake in other
critical organs. These properties can be further optimized by modification of the distance
between the two RGD motifs using PEG linkers. It was also shown that introduction of
1,2,3-triazole moieties has a positive impact on the pharmacokinetic profile of receptor-binding
ligands. All of this has been taken into consideration during the development of the dimeric
cRGD probe. This study described the synthesis, chemical characterization, and multi-scale
biological evaluation of both radiolabeled and fluorescent dimeric RGD peptide ligands for
molecular imaging of αV β3 integrin activation at the receptor, single cell, organ and whole-
body level. Here I demonstrated that the targeted PET-CT imaging of regional activation
of αV β3 integrin within ischemic tissue holds the potential to directly quantify the extent
and localization of ongoing angiogenic process in vivo and to assess this process on cellular
level in vitro using optical imaging with a fluorescent analogue of the targeted imaging agent.
The enhanced focal retention, favorable blood clearance kinetics and biodistribution, and
excellent quality of images obtained with 64Cu-NOTA-PEG4-cRGD2 suggest the potential for
future clinical translation. This and other molecular imaging-based approaches should lead
to better understanding of pathophysiology and development of novel paradigms for patient
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management.
2.3.6 Supporting Materials
Synthesis and Chemical Characterization
NMR spectra were recorded with a Varian Unity 500 spectrometer (Palo Alto, CA) in
DMSO-d6/TFA. 2D NMR techniques including DQF-COSY, NOESY, TOCSY, gHSQC
and gHMBC were used to confirm the structure of the synthesized NOTA-PEG4-cRGD2.
Preparative RP-HPLC purifications were performed using a Shimadzu preparative system
consisting of two LC-8A pumps controlled by a Shimadzu SCL-10A system controller, and
a Shimadzu UV/VIS detector SPD-6A (λ=220 nm) equipped with a preparative flow cell.
A Prochrom preparative column (50 mm x 35 cm) packed with Luna C18 (100A˚ pore size,
particle size 10 µm) from Phenomenex (Torrance, CA) was used for the separations at a flow
rate of 100 mL/min. Analytical HPLC runs were performed on Jupiter (Phenomenex) C18
column (4.6 mm x 250, pore size 300A˚, particle size 5 µm) with a flow rate of 1 mL/min.
Peptides were eluted using a linear gradient of 0.05% trifluoroacetic acid (TFA) in CH3CN
(Solvent B) and 0.05% aqueous TFA (Solvent A). High-resolution (HR) mass spectra (MS)
were recorded on HR electrospray mass spectrometer (Waters Synapt G2-Si ESI MS). MS
experimental conditions were as follows: the capillary voltage 3.5 kV, sample cone 25 V,
source offset 80, source temperature 100 ◦C, and desolvation temperature 150 ◦C, cone gas
nitrogen 5 L/h, desolvation gas nitrogen 800 L/h, nebuliser gas nitrogen 6.5 bar. Whole
samples were run by flow injection, and the mobile phase was CH3CN/water (1:1, v/v) at a
flow rate of 100 µl/min.
Within NOTA fragment all carbon resonances were distinguishable, however direct labeling
of few protons and carbon signals by N5, N6, N8, N9, N1a, N7b and N1b, N4b, N7b was
not possible (Figure 2.10). Also, due to the compound symmetry, the two identical cRGD
fragments cannot be differentiated; however, their integration in comparison to well separated
H-E3 and H-E4 protons could serve as proof of their presence. The amino acid sequence was
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established based on the NOE’s NH/CHα and the H/C NH/C=O/CHα correlation.
H and C atoms of the PEG and triazole fragments between lysine and glutamic acid, were
assigned upon series of H/C and NOE correlations, namely: H-K6/C-13/H-12/C-10/H-10 and
H-6/H-9, H-6/H-7, H-4/H-6, H-4’/H-6, H-2/H-4, H-2’/H-4’, H-2/H-1/H-E2, H-2’/H-1’/H-E4.
Similarly, bonds between glutamic acid and PEG as well as between benzyl groups and NOTA
were established.
Supporting Tables
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loc nr group δ (ppm)
G
lu
E2 CH 4.22
E2a NH 8.00
E3 CH2 1.70, 1.88
E4 CH2 2.09, 2.12
tr
ia
zo
le 1/1′ 2 × NH 8.33/8.26
2/2′ 2 × CH2 4.28/4.26
4/4′ 2 × CH 7.82/7.85
P
E
G
6 2 × CH2 4.47
7 2 × CH2 3.79
9,10 4 × CH2 3.53
12 2 × CH2 3.81
L
y
s
K2 2 × CH 3.90
K2a 2 × NH 8.02
K3 2 × CH2 1.39, 1.52
K4 2 × CH2 0.99
K5 2 × CH2 1.29
K6 2 × CH2 3.00
K6a 2 × NH 7.62
A
rg
R2 2 × CH 4.14
R2a 2 × NH 7.58
R3 2 × CH2 1.45, 1.69
R4 2 × CH2 1.35
R5 2 × CH2 3.08
R6 2 × NH 7.48
R7a, R8 2 × (2 × NH2)
+ 6.80, 7.20
G
ly G2 2 × CH2 3.23, 4.02
G2a 2 × NH 8.35
A
sp
D2 2 × CH2 2.37, 2.69
D3 2 × CH 4.62
D3a 2 × NH 8.06
P
h
e
F2 2 × CH 4.43
F2a 2 × NH 7.96
F3 2 × CH2 2.80, 2.89
FPh 10 × CH 7.10, 7.16, 7.22
P
E
G
2′′ CH2 2.38
3′′ CH2 3.55
5′′, 6′′, 11′′, 12′′ CH2 3.46
8′′, 9′′, 14′′ CH2 3.52
15′′ CH2 3.62
16′′ NH 7.69
18′′ NH 9.60
N
O
T
A
Bn2, Bn3 4 × CH 7.18, 7.40
Bn4a CH2 2.51, 2.80
N2 CH 3.33
N3 CH2 2.97, 3.04
N 7 × CH2 2.7–4.0
Table 2.3: 1H NMR data of NOTA-PEG4-cRGD2 in DMSO-d6/TFA
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loc nr group δ (ppm)
G
lu
E1 C=O 171.4
E2 CH 52.2
E3 CH2 28.2
E4 CH2 31.7
E5 C=O 171.4
tr
ia
zo
le 2/2′ CH2 34.3
3/3′ C=C 144.8
4/4′ =CH 123.0
P
E
G
6 CH2 49.3
7 CH2 68.6
9,10 2 × CH2 68.3
12 CH2 70.1
13 C=O 169.1
L
y
s
K1 C=O 172.2
K2 CH 54.5
K3 CH2 30.7
K4 CH2 22.7
K5 CH2 28.7
A
rg
R1 CH 171.3
R2 C=O 51.9
R3 CH2 28.7
R4 CH2 25.2
R5 CH2 40.3
R7 C=N 156.6
G
ly G1 CH2 169.6
G2 C=O 43.2
A
sp
D1 CH 171.7
D2 C=O 34.9
D3 CH2 48.4
D4 C=O 170.1
P
h
e
F1 CH 170.7
F2 C=O 54.3
F3 CH2 37.3
FPh C6H5 126.2, 128.2, 129.1, 137.3
P
E
G
1′′ C=O 170.3
2′′ CH2 35.8
3′′ CH2 66.6
5′′, 6′′, 11′′, 12′′ CH2 68.9–70.3
8′′, 9′′, 14′′ CH2 68.3–70.3
15′′ CH2 43.4
N
O
T
A
Bn C6H4 122.7,129.1,133.9,137.7
Bn4a CH2 33.4
N2 CH 58.6
N3 CH2 52.4
N CH2 42.9,44.5,50.8,51.5,53.2,54.2,54.2
N COOH 168.8, 171.6, 173.4
Table 2.4: 13C NMR data of NOTA-PEG4-cRGD2 in DMSO-d6/TFA (upon gHSQC and
gHMBC spectra ± 0.2 ppm)
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Figure 2.17: DQF-COSY spectrum of NOTA-PEG4-cRGD2 in DMSO-d6/TFA solution.
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Figure 2.18: NOESY spectrum of NOTA-PEG4-cRGD2 in DMSO-d6/TFA solution.
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Figure 2.19: TOCSY spectrum of NOTA-PEG4-cRGD2 in DMSO-d6/TFA solution.
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Figure 2.20: gHMBC spectrum of NOTA-PEG4-cRGD2 in DMSO-d6/TFA solution.
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Figure 2.21: gHSQC spectrum of NOTA-PEG4-cRGD2 in DMSO-d6/TFA solution
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Figure 2.22: Superposition of TOCSY, DQF-COSY and NOESY NMR spectra of NOTA-
PEG4-cRGD2 connectivities through amide protons.
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AB
Figure 2.23: ESI mass spectra of (A) NOTA-PEG4-cRGD2 ([M+3H]
+3 m/z = 823.7305,
[M+H]+4 m/z=618.0569) zoom in on triply charged ion revealed monoisotopic sig-
nal m/z=823.4048; (B) FITC-PEG4-cRGD2 ([M+3H]
+3 m/z = 803.3554, [M+H]+4
m/z=602.7690) zoom in on [M+3H]+3 ion revealed triply charged monoisotopic signal
m/z=823.4048
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Chapter 3
Development and image-based
characterization of preclinical model
of PAD †
3.1 Introduction
Patients with diabetes mellitus (DM) in particular have been shown to have diminished
capacity for neovascularization, which can lead to life-threatening complication in the heart
and/or extremities, conditions known as coronary arterial disease (CAD) and peripheral
arterial disease (PAD), respectively. So far, randomized clinical trials focused on the promotion
of angiogenesis using local administration of growth factors like vascular endothelial growth
factor (VEGF) or fibroblast growth factor (FGF) have shown no clear benefit in patients
with CAD or PAD [25, 127, 128]. Careful interpretation of these results revealed that the
unexpected failures could be attributed to a number of potential factors, including suboptimal
delivery strategies, suboptimal duration of the therapy (which could lead to either insufficient
growth of new vessels or excessive formation of nonfunctional vessels), and the myopic use of
only a single growth factor at a time. Moreover, the evaluation of therapeutic angiogenesis in
these trials was completed with relatively insensitive techniques focused on clinical endpoints
like exercise tolerance, quality of life and survival, peripheral pressure measurements, and
imaging of tissue perfusion.
More recently, focus within the scientific community has shifted towards the development
of novel therapeutic strategies, such as genetic and stem cell-based approaches, as well as novel
†Work includes previously published material incorporating contributions from Hedhli Jamila, Slania
Stephanie LL, P loska, Agata, Czerwinski Andrzej, Konopka, Christian J, Wozniak Marcin, Banach, Maciej,
Dobrucki Iwona T, Kalinowski Leszek, and Dobrucki, Lawrence W [1].
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noninvasive imaging techniques to evaluate molecular events associated with angiogenesis
[79,87,115,122,124,129]. It has been demonstrated that the extracellular matrix and integrins
(including αV β3 integrin a vitronectin receptor) are responsible for modulation of growth
factor production in response to mechanical strain, and that they may play an integral role
in the initiation of angiogenesis [64]. The physiological behavior of αV β3, characterized by a
very low expression in quiescent endothelium and upregulation in angiogenic cells, offer a
tremendous advantage for the targeted imaging of angiogenesis. By imaging αV β3 expression
using radiolabeled probes, optimized for PET or SPECT, altered angiogenic activity may
be diagnosed earlier and in a non-invasive manner, and the success of potential therapeutic
strategies may be evaluated in almost real-time, which may lead to more individualized
medical interventions and better patient outcomes.
Our group has previously evaluated a Technetium-99m labeled SPECT tracer (99mTc-
NC100692, maraciclatide) [123] based on the arginine-glycine-aspartate (RGD) binding
sequence for the imaging of αV β3 integrin expression in various preclinical animal models of
ischemia-induced angiogenesis [60]. This tracer, which showed a high αV β3 affinity (∼1 nM)
and a rapid and efficient renal clearance route, was successfully used to evaluate peripheral
angiogenesis in a murine model of hindlimb ischemia, and myocardial angiogenesis in both
mice and rats [60]. Building on this and work of others, the field has seen renewed interest
in developing chemically modified cRGD-based tracers with the hope of optimizing their
pharmacokinetics, biodistribution, and target affinity and specificity [93]. These efforts
resulted in the development of several multimeric tracers, which are particularly useful in
areas with multivalent binding sites and clusters of integrins [5, 70, 88, 89, 130].
A probe by itself, however, is not enough; a suitable animal model is also necessary for
preclinical work aimed at diagnosing and treating PAD. Although there exist a number of
methods for surgically inducing peripheral ischemia, and streptozotocin treatment remains a
preferred method for inducing diabetes, to my knowledge there is no systematic study aimed
at developing an optimal protocol for studying diabetes-associated PAD in mice.
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The goal of this investigation comes in two parts: first, determine an optimal animal
model; and second, evaluate the efficacy of a novel multimeric cRGD tracer targeted at αV β3
for the non-invasive PET imaging of peripheral angiogenesis in the onset of diabetes. The
tracer was carefully characterized and used previously to evaluate myocardial angiogenesis
in rats [5]. In the present study I demonstrate the feasibility of the probe for assessing
angiogenesis in diabetic mice subjected to hindlimb ischemia. The imaging tracer was used
to assess both temporal and spatial changes in local αV β3 integrin expression in diabetic and
non-diabetic animals subjected to surgical ligation of the right femoral artery in order to
induce an angiogenic response. I detected a significant reduction in the αV β3 activation in
DM mice when compared to non-DM control mice. En route to this result, I established a
number of other important findings relevant to both the murine model and the applicability
of the probe for quantitatively assessing angiogenesis in diabetic mice. First, I show that
the mouse model recapitulates several key markers of diabetes, including hyperglycemia,
and enhanced GSP and HbA1c levels. Second, I demonstrate that a fluorescent analogue
of the probe shows comparable specificity for αV β3 an anti-αV β3 antibody (LM609) when
incubated under both normal and high glucose conditions. Third, I establish an optimal
imaging protocol that allows for highly-detailed images. And finally, I validate the analysis of
the PET-CT images and show a strong agreement with gamma well counting experiments on
excised tissues, indicating that the probe can be used to accurately monitor αV β3 expression
in a non-invasive manner.
3.2 Methods
3.2.1 Diabetic Animal Model
All experiments were completed with the approval of the Institutional Animal Care and
Use Committee of the University of Illinois at Urbana-Champaign, following the principles
outlined by the American Physiological Society on research animal use.
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Glycated Serum Protein and Glycated Hemoglobin A1c Male C57BL/6 mice (Jack-
son Laboratories) were used for all surgical and imaging interventions. A subset of mice
(n=11) underwent streptozotocin (STZ, Sigma-Aldrich, USA) treatment to induce type-1
diabetes mellitus (DM). STZ was administered via intraperitoneal injection at a dose of
40 mg/kg for 5 days. Glucosuria and fasting glycemia (> 200mg/dL) two weeks after the
first STZ treatment marked the success of DM induction. Diabetic (6 weeks after STZ
treatment, n=11) and non-diabetic controls (n=4) were anesthetized with 1%-3% isofluorane
vaporized in O2 at a rate of 1 L/min via nose cone. Glycated serum protein (GSP) represents
a measure of short-to-medium term glucose control. GSP was measured colorimetrically in
the serum of blood collected from DM (2 and 6 weeks after streptozotocin administration)
and non-DM mice using an enzymatic assay (Diazyme, USA). Briefly, blood was collected in
a covered Eppendorf tube from the jugular vein of the animal and allowed to clot by leaving
it undisturbed at room temperature. Clots were removed by centrifugation at 1,000-2,000 ×
g for 10 minutes in a refrigerated centrifuge. The resulting supernatant (serum) was used to
measure GSP levels which were expressed in µmol/L.
Glycated hemoglobin A1c (HbA1c) is an important indicator of long-term diabetic control.
HbA1c was measured in whole blood collected from DM (at 2 and 6 weeks) and non-DM mice
using a direct enzymatic assay (Diazyme, USA). The HbA1c concentration was expressed
directly as %HbA1c by use of a calibration curve.
Surgical Procedures All animals underwent hindlimb occlusion of the right femoral artery
and a sham operation on the left hindlimb, following previously-described procedures [123].
Briefly, a small incision was made on the right leg to expose the femoral vasculature, and
dual ligation of the femoral artery was performed distal to the profundus branch to induce
unilateral hindlimb ischemia. All mice were allowed to recover for 7 days after surgery.
Ischemia Validation To validate the animal model, an additional group of normoglycemic
mice (C57BL/6, n=3), was used to verify the occlusion and the reduction of blood flow in
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ischemic hindlimb. Animals were imaged with laser doppler flowmetry Imager (moorLDI,
Moor Instruments, UK) before, immediately after, and 1 week post-surgery. To confirm the
presence of collateral vessels as a result of angiogenic and arteriogenic processes, Microfil
(Flowtech Inc, USA) casting followed by the tissue clearing technique was performed on the
same mice 4 weeks post-surgery using a procedure described previously [131].
Biodistribution One week after occlusion, 5 groups of animals were injected with 6.81
± 0.536 MBq of 64Cu-NOTA-PEG4-cRGD2 via the jugular vein and at various time points
(30min n=3, 1hr n=3, 2hr n=3, 4hr n=3, and 24hr n=2), different organs were excised and
subjected to gamma well counting. The mass and radioactivity of tissue sections were assessed
with a Voyager Pro. (Ohaus, USA) and Wizard2 gamma well counter (PerkinElmer, USA)
respectively. The 64Cu signal was then corrected to account for background radioactivity,
radioactive decay of the samples, and tissue weight.
3.2.2 In Vitro Binding Specificity
To validate the specificity of FITC-PEG4-cRGD2 to the αV β3 integrin receptor, human
umbilical vein endothelial cells (HUVECs) were first cultured on coverslips until confluent,
before being fixed using a 4% solution of paraformaldehyde for paired-staining with both
FITC-PEG4-cRGD2 (approximately 1 µM) and PE-labeled αV β3 antibody LM609 (1:100,
R&D Systems, USA). The cells on the coverslips were washed with buffer before and after
each independent hour-long room temperature incubation, and the coverslips were ultimately
mounted to microscope slides using DAPI Fluoromount (Southern Biotech). An Axiovert
200M inverted fluorescence microscope (Zeiss, USA) was then used for imaging (employing
the 10x and 20x objectives). Finally, the images were analyzed using the ZEN 2012 software
package (Zeiss, USA).
Because diabetes is characterized by high blood glucose levels, which could potentially
modify the structure of αV β3 via glycosylation and alter ligand-receptor interactions, I
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performed additional experiments to assess cellular binding of PEG4-cRGD2 under high-
glucose conditions. HUVECs were cultured in high-glucose (14 mM) growth media for 24
hours before incubation with FITC-PEG4-cRGD2 (0-1 µM) at 4
◦C for 2 hours. A control
group was cultured in normoglycemic (5.5mM) growth media followed by incubation with
FITC-PEG4-cRGD2. Binding of FITC-PEG4-cRGD2 to αV β3 integrin was assessed using
flow cytometry (LSR II Flow Cytometry Analyzer, BD Biosciences, USA).
3.2.3 In Vivo Imaging of PAD Associated Angiogenesis
One week after occlusion, DM and non-DM mice (n=15) were injected with 6.81 ± 0.536 MBq
of 64Cu-NOTA-PEG4-cRGD2 via the jugular vein and 60 minutes later in vivo microPET-CT
imaging was performed using a small animal dedicated Inveon system (Siemens Healthcare
USA). An additional group of non-diabetic mice (n=4) was injected with 7.21 ± 2.31 MBq
of 64Cu-acetate to study differential organ biodistribution of 64Cu-NOTA-PEG4-cRGD2.
Animals were placed on a polyacrylic bed in the supine position with legs secured in an
extended position. Mice underwent X-ray microCT imaging (80kVp, 500µA, 100µm spatial
resolution) followed by 15 min microPET imaging (15% energy window centered at 511
keV). All mice were euthanized immediately after last imaging session was completed and
tissue samples were taken for gamma well counting and snap-frozen in liquid nitrogen for
immunofluorescence analysis.
Image Analysis The microPET and microCT images were reconstructed using the
OSEM/3D algorithm (Siemens Healthcare USA) and the cone-beam technique (Cobra Exim),
respectively. MicroPET images were fused with microCT images and quantified using a
semiautomated approach developed and evaluated previously [132]. Briefly, complex irregular
volumes of interest (VOIs) were generated from the microCT images the proximal region was
selected above the knee and near the ligation site where as the distal area was below the knee.
The VOI’s were applied on the co-registered microPET images to calculate absolute 64Cu
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activities using the Inveon Research Workplace (Siemens Healthcare USA). These complex
VOIs included only soft tissue (skeletal muscles) after the removal of bone structures during
the image segmentation process. To validate the accuracy of the quantitative targeted imaging
approach, image-derived results were compared with the gamma well counting analysis of the
corresponding tissue samples.
3.2.4 Postmortem Analysis
Gamma Well Counting Skeletal muscles from both the ischemic and non-ischemic
hindlimbs were excised and separated into distal and proximal sections based on the lo-
cation of the ligature in the ischemic limb and anatomical landmarks in the non-ischemic
limb. The mass and radioactivity of tissue sections were assessed with a Voyager Pro. (Ohaus,
USA) and Wizard2 gamma well counter (PerkinElmer, USA) respectively. The 64Cu signal
was then corrected to account for background radioactivity, radioactive decay of the samples,
and tissue weight.
Histology and Immunofluorescence Ischemic and non-ischemic hindlimb sections col-
lected from diabetic and non-diabetic animals were embedded in the Optimal Cutting
Temperature (OCT) compound. The embedded tissue sections were then snap frozen in
liquid nitrogen and cut into 5µm sections using a cryotome. The cut sections were then fixed
in ice-cold acetone and stained with either a Cy-5 fluorescent endothelial cell marker (CD31,
EMD Millipore, USA), FITC-PEG4-cRGD2 (1µM), and inflammatory markers APC-CD14
(Santa Cruz Biology,USA), and PE-CD74 (R&D, USA). The stained sections were then
relocated to an incubator and allowed to incubate overnight. After incubation, the stained
sections were mounted using DAPI fluoromount (Southern Biotech, USA) and images were
acquired using a fluorescent microscope (Zeiss Axiovert 200M) at both 10x and 20x objectives.
For processing, the acquired images were assessed using Zeiss Zen Blue software for the total
area positively stained in several randomly chosen (200 ×) fields. This software was validated
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in a previous study conducted by our group [123]. Acquired stained images of the sections
were assessed for co-localization between the different fluorescent antibodies (PE-CD74,
APC-CD14, and Cy-5-CD13) and the FITC-PEG4-cRGD2. Different antibody channels were
separated and quantified using an ImageJ-plugin (Coloc2) to obtain the Pearson’s correlation
coefficient. This assessment was repeated for each of the images randomly chosen for percent
positive area quantification.
3.2.5 Statistical Analysis
The Student t test was used to compare 2 groups DM vs non-DM. One-way ANOVA was
used to compare multiple parameters. A value of P < 0.05 was considered significant.
3.3 Results
3.3.1 Radiochemical purity and stability of the cRGD probes
The radiochemical purity of 64Cu-NOTA-PEG4-cRGD2, determined in both pH 7.4 PBS
and blood plasma using C-18 RP-HPLC, was > 95% up to 24 hrs after labeling [5]. The
probe’s fluorescent analogue, FITC-PEG4-cRGD2, demonstrated similarly high stability in
both media (data not shown).
3.3.2 Animal model of peripheral angiogenesis in diabetes
Changes in blood biomarkers between 2 and 6 weeks after DM induction DM
was introduced in a subset of mice through streptozotocin (STZ) treatment. After induction, I
measured three key DM biomarkers: circulating blood glucose, GSP, and HbA1c blood levels.
I detected a change in all three markers as early as two weeks after STZ administration. While
I found no significant change in glucose level between weeks 2 and 6, I saw a significant surge
in GSP and HbA1c levels (3 and 1.3-fold, respectively, see Figure 3.1). These results indicate
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that many important diabetes-associated physiological changes can take up to 6 weeks to
manifest in the murine model, and as such, I opted to conduct the in vivo experiments 6
weeks after STZ treatment.
Validation of the animal model of peripheral ischemia The right femoral arteries
of the animals were surgically ligated in order to model peripheral vascular occlusion. This
resulted in distal ischemia followed by the initiation of both the angiogenic and arteriogenic
processes. Microfil casting and tissue clearing techniques were used in a subset of animals to
visualize the location of the occlusion and the predicted ischemic area in relation to other
anatomical structures (see Figure 3.2). To verify the completeness of the surgical ligations,
I performed Laser Doppler imaging of peripheral perfusion. Immediately after the surgery
I observed dramatic reduction (> 80%) in blood perfusion within the ischemic hindlimb,
which was partially recovered at 1 week after the ligation (see Figure 3.2). Based on this
observation, and results published previously [5], I used the 1 week time point to study the
differences in peripheral angiogenesis in the DM and non-DM mice.
3.3.3 Properties Of FITC-PEG4-cRGD2–αV β3 binding In a
high-glucose microenviroment
The specificity of the probe was assessed by co-incubating FITC-PEG4-cRGD2 and the com-
mercially available phycoerythrin-labeled αV β3 antibody, PE-LM609. For these experiments
I used human umbilical vein endothelial cells (HUVECs), which are known to constitutively
express αV β3. As shown in Figure 3.3 there is a strong colocalization between the fluorescein
and phycoerythrin signals. This is in accordance with the previously published studies
showing a high correlation between FITC-PEG4-cRGD2 and PE-LM609 fluorescence using
single cell flow cytometry [5].
Of particular importance to imaging αV β3 expression in DM patients is to determine
whether a high-glucose environment can affect the αV β3 receptor’s binding properties. To
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Figure 3.1: Characterization of diabetes-associated blood markers. (A) Glucose level was
found to rise as soon as 2 weeks after induction of diabetes, but no further increase was
found at the 6 week time point. (B) Glycated serum protein (GSP) showed an increase at 2
weeks, and surged dramatically by week 6. (C) Glycated hemoglobin A1c (HbA1c) increased
consistently over the 6 week time frame.
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before surgery
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A. B.
Figure 3.2: Surgical model of murine hindlimb ischemia. (A) Animals underwent surgical oc-
clusion of the right femoral artery by placing two ligatures distal to profundus branch inducing
unilateral hindlimb ischemia (bottom, yellow arrow). Placement of ligatures (top,black arrow)
and vascular occlusion was visualized with the Microfil casting and tissue clearing technique.
(B) The surgery resulted in an immediate decrease in perfusion in ischemic hindlimb with a
partial recovery at 1 week after the surgery, as assessed using Laser Doppler flowmetry.
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Figure 3.3: Colocalization of FITC-PEG4-cRGD2 and LM609 to human umbilical vein
endothelial cells (HUVECs) expressing αV β3 integrin. (A) Incubation of HUVECs with 1 µM
FITC-PEG4-cRGD2 (green) and phycoerythrin-conjugated LM609 (1:100, red). The high
degree of overlap indicates specific binding of the probe to αV β3. (B) HUVECs incubated
for 24 hrs in low-glucose (5.5mM) or high-glucose (14mM) medium did not result in any
significant differences in FITC-PEG4-cRGD2 uptake, as assessed by flow cytometry.
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exclude this possibility, I incubated HUVECs with the FITC-PEG4-cRGD2 in growth media
supplemented with 14 mM glucose. Comparison with a control HUVECs cultured in normal
growth media showed no significant difference in FITC-PEG4-cRGD2 uptake under elevated
glucose conditions (see Figure 3.3). This observation indicates that any differences in the
uptake of the imaging probe that arise between diabetic and non-diabetic animals is likely
due to changes in αV β3 integrin expression/activation levels and not glycation-associated
modification of the vitronectin receptor.
3.3.4 Pharmacokinetics and biodistribution
To demonstrate that the radiotracer exhibits favorable organ retention for the purpose of
imaging peripheral angiogenesis, I performed comparative biodistribution studies using both
targeted 64Cu-NOTA-PEG4-cRGD2 and the non-targeted
64Cu-acetate as control. Figure
3.4 shows the difference in the biodistribution profiles of both radiotracers. As expected,
non-targeted 64Cu-acetate demonstrated increased uptake in all organs (including blood)
with a very high uptake (> 20%I.D./g) in the liver, gallbladder, kidneys, and intestines due
to non-specific affinity to tissue proteins. In contrast, 64Cu-NOTA-PEG4-cRGD2 uptake
was significant in the gallbladder, kidney cortex and intestines. In addition, PET imaging
revealed that 64Cu-NOTA-PEG4-cRGD2 cleared rapidly from the blood (contributing to an
overall low background) and was excreted predominantly by kidney filtration.
We performed additional biodistribution studies of 64Cu-NOTA-PEG4-cRGD2 at a series
of time points (30 min, 1 hr, 2hr, 4h and 24hr after injection) to evaluate the clearance of
the probe and establish the optimal post-injection timing for a PET-CT scan (see Figure
3.5). I found that PET imaging at 1-2 hours post injection resulted in the optimal blood
clearance and uptake within the ischemic muscle.
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64Cu-acetate
64Cu-PEG4-cRGD2
Figure 3.4: Organ-specific uptake (right, assessed using PET-CT) and biodistribution (left,
assessed using gamma well counting) of 64Cu-NOTA-PEG4-cRGD2 and the non-targeted
64Cu-acetate one hour after jugular vein injection demonstrates a favorable biodistribution
and optimal retention for targeted in vivo imaging of peripheral angiogenesis.
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Figure 3.5: Biodistribution of 64Cu-NOTA-PEG4-cRGD2 at various time points after injection.
At the 30 min time point, the probe was mainly in the bloodstream, while the one and two
hour time points showed the greatest accumulation in the distal ischemic tissue. Later time
points showed little accumulation in the ischemic limb, and largely resembled the non-ischemic
tissue. These results indicate the optimal time point for imaging is between one and two
hours after administration of the tracer.
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3.3.5 PET-CT imaging analysis versus gamma well counting
Representative PET-CT images of peripheral angiogenesis acquired 1 week after surgical
ligation are shown in Figure 4.7. Confirmed by biodistribution studies, PET-CT images
obtained 1 hr after intravenous injection of the radiotracer were of excellent quality and
demonstrated “hot spots”—of increased 64Cu-NOTA-PEG4-cRGD2 uptake within the ischemic
hindlimb—whereas the non-ischemic muscle showed no significant uptake. Moreover, VOI-
based image analysis of PET-CT images (see Figure 4.7) correlated well (R2=0.9602) with
postmortem 64Cu-NOTA-PEG4-cRGD2 activities in the hindlimb muscle sections measured
using gamma well counting immediately after PET-CT imaging (see Figure 4.7).
3.3.6 Diabetes-associated reductions in αV β3 can be monitored
non-invasively using 64Cu-NOTA-PEG4-cRGD2
Most importantly, I found a significant (P < 0.05) reduction of 64Cu-NOTA-PEG4-cRGD2
uptake in all muscle segments (distal and proximal) of diabetic animals when compared
to the non-diabetic control segments (see Figure 3.7). Quantitative analysis of PET-CT
images confirmed this result, indicating that DM mice had significantly lower %I.D./g in their
distal ischemic tissue than non-diabetic mice. PET imaging showed a significant increase
in the retention of 64Cu-NOTA-PEG4-cRGD2 in the ischemic (relative to non-ischemic)
hindlimbs, which demonstrates the probe’s specificity to areas of active angiogenesis and
αV β3 expression. Together, these findings indicate that molecular imaging with
64Cu-NOTA-
PEG4-cRGD2 is suitable to quantitatively asses different angiogenic responses in DM and
non-DM environments.
In order to investigate the physiological effects that are associated with αV β3 expression
in both DM and non-DM mice, I evaluated tissue samples collected from all animals. Both
ischemic and non-ischemic distal hindlimb muscle sections were stained with FITC-PEG4-
cRGD2, Cy-5 labeled endothelial cell marker (CD31), CD14 (a marker mostly associated with
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Figure 3.6: PET-CT imaging analysis. (A) Representative in vivo PET-CT images of
peripheral angiogenesis 1 week after surgical ligation of the right femoral artery. One
hour after intravascular injection of 64Cu-NOTA-PEG4-cRGD2 a significant uptake of the
radiotracer (“hot spot”) was observed in the ischemic hindlimb. (B) For the image analysis,
volumes-of-interests (VOIs) were drawn on CT images of ischemic and non-ischemic hindlimbs
(left) followed by segmentation of hindlimb muscles (middle). These irregular VOIs were
placed on PET images to calculate the radiotracer’s uptake (expressed in %I.D./g tissue,
right). (C) Correlation between the two methods (PET-CT and gamma well counting) used to
measure radiotracer uptake in mice hindlimbs showed a strong linear correlation (R2 = 0.9602,
solid line).
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Figure 3.7: Analysis of 64Cu-NOTA-PEG4-cRGD2 retention in the hindlimbs of DM and
non-DM mice 1 week after surgical ligation of the right femoral artery. Overall there was a
significant (#P < 0.05) increase in 64Cu-NOTA-PEG4-cRGD2 retention in the distal segments
of the ischemic relative to the non-ischemic hindlimbs, as well as a significant (∗P < 0.05)
decrease in the distal ischemic hindlimb of DM mice compared to non-DM controls.
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macrophages and dendritic cells), or CD74 (a cell surface receptor expressed by macrophages
and endothelium cells which has been linked to reperfusion after vascular injury [133]).
Representative immunofluorescence images taken from DM and non-DM mice are shown in
Figure 3.8 A, B, C. I found CD31 positive endothelial cells within the capillaries and small
arterioles of the non-diabetic ischemic hindlimb sections, which correlated with high αV β3
expression. By comparison, the DM mice showed significant reduction in CD31 positive
staining and FITC-PEG4-cRGD2 (3.5- and 3.8-fold respectively) in their ischemic muscle
tissues, suggesting both a reduction in capillary density and decreased αV β3 expression in DM
animals relative to the non-DM controls. I found as well that DM mice showed a statistical
significant reduction (3.2 and 4 fold) for both CD14 and CD74 respectively as shown in Figure
3.8 A, B. These results demonstrate the dynamic changes in the DM microenvironment. I
performed additional histology studies to determine the extent of co-localization between
the FITC-labeled probe and CD14 or CD74. The FITC-PEG4-cRGD2 showed a modest
degree of co-localization (Pearson coefficient of 0.50) with the labeled CD14, but a much
stronger correlation (Pearson coefficient of 0.71) with the labeled CD74 see Figure 3.8 D.
This supports the idea that the probe is effectively targeting regions of active angiogenesis
and vascular repair. As expected, the greatest degree of co-localization occurred with CD31
(correlation coefficient of 0.765), indicating that the probe targets endothelial cells much more
strongly than macrophages, dendritic cells, or other cell types associated with the ischemic
response. Finally, I also found that both CD14 and CD74 staining were significantly reduced
in DM relative to non-DM ischemic tissues (by about 3.2 and 4.0 fold, respectively). This
once again underscores the negative impact of DM on vascular regeneration.
3.4 Discussion
The study presented here focuses on finding an optimal animal model for the study of PAD
and the feasibility of assessing diabetes-associated differences in peripheral angiogenesis using
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Figure 3.8: Representative cross sections taken from ischemic lower hindlimbs of both DM
(left) and non-DM (right) mice 1 week after femoral occlusion. (A) Sections were stained with
inflammation marker CD14 (red) and co-stained with DAPI (blue) to visualize nuclei. (B)
Sections were stained with reperfusion marker CD74 (red) and co-stained with DAPI (blue) to
visualize nuclei. (C) Sections were stained with endothelial marker CD31 (red) and co-stained
with DAPI (blue) to visualize nuclei. (D) Sections were stained with CD14, or CD74, or CD31
(red) and fluorescent analogue FITC-PEG4-cRGD2. Fluorescence quantification showed
a reduction in both capillary density (CD31 staining), inflammation (CD14), reperfusion
(CD74), and FITC-PEG4-cRGD2 (αV β3) retention in DM animals when compared with
non-DM controls ∗P < 0.05. I found a strong correlation between CD31, CD74 and FITC-
PEG4-cRGD2, and a modest degree of co-localization between CD14 and FITC-PEG4-cRGD2.
92
a 64Cu labeled dimeric cyclic RGD-based PET-CT probe targeted at αV β3. The design of the
probe benefitted from years of prior results; it is characterized by high chemical stability, a
favorable biodistribution, and a focal retention that results in an excellent quality of obtained
images. 64Cu was chosen as a PET imaging isotope due to its relatively easy chemistry,
the availability of strong chelators capable of providing a firm backbone for the radioactive
label, and the potential for clinical translation due to its relatively long half-life (∼ 12.7
hours). Furthermore, a fluorescent analogue of the targeted tracer (FITC-PEG4-cRGD2), was
developed and successfully used for in vitro studies in cell and tissue samples. The availability
of this type of dual-modality probe may allow for future clinical translation in the field of
image-guided surgery or intraoperative microscopy.
The αV β3-targeted probes used in this study have been characterized our group in detail
previously [5]. Briefly, in order to verify its specificity and cellular binding kinetics, I evaluated
the colocalization of FITC-PEG4-cRGD2 with the αV β3-specific antibody LM609 in cultured
integrin-expressing endothelial cells (HUVECs, chosen because there are no mouse-specific
antibodies for αV β3). Importantly, because diabetic animals are known to have uncontrollably
high circulating glucose levels (which can alter the endothelial microevironment, induce
conformational changes in the vitronectin receptor, and possibly impact other receptor-ligand
interactions), in the present work, I also investigated the binding affinity of FITC-PEG4-
cRGD2 in a high-glucose environment. I observed no significant change across a range of
probe concentrations spaning from 0.01 to 1 µM. This indicates that the differences in the
angiogenic response I observed between diabetic and non-diabetic mice were associated with
physiological changes due to changes in αV β3 expression and not the binding affinity of the
probe. Intriguingly, I note a relative decrease in probe accumulation in the non-ischemic
diabetic limbs relative to the non-diabetic limbs. Because the binding affinity of the probe is
unaffected by a high-glucose environment, I attribute this to a decrease in αV β3 expression
in the diabetic animals.
Following the in vitro applications, I evaluated the specificity of the probe in vivo. The
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labeling protocol I use involves first dissolving 64Cu in acetate buffer, and then combining
that with a solution of the unlabeled probe. It is therefore important to show that labeled
acetate exhibits no obvious accumulation in ischemic tissue. I subjected animals to a surgical
femoral artery ligation and injected them with either 64Cu-NOTA-PEG4-cRGD2 or the
non-specific 64Cu-acetate. I found a greater accumulation of 64Cu-NOTA-PEG4-cRGD2
in the ischemic hindlimb relative to the non-ischemic hindlimb while 64Cu-acetate showed
comparable accumulation in both limbs paralleled by strong uptake in other organs. This
further verifies the suitability of the 64Cu-NOTA-PEG4-cRGD2 for in vivo targeted imaging
of angiogenesis.
In order to establish that the animal model used in the investigations faithfully mimics
diabetes-associated pheripheral ischemia in human patients, I measured a number of important
diabetic markers in experimental animals. The animals were first treated with STZ for three
days which resulted in significant increase of circulating blood glucose levels. In humans, this
can caused changes in both the short term (altering the expression levels of several proteins)
and long term (giving rise to glycosylated hemoglobin) [134, 135]. These animals showed
similar clinical signs of short- and long-term effects, including enhanced GSP and HbA1c
levels (taking about 6 weeks after STZ treatment to fully materialize). Moreover, these
enhancements were found to correlate with the decrease in angiogenic response confirmed with
PET-CT imaging. Taken together, these findings represent an important part of establishing
the utility of the model for the study of diabetes-associated vascular complications.
We next sought to establish the optimal time point for PET-CT imaging after adminis-
tration of the 64Cu-NOTA-PEG4-cRGD2 by performing biodistribution studies at various
time points after injection of the radiotracer. I found a time interval between 1 and 2 hours
to be optimal, demonstrating low blood activities and significant accumulation within the
ischemic tissue. I found that the main excretion route was via the bladder, which is favorable
for probes with translational applicability because it avoids accumulation within the digestive
track, and poses relatively little risk to other organs.
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We validated the results from the PET-CT imaging and quantitative image analysis by
postmortem evaluation of the radioactivity of excised tissues using gamma well counting.
Gamma well counting is traditionally considered a “gold-standard” technique that enables
measurement the absolute values of radiotracer activity. It is immune to several limitations
that image-based whole body analyses face, including the partial volume effect and tissue
attenuation. Unfortunately, gamma well counting is highly invasive, the animals need to be
euthanized and tissues samples collected postmortem. I found a strong positive correlation
between the image-based analysis and gamma well counting results. As expected, uncorrected
PET-CT image analysis tended to underestimate the magnitude of the absolute 64Cu-NOTA-
PEG4-cRGD2 uptake (expressed as %I.D./g) which I attribute predominantly to partial
volume errors (tissue attenuation is negligible in small animals), detector sensitivity and
different energy ranges. This discrepancy could be potentially eliminated using partial volume
correction techniques, normalization of detector efficiency and allowing comparable energy
ranges.
The results of the PET-CT study strongly suggest reduced αV β3 activity in the onset of
diabetes, which negatively affects the angiogenic process. This observation is further verified
by immunofluorescence staining in which diabetic tissues showed a significant reduction in the
expression of CD31, CD14, and CD74 (markers of endothelial cells, macrophages, dendritic
cells, and vascular repair) and retention of FITC-PEG4-cRGD2. This finding is in agreement
with studies performed previously by the group using both SPECT and PET cRGD-based
tracers, and by others using more invasive techniques [136]. Diabetes-induced impairment
of collateral blood vessel formation has also been demonstrated in other preclinical animal
models of diabetes [5, 137].
While the underlying causes are not completely understood, attenuated angiogenesis in
diabetes has been linked to improper degradation of the basement membrane, to alterations
in the delicate balance of growth factors and cytokines that regulate vascular stability, and
to problems in signal transduction including VEGF dysregulation (as shown by reduced
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expression of VEGF mRNA and protein) [136]. Rivard et al. in particular, demonstrated
that hindlimb ischemia created by ligation of the femoral artery was associated with a greater
reduction in capillary formation and blood flow to the ischemic limb in diabetic transgenic
mice (NOD) relative to non-diabetic (C57) wild type mice. In these studies, NOD mice
showed a much lower rate of perfusion (ischemic limb to normal limb) 14 days following
femoral artery ligation and a reduction in capillary density in ischemic hindlimb muscles at
35 days when compared with healthy littermates [136].
Although others have investigated the effects of diabetes on neovascularization, most
have relied on invasive assessment techniques with little applicability in the clinical setting.
Due to its non-invasive nature, PET-CT imaging represents a powerful tool for studying the
vascular complication of diabetes, in the laboratory, and perhaps some day in the clinical
practice. The ability to image active angiogenesis may enable earlier detection of vascular
pathologies, and better evaluation of treatment options for patients with peripheral arterial
disease. These could lead to more personalized therapeutc interventions and ultimately better
patient outcomes.
3.5 Conclusions
Diabetes is known to cause severe vascular complications that can lead to debilitating injury,
and in some cases even death. While early detection of these complications remains a
challenge, new methods involving focused regional PET-CT acquisitions of αV β3 activity are
showing promise as a means of assessing tissue angiogenesis in vivo. I have demonstrated
this promise using a new molecular probe to image neovascularization within ischemic tissue
in diabetic and non-diabetic mice. To achieve that goal I established an optimal animal
model to mimic PAD in DM patients. This approach enables a quantitative spatio-temporal
characterization of αV β3 activity that may one day allow for the real-time evaluation of
the therapeutic efficacies of different medical interventions (medicinal, surgical, or emerging
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genetic or cell-based interventions). The dimeric cRGD-based imaging probe displays intense
focal retention, leading to in vivo acquisitions of superior image quality. Coupled with
favorable blood clearance kinetics and optimal biodistributions, its potential for clinical
use in imaging and monitoring angiogenesis in patients with peripheral vascular disease is
significant.
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Chapter 4
Multidimensional Assessment of
PAD †
4.1 Introduction
The main function of the cardiovascular system is to provide the tissues of the body with
well-perfused vascular beds capable of delivering vital oxygen, nutrients, humoral agents, the
collecting and removing metabolic waste [138,139]. Angiogenesis, the process by which new
vessels are formed from preexisting ones, is involved in the maintenance of these vascular beds,
as well as a wide range of other biological processes—both benign and pathological—including
vascular remodeling, wound healing, endometriosis, and cancer [22, 24, 25,140].
Peripheral arterial disease (PAD) is characterized by a progressive arterial stenosis often
leading to the occlusion of the peripheral arterial bed, and is associated with an elevated risk
of cardiovascular and cerebrovascular events. Although approximately 27 million people in
Europe and North America have the disease, PAD still remains largely underdiagnosed [141].
As PAD progresses, the narrowing vasculature reduces blood flow to the periphery, resulting
in a decreased perfusion and increased hypoxia. These changes in microenvironmental
conditions can in turn activate one or both of the primary revascularization pathways.
Angiogenesis, which is triggered under hypoxic conditions, leads to the formation of new
capillary beds from preexisting vessels. It is a dynamic and complex multistep process,
which requires endothelial proliferation and remodeling, an interplay of various pro- and anti-
†Work includes material incorporating contributions from Jamila Hedhli MinWoo Kim, Hailey J. Knox,
Than Huynh, Matthew Schuelke, Iwona T. Dobrucki, Leszek Kalinowski, Jefferson Chan, Albert J. Sinusas,
Michael F. Insana, Lawrence W. Dobrucki.
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angiogenic factors, and interactions among endothelial cells, extracellular matrix (ECM) and
smooth muscle cells [128]. Arteriogenesis, which is triggered by changes in the biomechanical
properties of the vasculature as a result of decreased blood flow, leads to the enlargement of
preexisting arteriolar connections in order to establish collateral circulation.
Despite significant progress, a complete understanding of the complex web of interactions
that mediate the angiogenic and arteriogenesis responses remains elusive. This is not for lack
of effort; a large and growing list of experimental techniques have been brought to bear over
the last decades, each illuminating its own piece of the larger puzzle. Traditional molecular and
cellular biology methods have elucidated many biochemical details of intracellular angiogenic
signalling [62, 142,143], while more physiologically-minded approaches, such as measurement
of blood flow, blood volume, and vessel permeability, have been used to characterize hypoxia-
induced angiogenesis at the tissue level and in whole animal [4, 144,145].
Of particular importance, the past several years have revealed new methods for the
non-invasive in vivo imaging of peripheral vasculature. These include major advances aimed
at imaging blood perfusion using ultrasound (US) [3, 146], photoacoustic imaging (PA) [147],
and laser speckle contrast imaging (LSCI) [148], as well as quantitative molecular imaging
approaches using radiolabeled probes targeted at specific angiogenic biomarkers such as matrix
metalloproteinases, VEGF isoforms, and αV β3 integrin [5, 60, 89, 102,107,122,127,149,150].
While each of these imaging modalities is powerful on its own, and capable of providing
functionally relevant windows into the molecular and physiological processes in both animals
and humans, their greatest potential lie in their combined use as part of a broader multimodal
imaging strategy. A 2008 review by Cai et al. highlighted the importance of such a multimodal
approach, and predicted that the future of angiogenesis research rests in the combination
of multiple imaging modalities yielding a synergistic and complementary view [129]. This
vision was recently realized in the recent study [2], in which LSCI was paired with targeted
PET-CT imaging of αV β3 to demonstrate multifaceted actions of mesenchymal stem cells
resulting in an increase of angiogenesis and blood perfusion recovery in a murine model of
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peripheral arterial disease (PAD).
Understanding both the progression of PAD and the bodily response to the disease, requires
the simultaneous evaluation of several interrelated molecular, anatomical, and functional
parameters, all within a living subject. These parameters include various gene expression,
blood perfusion, and oxygenation levels in different muscle tissues. In this article, I employ
an integrated multimodal approach to study PAD with SPECT imaging using two molecular
probes targeted at HIF-1α and αV β3, as well as high resolution Ultrasonic Power Doppler,
PA, and LSCI for perfusion and blood oxygenation imaging. Combined, these methods offer
a unique profile of hypoxia-induced angiogenesis that ties together the roles of a key regulator
(HIF-1α), one of its biologically-important targets (the αV β3 integrin), and the effects of
their combined activity on angiogenesis, perfusion, and tissue oxygenation. In addition, this
study also reports on one of the first preclinical uses of label free power Doppler US for blood
flow imaging [3], with improved sensitivity to enable greater differentiation between fast
(arterial) and slow (capillary) flows. Once developed, this technology may allow for routine
assessments of microvascular health by primary care professionals, and ultimately, improved
patient management leading to better outcome.
4.2 Methods
Our research plan is outlined in Figure 4.1. Briefly, 4 to 6 week old mice were subjected to
the right femoral artery ligation to induce peripheral ischemia. Animals were imaged serially
with several modalities at various time points to investigate spatiotemporal changes within
the ischemic microenvironment.
4.2.1 Animals
All experiments were performed according to the guiding principles of the American Physio-
logical Society and approved by the Institutional Animal Care and Use Committee.
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Figure 4.1: Study overview. The right femoral artery was ligated to mimic PAD. The animals
were serially evaluated for αV β3 and HIF-1α (using SPECT), measures of blood perfusion
(using US, LSCI, and PA). At days three, seven and 14, skeletal muscle tissue was extracted
for immunohistochemistry experiments (denoted Tissue).
Induction of unilateral hindlimb ischemia via surgical ligation of the right femoral artery
to was performed according to procedures described previously [123]. Briefly, 29 male black
C57BL/6 mice (Charles River Laboratories, US) were anesthetized with 1-3% isofluorane.
The right femoral artery was exposed and two ligatures were placed distally to the profundus
branch and proximally from the artery bifurcation. On the opposite leg, a sham operation
was performed which included a skin incision, and exposure of the left femoral artery, but
no ligatures were placed. The surgical model used in all experiments resulted in small
postoperative wounds with minimal inflammation, and the formation of collaterals between
several proximal vessels including the profundus branch and the distal section of the femoral
artery. The mice were allowed to recover for serial scintigraphic imaging of αV β3 integrin
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and hypoxia.
4.2.2 Ultrasound Imaging
A subset of seven (n=7) animals were used for perfusion assessment employing US. Mice
were placed in a supine position on a heating pad set to 37 ◦C, and both hindlimbs extended.
Animals were imaged prior to ligation surgery and at a series of post-operative time points
(10, 20, 30, 40, 50, and 60 minutes, and 1, 2, 7, and 14 days). Echo data were acquired
using a Vevo 2100 system and an MS 400 linear-array transducer (FUJIFILM VisualSonics
Inc. Toronto, Ontario, Canada). The transducer, emitting 2-cycle pulses with a 24 MHz
center frequency, was positioned on an ischemic region of each animal’s hindlimb. The focal
depth was set between 4–6 mm, and the aperture size was adjusted to maintain f/2. A
color-Doppler acquisition frame included a packet size of 17 pulses transmitted at a time
interval of 1 ms giving a slow-time pulse repetition frequency (PRF) of 1 kHz. For each pulse
transmission, beam formed IQ echo data were recorded for off-line analysis. The scan-lines
were separated laterally by 0.06 mm. For each animal, 100 Doppler frames were recorded
with a frame-time interval of 0.11s. The complex-valued IQ echo data are represented by 3-D
data array, X ∈ CN×S×K , where N , S and K are the numbers of slow-time samples, spatial
samples, and frames, respectively (see Figure 4.2).
A filtering procedure can then be applied in order to isolate blood components from
unwanted clutter (e.g. surrounding tissue motion and acquisition noise). I adopt a block-wise
method to enhance the filter performance. This technique is robust to the high degree of
complexity associated with the spatiotemporally-varying characteristics of the data sources.
The full data array X are divided into overlapping sub-arrays X˜j ∈ C
N˙×S˙×K˙ , j ∈ {1, · · · , J},
where J is the total number of blocks. Each sub-array is individually processed by a higher-
order singular value decomposition (HOSVD) technique to detect the local perfusion. The
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Figure 4.2: Ultrasound imaging and data analysis protocol. An anesthetized mouse is placed
in a supine position and its right femoral artery is ligated to induce ischemia. Without
contrast-enhancement, standard Doppler ultrasound acquisition results at 24MHz in 3D
data array involving spatial, slow-time (kHz-order sampling rate), and frame-time (Hz-order
sampling rate) axes. The data array is divided into sub-blocks and each data block is
individually processed by the HOSVD methodology [3] to detect local blood perfusion.
HOSVD of X˜j is expressed as
X˜j =
∑
(i1,i2,i3)∈Ω
gi1,i2,i3ui1 × vi2 ×wi3 , (4.1)
where Ω signifies full space and × is an outer-product operation. The vectors ui1 , vi2 and wi3
are i1, i2 and i3th eigenvectors for the slow-time, spatial and frame-time modes, respectively.
The new coordinates, by means of combination of the eigenvectors, naturally give rise to a
separation of the sources through their statistical independence. gi1,i2,i3 is associated with
signal power at (i1, i2, i3)th coordinates. The filtering is performed by selecting the subspace
where blood dominates and rejecting the rest where clutter and noise dominates. The process
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can be expressed as
B˜j =
∑
(i1,i2,i3)∈B
gi1,i2,i3ui1 × vi2 ×wi3 , (4.2)
where B˜j is the filtered data and B is the blood subspace. The subspace is roughly determined
by prior knowledge of properties of the sources. The optimal one is empirically selected
by comparison of the resulting image contrast. The local spatial perfusion is estimated by
averaging signal power |B˜j|
2 over slow-time and frame-time axes, and converting the result
to dB-scale. The final image is obtained by compounding all J local estimates (Figure 4.3).
See the table 4.1 summarizing all parameter values.
Parameter Value
Axial (fast-time) samples (M) 200-272
Axial sampling rate 24.0 MHz
Axial size 6.4-8.7 mm
Slow-time samples (N) 17
Slow-time sampling rate 1.0 kHz
Frame-time samples (K) 100
Frame-time sampling rate 9 Hz
Scan-line numbers (L) 240-250
Scan-line density 16.67 lines/mm
Lateral size 14.4-15.0 mm
Spatial samples (S=LM) 48000-68000
Sub-block size (N˙×S˙×K˙) 17×768×30
Slow-time division (J1) 1
Spatial division (J2) 1600
Frame-time division (J3) 10
Sub-block numbers (J=J1J2J3) 16000
Table 4.1: Parameters
4.2.3 Laser speckle contrast imaging
Seven (n=7) animals imaged previously with ultrasonic Power Doppler were also scanned
using laser speckle contrast imaging prior to ligation surgery and at a series of post-operative
time points (10, 20, 30, 40, 50, and 60 minutes, and 1, 2, 7, and 14 days). Images were obtained
104
Average Average
+
+-
Sample	Mean	&	SEM
Pre-ligation Post-ligation
US LSCI
Pre-ligation Post-ligation
Average Average
Ratio
Average Average
Ratio
+
Sample	Mean	&	SEM
1
- +
+
𝑝"# 𝑝$#
𝑞$#
𝑟"# 𝑟$#
𝑔$#
Right Left
1 2 M… i
0
-5
1 2 M… i
1
0
d
B
R
a
ti
o
Figure 4.3: Perfusion quantification using US and LSCI. US and LSCI images were obtained
at multiple time points before and after femoral artery ligation. The white rectangular
windows in the images represent individual ROIs over which perfusion was averaged. In the
US images, the difference between the pre- and post-operative state was computed for each
mouse sample. Subsequently, the mean and SEM of this difference was plotted at each time
point. The graph shows 0 dB pre-ligation (i = 1) as a reference, and the relative changes for
all post-ligation timepoints (i > 1). In the LSCI images, the ratio between an ischemic right
hindlimb region and its corresponding healthy left hindlimb region was computed, and their
difference (plus unity, such that all values are relative to 1) was plotted.
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using a moorFLPI-2 laser perfusion imager (Moor Instrument, UK) operated from a Windows-
based computer system installed with the moorFLPI software (moorFLPI Measurement V3.0,
Moor Instruments, Devon, UK). Before initiating measurements, the laser speckle instrument
was calibrated according to the manufacturer’s recommendations. Then, a divergent beam
(785 nm, near-infrared) illuminated hindlimb tissue to a 1 mm in depth. High-resolution
speckle images were acquired using a 768 × 576 pixel grayscale charge-coupled device camera
set to record each frame for a duration of 60 seconds. In addition, the feet of three (n=3)
mice were imaged prior to surgery and at 1 hr, 1 day, 2 days and 7 days post-surgery. For
collateral circulation assessment, the skin was removed from the right hindlimb of the animal.
The mice were imaged prior to surgery, and subsequently at 2,10, and 25 min post-ligation.
4.2.4 Photoacoustic imaging
Another subset of seven (n=7) mice was used for PA imaging. Each animal, was imaged with
Endra Nexus 128 PA tomographer (Endra, Inc., Ann Arbor, MI, USA) at (20, 30, 40, 50,
and 60 minutes, and 1, 2, and 7 days) post-surgery. Images were acquired at 750 and 850
nm using continuous rotation mode with a 6 second rotation time. A 3D reconstruction was
performed for each image, and signal intensity was accumulated over an 8 mm thick slab.
The signal in each PA image was quantified by determining the mean PA signal in a 2 mm2
region of interest (ROI). A ratiometric signal was determined by taking the ratio of signal
at 750 nm to 850 nm. Data was processed using the freely available Horos software (Horos
Project, https://www.horosproject.org/).
4.2.5 Perfusion trend analysis for ultrasound and laser speckle
contrast imaging
Perfusion images obtained through Power Doppler US were used to track tissue perfusion
changes over the course of two weeks. Through imaging the animal hindlimbs at various time
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points (before and after ligation), I were able to track the average perfusion changes over the
regions illustrated in (Supplementary Data, Figure S1). These regions intentionally exclude
arteries in order to focus on tissue perfusion. The depth of each region was set to less than 6
mm to provide a consistently high echo signal to noise ratio. The average perfusion during
the ith time point in the jth mouse is represented as
pij, i ∈ {1, · · · ,M}, j ∈ {1, · · · , N}, (4.3)
where M and N are the number of time points and mice included in this study, respectively.
We compute the change in perfusion over time as qij = pij − p1j where p1j is the preligation
regional perfusion value. The temporal variation is analyzed by plotting sample mean
q¯i =
1
N
∑N
i=1 qi and standard error of the mean (SEM) q˜i =
√
1
N
√
1
N−1
∑N
i=1(qi − q¯i)
2 for
every time point i.
The trend for LSCI was obtained by a comparable procedure, but I report the ratio of
signal from the right ischemic hindlimb to that of the left control hindlimb:
rij = 〈p
(R)
ij 〉/〈p
(L)
ij 〉 (4.4)
where 〈p
(R)
ij 〉 and 〈p
(L)
ij 〉 are perfusion averages over the boxes on right and left hindlimbs,
respectively. Because the spatial absolute image values are highly sensitive to ambient light
conditions I normalize the perfusion change using gij = rij − r1j + 1 and plot the mean and
SEM for gij at every time point.
4.2.6 Blood oxygenation analysis for Photoacoustic Imaging
Because the oxygenated (HbO2) and deoxegenated (HbR) forms of hemoglobin have different
near-infrared absorbsion properties, PA is able to detect the relative level of blood oxygenation
[151]. Briefly, the amplitude of the acquired PA image describes the local energy absorption
at wavelength λi. This in turn can be expressed as φ(λi, x, y, z), with a spatial average φ¯(λi).
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The contribution of the two forms of hemoglobin to the spatial mean absorption can be
represented as
φ¯(λi) = ǫHbR(λi)[HbR] + ǫHbO2(λi)[HbO2] (4.5)
where ǫHbR and ǫHbO2 are the molar extinction coefficients of HbR and HbO2 at wavelength
λi, respectively. The operator [·] denotes the relative concentration of hemoglobin. The two
concentrations can thus be estimated by a least squares solution as

 [HbR]
[HbO2]

 =
(


ǫHbR(λ1) ǫHbO2(λ1)
...
...
ǫHbR(λL) ǫHbO2(λL)


)†


φjk(λ1)
...
φjk(λL)

 (4.6)
where M † = (MTM)−1MT denotes pseudo-inverse of matrix M . The relative change
in oxygenation is consequently given as η = [HbR]/[HbO2]. Three wavelengths, λ1=750
nm, λ2=800 nm, and λ3=850 nm were used to reduce the estimation error, although two
measurements could have sufficed in order to determine the concentrations. We employed the
table in [152] for corresponding molar extinction coefficients. A total of seven (7) mice were
scanned at several time points before and after ligation. I computed each ratio ηjk where j
and k are indices of the time point and sample, respectively, and finally plotted the sample
mean and SEM for every time point to trace the change.
4.2.7 Serial Scintigraphic Imaging
To uniformly assess the in vivo specificity of the 99mTc-labeled peptides, for the purpose of
PAD imaging, all animals followed a routine setup. Namely, all animals were laid in a supine
position with legs fully extended and immobilized on a polyacrylic board. Animals were then
injected intravenously with 1.5± 0.2 mCi of the targeting agent on 0, 3, 7 and 14 days of
hindlimb ischemia and subjected to dynamic pinhole planar imaging. Planar imaging utilized
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a gamma camera (VariCam, GE Healthcare) set with a large field of view and a pinhole
collimator coupled to a 1-mm aperture and 15% energy window centered at 140 keV. At 75
minutes post-injection of the radiotracer, a static 15-minute image was acquired. Immediately
after the completion of static imaging, all animals were euthanized and tissue samples were
collected for gamma well counting for biodistribution and processed for immunostaining.
4.2.8 Biodistribution
For biodistribution studies, a subset of animals (n=6) for 99mTc-BRU-5921 and (n=5) for
99mTc-NC100692 were euthanized and selected organ samples were collected for gamma
well counting analysis. The weight and the 99mTc radioactivity of each tissue sample was
measured using a gamma well counter (Cobra Packard). The activity measured was corrected
for background, decay time, and sample weight.
4.2.9 Histological Validation
A subset of the animals were euthanized before (control) and at 3, 7, and 14 days after the
surgical ligation of right femoral artery. Their gastrocnemius/soleus muscle complexes were
excised, embedded in TissueTec (Sakura, USA) and snap frozen in -150◦C methylbutane.
Frozen sections (5 nm) were placed on microscope slides, fixed with pre-cooled acetone, and
stored at -80◦C before staining. To evaluate skeletal muscle vascularity, muscle samples
were stained with either an endothelial cell-specific marker anti-mouse CD31 Antibody (BD
Pharmingen) or hypoxia specific marker anti-HIF-1α (BD Pharmingen). To assess probe
specificity (FITC-labeled NC100692), muscle samples were stained with both AlexaFluor647-
labeled anti-αV (Abcam, USA) antibody and FITC-labeled NC100692. All staining procedures
were performed according to the product-specific protocols. The stains for HIF-1α and CD31
were quantified for extent (percentage area) of positive staining in randomly chosen high-
powered (200×) fields using algorithms validated by the group previously [123]. Colocalization
analysis of the histological images was performed using the Fiji image processing package.
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Correlated αV -stained and FITC-labeled NC100692-stained images were analyzed using
the Coloc 2 plugin of ImageJ software package. Using this plugin, Manders’ coefficients
were calculated using Costes method for thresholding [153]. Three images per animal were
analyzed, with four animals per experimental group.
4.3 Results
4.3.1 In vivo assessment of perfusion using US, LSCI, and PA
The primary goal of monitoring the circulatory system using multiple imaging techniques is
to find an accurate, continuous, and non-invasive strategy that can help assess changes in
tissue perfusion and the breakdown of homeostasis. Although several methods have been
established for perfusion imaging in the clinical setting, none by themselves can offer the fine
resolution and variable ranges of depth necessary for detecting microvascular changes. To
bridge this divide I adopted three complementary imaging techniques (US, PA, and LSCI)
with various penetration depth and imaging contrasts (see Table 4.2).
Imaging Modality Depth Contrast Source Pixel/Voxel representation
US (24 MHz) 4-6 mm Endogenous Echo power in dB scale
PA 3-4 mm Endogenous Optical absorption
LSCI 1 mm Endogenous Optical power in flux scale
Scintigraphic Imaging No limit Exogenous Counts per second
Table 4.2: Non-Invasive Imaging in Small Animal PAD model.
These imaging modalities enable us to “connect the dots” between changes in blood flow
through microvascular networks shortly after the onset of ischemia, all the way through to
large-scale changes in blood supply seen days or weeks later (Figure 4.4).
Ultrasound enables estimation of deep-tissue peripheral perfusion For each of
seven experimental mice, US imaging sessions were performed before the surgical ligation,
every 10 minutes after surgery (up to an hour), and at one day, two days, seven days and
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Figure 4.4: Representative multimodal imaging data presented at a series of time points
(prior to and following ligation). Each column shows how a different circulatory parameter
changes over time as the mice recover. The first column highlights perfusion as a series of 10
mm × 15 mm vertical cross-sections of ischemic tissue imaged using US. Prior to ligation,
perfusion generally appears strong, except for the distal regions of the limb where the signal
appears to be diminished primarily due to acoustic attenuation. The second columns show
PA images of the ischemic tissues excited at 750 nm (for HbR detection, green color) and 850
nm (for HbO2 detection, red color). The third column represented LSCI images of the legs in
a horizontal view. The right hindlimbs (appearing on the left side of the images) underwent
femoral artery ligation, while the left hindlimbs were used as controls within each animal.
The fourth column represents LSCI images of feet.
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14 days to monitor spatiotemporal changes in blood perfusion. I found that within the first
10 minutes, a significant drop in the perfusion signal was detected (see Figure 4.5 A). The
lowest perfusion levels, however, were not observed until the one or two days post surgery.
By day seven perfusion was found to have recovered to near pre-ischemic level.
LSCI reveals the rapid dynamics of the subcutanous tissue perfusion While the
deep tissue (imaged with US) showed a relatively slow decrease in blood perfusion after
surgery, the dynamics of the surface tissue (assessed via LSCI) were considerably faster. The
LSCI signal was observed to continuously decrease over the entire first hour after ligation,
and by day one had already started to recover (see Figure 4.5B). Indeed, while the deep
tissue showed its lowest level of perfusion at the day two timepoint, the superficial tissue
measurements indicated almost complete recovery. This is likely due to the fact that surface
tissue contains a higher density of collateral blood vessels, which, during vascular occlusion,
can help to rapidly recover blood perfusion [154].
LSCI demonstrates a slow perfusion recovery in lower extremities The traditional
approach of assessing perfusion in a laboratory setting, involves imaging the feet of animals
using LSCI. As shown in Figure 4.5C I observed an immediate decrease in the ischemic-
to-non-ischemic perfusion ratio followed by a slow but steady recovery that takes up to 14
days.
The dynamics of collateral blood vessels post-ischemia To illustrate the transient
behavior of blood perfusion found with LSCI, I imaged the collateral blood vessels near the
profundus branch before and after ligation. Following the surgery, I observed an abrupt
increase in the perfusion of many collateral vessels near the ligation site (see Figure 4.6).
This indicates that these smaller vessels, which under normal circumstances play a relatively
minor role in blood perfusion, can rapidly increase their flow rate in order bypass a vascular
occlusion and maintain downstream blood delivery.
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Figure 4.5: Changes in perfusion and hypoxia over a logarithmic timeline. Points marked
(◦) and () are for perfusion estimates using US and LSCI, respectively. Points marked (⊳)
indicate the ratio of deoxygenated to oxygenated hemoglobin (HbR/HbO2) as measured via
PA. (A)–(D), represents plots of each measure individually. The mark (∗) above each point
indicates a statistically significant (p < 0.05) difference from the preligation state.
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Figure 4.6: Representative LSCI collateral imaging data presented at a series of time points
(prior to and following ligation). (A) An intact femoral artery and profundus branch prior to
ligation. (B)-(D) The same regions two, 10, and 25 minutes after ligation. An immediate
halt in blood flow via the femoral artery can be seen after two minutes. Within the first
10 minutes, a transient increase in collateral blood perfusion can be observed followed by
decrease at minute 25. In the images, ‘pF’ indicates proximal femoral artery, ‘P’ indicates
the profundus branch of femoral artery, and ‘dF’ indicates the distal femoral artery; white
arrows indicate collateral blood vessels that help to maintain perfusion after ligation.
114
Photoacoustic imaging imparts functional microvascular parameters In constrast
to ultrasonic and laser doppler imaging, photoacoustic imaging is capable of quantifying
several important physiological parameters, including levels of oxygenated (HbO2, detected at
850 nm) and deoxygenated (HbR, detected at 750 nm) hemoglobin. Using light at wavelengths
in the near-infrared region I found that the ratio of HbR to HbO2 increased approximately
1.2 fold after ligation (see Figure 4.5D), and maintained this high level throughout the first
day. Some recovery was seen by day two, however by day seven, the ratio had reverted to its
preligation value.
4.3.2 In vivo monitoring of hypoxia and angiogenesis using
BRU-5921 and NC100692.
BRU-5921 and NC100692 exhibit favorable pharmacokinetics
To demonstrate that the radiotracers exhibit favorable organ excretion for the purposes of
imaging hypoxia-induced peripheral neovascularization, I performed biodistribution studies
75 minutes after injection of 99mTc-NC100692 (for angiogenesis) and 99mTc-BRU-5921 (for
hypoxia). 99mTc-BRU-5921 showed high activity in the kidneys, and substantial accumulation
in both the liver and pancreas, whereas 99mTc-NC100692 demonstrated highest retention in
the kidneys and little activity in other organs (Figure 4.7).
Changes in HIF-1α precede changes in αV β3 expression To investigate the role of
HIF-1α and αV β3 in peripheral angiogenesis over time (3 days, 7 days, and 14 days), animals
were injected via tail vein with either 99mTc-NC100692 or 99mTc-BRU-5921. Representative
scintigraphic images are shown in Figure 4.8A. With the knowledge that the radiotracers
exhibit optimal organ excretion for the purposes of imaging hypoxia-induced peripheral
neovascularization (Figures S1), I found that the HIF-1α expression peaked rapidly, within
about three days, before returning to normalcy around day seven (Figure 4.8B). αV β3
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Figure 4.7: Biodistributions of 99mTc-BRU-5921 and 99mTc-NC100692 in selected organs
at 75 min after intravenous injection. The principal clearance route for 99mTc-NC100692
was through urination, as evidenced by a very high radiotracer uptake in both kidneys.
99mTc-BRU-5921 was also principally excreted via urination, although it took somewhat
longer, as evidenced by its greater liver retention.
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expression, on the other hand, took somewhat longer to peak (approximately seven days),
and was not observed at its basal expression level until day 14. These findings are consistant
with the role of HIF-1α as a regulator of the angiogenic response—its early induction by
hypoxic conditions sets off a cascade of downstream responses, including a significant and
sustained enhancement of αV β3 expression.
4.3.3 In vitro postmortem evaluation of the ischemic
microenviroment
In order to investigate the physiological effects associated with HIF-1α and αV β3 expression,
I evaluated tissue samples collected from all experimental animals.
Representative immunohistochemistry are shown in Figure 4.9A, and immunofluorescence
images are shown in Figure 4.10A. As shown in Figure 4.9B relative to the non-ischemic
control samples, the ischemic tissues exhibited an approximately 14-fold surge in HIF-1α
expression three days after ligation which then gradually returned to baseline levels over the
remainder of the experiment. Nevertheless, even at the 14 day timepoint, HIF-1α expression
remained significantly above its basal level.
In contrast, CD31 positive endothelial cells within the capillaries and small arterioles
increased gradually over the course of the experiment, peaking at day 14.
Additional staining, using both AlexaFluor647-labeled anti-αV antibody and FITC-
labeled NC100692, demonstrated not only a strong colocalization, indicating that NC100692
selectively targets cells engaged in angiogenesis, but also a rapid rise coupled with a slow
decrease in the angiogenic response (see Figure 4.10B).
4.4 Discussion
PAD, a condition closely associated with coronary artery disease, is a powerful predictor of
future cardiovascular pathologies. Despite this, PAD remains largely underdiagnosed and
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Figure 4.8: (A) Representative planar scintigraphic images of murine hindlimbs acquired at
75 min after injection of HIF-1α-targeted 99mTc-BRU-5921 (left) or αV β3-targeted
99mTc-
NC100692 (right) prior to, as well as three, seven, and 14 days after surgical ligation. Arrows
mark focal uptake of both radiotracers within the ischemic hindlimb. (B)Results from the
image analysis using two-dimensional regions-of-interest (ROIs) drawn on planar scintigraphic
images of 99mTc-BRU-5921 (solid bars) and 99mTc-NC100692 (dashed bars) prior to, as well
as three, seven, and 14 days after ligation. Values were expressed as % ratio (ischemic to
non-ischemic). Asterisks (*) indicate significant differences (p < 0.05) in measured 99mTc-
BRU-5921 activity values relative to the pre-ligation state, while number signs (**) indicate
significant differences in 99mTc-NC100692 activity.
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Figure 4.9: (A) Representative immunohistochemical microscopic images of gastronemius
muscle collected from the ischemic hindlimb prior to (control), and at three, seven, and 14 days
after ligation. Tissue samples were stained with primary antibodies against hypoxia-inducible
factor-1 (HIF-1α, left) and platelet endothelial cell adhesion molecule, or PECAM (CD31,
right).(B) Quantitative analysis of immunohistochemical microscopic images. Values were
expressed as % area of positively stained tissue (HIF-1α shown in black, CD31 shown with
diagonal lines). Asterisks (*) indicate significant differences (p < 0.05) in measured HIF-1α
expression relative to the pre-ligation state, while number signs (#) indicate significant
differences in CD31 activity.
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Figure 4.10: (A) Representative microscopic images of gastrocnemius muscle collected from
ischemic hindlimb before (control), and at 3, 7, and 14 days after the surgical ligation of right
femoral artery simultaneously incubated with an antibody against αV integrin (left) and
fluorescent FITC-labeled analogue of NC100692 (middle). Right column represents a result
of merging of two color channels (αV integrin and fluorescent analogue of NC100692).(B)
Quantitative analysis of co-localization between αV integrin and fluorescent analogue of
NC100692 in ischemic gastrocnemius muscle samples collected before (control) and at 3,
7, and 14 days after the surgical ligation of right femoral artery. Values are presented
as percentage of cells expressing αV integrin co-localized with fluorescent FITC-labeled
NC100692 analogue (solid bars). ∗P < 0.05 vs. control. #P < 0.05 vs. 14 days after ligation.
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undertreated [141].
One of the primary drivers of this investigation was to explore applications of a new Power
Doppler US technology sensitive enough to not require exogenous contrast enhancement when
detecting spatiotemporal changes in muscle perfusion. Although US imaging has been a
mainstay in the healthcare industry for over sixty years, and it is widely used for the detection
of blood circulation, its limited sensitivity in low-flow conditions has rendered it unsuitable for
imaging the peripheral microvasculature until now [155]. The Power Doppler US methodology
I employed in this study can detect relative perfusion changes within capillary beds using
conventional instrumentation that samples and filter echos signals in new ways. Using this
method, I monitored the 14 day ischemia-reperfusion time course in healthy mice throughout
the hindlimb (Figure 4.5A). I used 24MHz (about 3 times the frequency of clinical imaging)
because of the small size of the hindlimb. This method offers a safe and low cost approach to
serially assess tissue perfusion.
We used this Power Doppler method, along with several other imaging techniques, to
construct a comprehensive timeline of the bodily response to peripheral vascular occlusion at
both the molecular and physiological levels (Figure 4.11).
In the deep tissue, I found a slow decrease in the perfusion feature that manifested over
the course of approximately 48 hours (although the shallower tissue showed a considerably
faster drop-off). Shortly thereafter (approximately 72 hours after ligation), molecular markers
for hypoxia and angiogenesis (HIF-1α, CD31, and αV β3) were then found to be up-regulated.
In the case of HIF-1α specifically, this up-regulation persisted until approximately day seven,
before falling off as the tissue oxygenation returned to normalcy.
The ability to perform fast serial assessments also proved critical to the possible detection
of a reactive hyperemia response shortly after ligation. Although modest in size, I note
an increase in tissue perfusion at the 20 min time point relative to the 10 and 30 minute
values (a similar uptick in oxygenation was noted at the 30 min time point (Figure 4.5A&D).
One possible explanation may lie in a surge of endothelial nitric oxide (NO) production
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Figure 4.11: Heatmaps depicting measured circulatory parameters over a log-time axis. In
each case, darker colors represent lower relative measurements, and the 0 timepoint indicates
pre-ligation. While US (red) measures perfusion of the deep tissue (∼ 6 mm), LSCI (orange)
measures perfusion within 1mm of the tissue surface. Hypoxia (yellow) and αV β3 (green)
expression were both measured using SPECT imaging with the targeted probes 99mTc-BRU-
5921 and 99mTc-NC100692, respectively. HIF-1α (blue) and CD31 (purple) expression in
ischemic tissue were quantified from immunohistochemistry images.
stimulated by the hypoxia conditions as shown by see Figure 4.6. A complete understanding
of the role of NO in vascular remodeling and angiogenesis remains elusive, and the available
research can be somewhat contradictory [156]. Nevertheless, previous studies have shown that:
1) NO modulates the consumption of oxygen when blood flow is restricted by competitive
inhibition of cytochrome oxidase [157], 2) hypoxic tissue expression increased levels of vascular
endothelium growth factor (VEGF), which in turn gives rise to endogenous release of NO.
Other pathways have also been implicated in the reactive hyperemia response, including
endothelium-derived relaxing factor (EDRF), a vasodilator with similar biological function as
NO [158–161]. Additional studies will be required to establish the role of NO in short-term
perfusion the nature of the enhancement in perfusion I see at the 20 minute time point, and
to investigate possible therapeutic effects of NO on the ischemic microenvironment.
With the utility of the new ultrasonic Power Doppler technology established, I next sought
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to use it as part of a broader multimodal imaging strategy to study the onset of and recovery
from PAD. To that end, I employed LSCI and PA over the study time course to non-invasively
inspect superficial blood perfusion and oxygenation, respectively.
Within the surface tissue, the LSCI data showed that hindlimb recovery from ischemia
occurs considerably faster than in deeper tissue. While the US imaging revealed that it took
approximately 7 days to show signs of vascular recovery within the muscle mass, the surface
tissue was clearly recovering as early as 48 hours post ligation. The simplest explanation
for this observation lies in the differences in vascular physiology of the surface and deep
tissues. In addition to angiogenesis, there exists a secondary type of vascular remodeling
which involves the growth of preexisting collateral arterioles into functional collateral arteries.
Dubbed arteriogenesis, this type of blood vessel growth is not regulated by hypoxia, but by
the changes in sheer stress that accompany the decrease in blood pressure associated with
ligation [162,163]. Because the vascular density in the surface tissue is generally quite high
(presumably due to selection pressure favoring fast wound healing), arteriogenesis in these
tissues might lead to the recovery of blood flow much faster than would otherwise be possible
relying on angiogenesis alone.
For patients with PAD, amputation of the extremities may become necessary in situations
where there is extensive tissue death due to prolonged ischemia. Indeed, the clinical presen-
tation of severe ischemic ulcers or frank gangrene are recognized as the sixth stage of PAD
manifestation according to Rutherford’s classification [155]. I therefore investigated perfusion
within the feet of the animals using LSCI and found that blood flow recovered more slowly
in the feet than in the distal muscle mass, taking approximately 14 days on average (in close
agreement with reports by other authors) [148]. This slow recovery highlights the necessity
of developing new screening methods capable of detecting PAD early on, before irreperable
damage is done.
PA with a penetration depth of 5 mm enables label free imaging of microvascular flow
with high signal-to-noise ratio. This allows users to easily differentiate superficial capillaries
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and deep tissue vessels [164], but it can also be used to characterize functional microvascular
parameters including HbO2 and HbR concentrations [164, 165]. I found that 20 min after
ligation, the ratio of HbR/HbO2 increased (suggesting hypoxia condition), and this enhance-
ment continued until approximately two days after ligation, when the blood oxygenation
began to rise (Figure 4.5D). Because the US measurements indicated that perfusion did not
show signs of recovery until day seven, these results seem to indicate that blood oxygen levels
can recover early in the angiogenic response.
While US, LSCI, and PA give valuable information on the anatomical and functional
changes that occur during the body’s response to vascular occlusion, they offer little infor-
mation on the biomolecular cascades that underpin this response. To that end, I added
nuclear imaging techniques to investigate two different aspects of angiogenic signalling at the
molecular level.
There are two known pathways capable of activating the quiescent angiogenic process:
HIF-1α activation by hypoxia; and alterations in oncogene activity. Either way, once started,
the angiogenic process depends on αV β3 to regulate the migration of vascular endothelial cells.
I concluded the inquiry by non-invasively monitoring tissue hypoxia and αV β3 expression in
the ischemic mouse hindlimb. The animals were injected via tail vein with either peptide based
probe 99mTc-NC100692 or small molecule 99mTc-BRU-5921—to target αV β3 and hypoxia,
respectively. Over the course of two weeks, I monitored both targets’ expression levels in
the ischemic tissue and determined that the highest hypoxia level occurred three days after
ligation (confirmed by HIF-1α expression using immunohistochemistry) and that this was
followed by a steady decline over the next few imaging sessions. αV β3, on the other hand, did
not achieve its highest signal intensity until day seven (also confirmed by immunofluorescence
experiments, and coinciding with the first indications of perfusion recovery in the US data).
Taken together, these results are in agreement with the known in vitro model of hypoxia-
induced angiogenesis [166]. The ischemic environment upregulates HIF-1α activity, which in
turn sets off a signaling cascade that eventually leads to vascular remodeling and enhanced
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αV β3 expression. As the vasculature is repaired, the hypoxia that originally upregulated
HIF-1α begins to diminish, and by day seven I observe a decline in HIF-1α expression followed
by a corresponding decline in αV β3 expression a few days later.
Although HIF-1α and αV β3 have been the subjects of intense scientific scrutiny over the
years, to the knowledge no other group has monitored their expression dynamics simultaneously
in an in vivo animal model. Both 99mTc-NC100692 and 99mTc-BRU-5921 showed favorable
biodistributions and pharmacokinetics, and their potential for translation is high, with
obvious applications in the diagnostics and monitoring of various pathologies including
vascular diseases and cancer.
When viewed together, multimodal imaging approach paints a holistic picture of peripheral
limb responses to vascular occlusion at the anatomical, functional, and molecular levels. I
observe that the effects of ligation are almost immediate, with perfusion and oxygenation
levels dropping substantially just minutes after the operation. From there, I noticed that in
the deep tissue, the angiogenic response can take approximately three days or more to be
fully elicited, beginning with a rapid rise in HIF-1α expression followed by a slower rise in
αV β3 expression. The effects of angiogenesis, viv-a-vis blood perfusion, do not manifest until
approximately a week after ligation. I also see that the surface tissue undergoes a very different
mode of recovery than does the deep tissue, beginning to reestablish normal blood perfusion
within just two days, likely through arteriogenesis rather than angiogenesis. I believe that
medicine is already shifting toward the type of multimodal imaging assessment employed in
this study. And while several challenges remain, the insights gained through this multifaceted
approach is considerably greater than would be possible using any of its constituent imaging
methods alone. The unique platform constructed by the different imaging techniques will
allow to develop new therapeutic strategies for PAD and non-invasively monitor their effects.
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4.5 Conclusions
Although significant advances in non-invasive vascular imaging have been made, arteriography,
a relatively invasive technique which requires injection of the vascular contrast, remains the
standard method for evaluating PAD in the clinical setting. Meanwhile, the prevalence of
PAD in Europe and North America is currently estimated at 27 million people and growing.
Fifteen years ago, a commentary by Belch et al. called for new diagnosis and treatment
options for PAD [141]. In this study, I employ a new Power Doppler US methodology that I
believe has the potential to answer that call. It enables the detection of PAD in its early stages
without exogenous contrast agents using low cost instrumentation commercially available
today. This will allow general practitioners, who are usually the first point of contact with
a patient, to recognize and diagnose the disease early and often at a lower cost, ultimately
leading to more effective treatment and better patient outcomes.
We also present an integrated, non-invasive, multimodal study to image the bodily re-
sponse to vascular occlusion. In many respects, these results show a great deal of promise.
The molecular probes, 99mTc-NC100692 and 99mTc-BRU-5921, demonstrated favorable biodis-
tributions and pharmacokinetics, and their resulting images are readily quantifiable. They
clearly show the dynamics of hypoxic condition and stimulation of αV β3 expression within
the ischemic microenvionment, and their potential for translation appears high. Just as
exciting, the US, LSCI, and PA—all fast, relatively inexpensive, and label-free non-invasive
techniques—gave rise to a very detailed picture of spatiotemporal changes in blood perfusion
and oxygenation. It’s through these methods, for example, that the divergent responses to
ischemia of superficial and deep tissues can be detected and understood. Overall, I believe
that this work represents an important step in the development of multimodal imaging
strategies, with applications in both the research and clinical settings.
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Chapter 5
Non-invasive Monitoring of
Therapeutic Intervention in PAD †
5.1 Introduction
The main cause of the poor clinical outcome of diabetes mellitus (DM) patients suffering
from PAD is their reduced capacity for neovascularization, an important bodily response to
vascular occlusion [136]. Despite considerable technological advancement, mortality and both
morbidity resulting from PAD remain high, even before diagnosis or treatment thresholds are
met. Lifestyle changes and increased exercise are regarded as the most effective treatment
for complications associated with PAD. In more critical PAD cases, therapies generally
rely on mechanical revascularization through either percutaneous or surgical approaches.
Unfortunately, these approaches are frequently unsuccessful in the long term. More recently,
novel therapies involving the delivery of proangiogenic factors, either directly or through
gene transfer, have been introduced, with some now in clinical trials [128, 167, 168]. The
majority of these new therapies target only a single biomarker associated with PAD, such as
vascular endothelial (VEGF) or fibroblast growth factors (FGF). Due to the complexities of
the biochemical networks involved, however, such oversimplified approaches often fail to give
rise to demonstrable improvements in actual patients. More holistic interventions capable of
altering the microenviroment of endothelial cells and rendering them suitable for angiogenesis
could be more effective. As a result, interest has shifted toward cell-based approaches utilizing
†Work includes previously published material incorporating contributions from Hedhli Jamila, Konopka
Christian J, Schuh Sarah, Bouvin Hannah, Cole John A, Huntsman Heather D, Kilian Kristopher A, Dobrucki
Iwona, Boppart Marni D, and Dobrucki, Lawrence W [2].
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the potential of progenitor and stem cells as agents of tissue repair and neovascularization.
Targeted stem cell-based therapies appear to provide clinical improvement for PAD
patients by enhancing vascular density (angiogenesis), initiating large vessel remodeling
(arteriogenesis), and ultimately improving blood perfusion [169]. Of the various potential
candidate cells that might be used in treating PAD patients, mesenchymal stem cells (MSCs)
are being pursued the most actively at both preclinical and clinical levels [169]. Several
properties of MSCs make them well suited to the task. Most importantly, through their
paracrine-related effects, MSCs have been shown to promote angiogenesis, arteriogenesis, and
terminally differentiate into vascular cells and myocytes [170]. They have also been shown
to release anti-apoptotic, anti-fibrotic, immunomodulating, and chemoattractant factors,
and their inherent metabolic flexibility and resistance to ischemic stress has been shown to
fascilitate their survival in ischemic environments [171]. Muscle-derived MSCs (mMSCs) are
particularly attractive due to their abundance and the ease with which they can be extracted.
The surgical excisement of skeletal muscle tissue carries little risk, and the subsequent isolation
and culturing of mMSCs is extremely straightforward. Moreover, their long-term passaging
capacity and immunomodulatory properties could allow for allogeneic transplantation into
many different tissues with little risk of rejection.
Previous studies involving diabetic mice have shown that angiogenesis is directly impaired
by the high endothelial glucose levels associated with diabetes [172]. As a result, the longterm
effects of uncontrolled diabetic hyperglycemia include ischemia, especially in the extremities,
and subsequent debilitating injury. In this article, I investigate the use of mMSCs to
treat surgically-induced hindlimb ischemia in a diabetic mouse model of PAD. I employ
several minimally invasive in vivo imaging and diagnostic approaches (nuclear, laser doppler
perfusion, muscle function and microarray transcriptomics) in order to construct an accurate
picture of the effects of the transplanted mMSCs, as well as the response of the mice to
treatment, and their long-term prognosis. I find that mMSCs lead to greatly enhanced
neovascularization roughly one week after treatment. I also find that at the two-week
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timepoint, the transcriptional profile of the stem-cell treated mice resembles that of healthy
mice while a control group treated with saline continue to express anti-angiogenic factors,
indicating a relative lack of healing. The translational nature and timeliness of this work is
significant, and the results have potentially important clinical implications for the evaluation
and management of diabetic patients with PAD. Also, noteworthy is the impressive specificity
and favorable biodistribution of the molecular probe used in the nuclear imaging studies.
The clinical implications of using targeted molecular imaging in PAD are substantial, as they
can help to detect diseases earlier, evaluate treatment effectiveness over time, and ultimately
help to tailor therapy regimens to individual patients.
5.2 Methods
The research plan is outlined in Figure 5.1. Briefly, type 1 diabetes was chemically induced
in 4 to 6 week old mice; their right femoral arteries were ligated to mimic PAD, and they
were treated with either sterile saline (control) or transplanted with mMSCs isolated from
a different group of animals of similar age and genotype. After treatment, the ischemic
DM animals were assessed for angiogenesis (PET-CT), blood perfusion (LDF), and muscle
function (FUNC) at different timepoints after surgery.
5.2.1 Isolation of muscle-derived mesenchymal stem cells
(mMSCs) from skeletal muscle
Five-week old C57BL/6 mice gastrocnemius-soleus complexes were excised, mechanically and
enzymatically digested, filtered, and incubated with anti-mouse CD16/CD32 (Ebioscience,
USA) in order to block non-specific Fc-mediated interactions. Cells were then stained with
both monoclonal anti-mouse Sca-1+PE (Ebioscience, USA) and CD45−APC (Ebioscience,
USA) antibodies and isolated with FACS. Sca-1+CD45− cells were then collected in media
for culture.
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5.2.2 Cell Culture
mMSCs were grown to confluence in Dulbecco’s Modification of Eagle’s medium (DMEM,
Fisher Scientific, USA), containing 10% heat-inactivated FBS (Invitrogen), 100 U/mL peni-
cillin G, and 100 µg/mL gentamicin, and were maintained in a humidified incubator at 37◦C
with 5% CO2.
5.2.3 Western blotting
mMSCs and human umbilical vein endothelial cells (HUVEC, known to express αV β3) were
washed three times in sterile phosphate-buffered saline (PBS). Cell pellets were collected
by centrifugation and incubated in a solution of RIPA buffer (Sigma-Aldrich, USA) and
Protease Inhibitor (Sigma-Aldrich, USA). The cocktail was sonicated 3 times for a length of
20 seconds with a 10 second incubation on ice. The lysed cells were centrifuged for 15 min
and the supernatant (protein) was collected. The concentration of protein was determined
using Gen5 Microplate Reader and Imager Software (BioTek Instruments, USA). A total
of 20-10 ng of proteins were resolved on 10% SDS-polyacrylamide gel electrophoresis and
transferred onto PVDF membranes (Immobilon, Millipore). Membranes were blocked in
Tris-buffered saline (TBS) containing 10% non-fat dry milk and 0.1% Tween 20, prior to
incubation with 80 µCi of 64Cu-NOTA-PEG4-cRGD2 targeted to αV β3 (a well characterized
marker of angiogenesis) for 1 hour at room temperature. After washing the membrane with
PBS, they were transfered on the multisensitive phosphor screen (Perkin-Elmer, USA) and
imaged with Cyclone Plus Storage Phosphor System (Perkin-Elmer, USA).
5.2.4 Angiogenic cytokines array
For cytokine analysis of protein extracted from ischemic tissue of stem cell and saline
animals, I used mouse antibody angiogenesis array membrane (Abcam – ab139697, 24 target
proteins) as per manufacturer instructions. Protein samples were incubated with blocked
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membranes overnight with the membranes at 4◦C. Prepared membranes were exposed for the
protein detection. The membranes were scanned and analyzed using Biorad Image Lab 5.2
software. The signal was normalized to the positive control signal intensity as proposed by
the manufacturer.
5.2.5 In vivo evaluation
Animal preparation All in vivo imaging experiments were performed with the approval
of the Institutional Animal Care and Use Committee of the University of Illinois at Urbana-
Champaign, following the principles outlined by the American Physiological Society on
research animal use.
Permanent hindlimb ischemia in DM mice Type-1 DM was induced by streptozotocin
(STZ) administration (50 mg/kg, i.p. daily for 5 consecutive days) in two months old male
wild-type mice (C57BL/6). Previous studies have documented that STZ induces moderate
diabetes in 85% male mice with survival up to 4 months after treatment without receiving
insulin administration. Mice with fasting glycemia (>200 mg/dL) at 14 days after the
first STZ treatment were considered diabetic. Mice were anesthetized with isofluorane and
unilateral hindlimb ischemia was surgically induced by femoral artery ligation following
previously published approaches [132]. Animals were matched for age and sex, and divided
into two groups: a control group (n=10) which was subjected to saline i.m. injections, and an
experimental group (n=10) that recieved mMSC i.m. injections. Before the ligation, and at 1,
2, 3 and 4 weeks after the ligation, all animals were delivered to the microPET/SPECT/CT
facility for molecular imaging, assessment of perfusion and muscular function.
mMSCs transplantation into hindlimb muscle Cultured muscle-derived Sca-1+CD45−
cells were collected and suspended in Hank’s Balanced Saline Solution (HBSS). Immediately
after ligation of the femoral artery (see Section 5.2.5), the experimental group received
intramuscular injections of ∼ 4× 104 cells in 50 µL of sterile HBSS into three sites in the
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gastrocnemius muscle of right hindlimb, while the control group recieved injections of sterile
HBSS only. The group has established the optimal number of cells for injection from a
previously [171].
In vivo molecular imaging of angiogenesis and perfusion One week prior to surgical
induction of hindlimb ischemia, as well as 1, 2, 3, and 4 weeks after, all animals were
anesthesized with 1-3% isoflurane, the neck area was shaved, and the left jugular vein was
isolated for placement of a PE-10 polyurethane catheter (Fisher Scientific, USA) to facilitate
administration of the radiotracer. The animals were injected with ∼30 MBq of 64Cu-NOTA-
PEG4-cRGD2 targeted at αV β3, a well characterized marker of angiogenesis [5]. Imaging
was performed using a dedicated small animal microPET-CT scanner (Inveon, Siemens
Healthcare, USA). The animals were placed on the animal bed and ∼60 min after radiotracer
injection, a 15 min microPET imaging session was performed. PET imaging was followed by
a high-resolution anatomical microCT imaging (360 projections, 80 keV/500 µA energy).
The microPET and microCT images were reconstructed using OSEM/3D algorithm
(Siemens Healthcare USA) and cone-beam technique (Cobra Exim), respectively. MicroPET
were fused with microCT images and quantified using semiautomated approach developed and
evaluated by the group previously [132]. Briefly, complex irregular volumes of interest (VOIs)
were generated from the microCT images and applied on the co-registered microPET images
to calculate absolute 64Cu activities using Inveon Research Workplace (Siemens Healthcare
USA). These complex VOIs included only soft tissue (skeletal muscles) after the removal of
bone structures during the image segmentation process.
At the same timepoints (one week prior, and 1, 2, and 4 weeks after surgery) all animals
were measured with a needle-like laser Doppler probe (Biopac systems, USA) to asses
peripheral perfusion as described in [173]. Succinctly after the probe was calibrated to a
known motility standard, the needle was inserted into the gastrocnemius muscle to output a
signal that was proportional to the red blood cell perfusion in that area and expressed in
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blood perfusion units. Peripheral perfusion was reported as a ratio of ischemic to non-ischemic
limb of the same animal.
Measurement of the muscular function To assess the muscular recovery of the animals,
an invasive contractile force measurement technique was employed. After the final imaging
session at four weeks after surgery animal’s maximal isometric hindlimb plantar flexor force
was measured using a dual-lever system described previously [174]. Briefly, under anesthesia
the animal’s sciatic nerve was electrically stimulated, and the resulting muscle forces were
measured with a servomotor and control unit (Aurora Scientific, USA). Stimulation was
repeated 9 times with 5 s recovery periods for a total of 10 measurements. For each animal,
the value of the maximal force output (g) was normalized to the muscle mass (g), and
expressed as a ratio of ischemic to non-ischemic limb of the same animal.
Statistical analysis The Student t test was used to compare 2 groups. One-way ANOVA
was used to compare multiple parameters. A value of P < 0.05 was considered significant.
5.2.6 Post mortem Analysis
Biodistrubution For biodistribution studies, all animals were euthanized at 90 min post-
injection and selected organ samples were collected for gamma well counting analysis. All
collected sections were weighed and the tissue radioactivity was measured with Wizard2 gamma
well counter (Perkin-Elmer, USA). Measured 64Cu activity was corrected for background,
decay time, and tissue weight, and expressed as percent of injected dose per tissue weight
(%I.D./g).
Histology and immunohistofluorescence A subset of the animals were euthanized at 2
weeks post surgery and their gastrocnemius/soleus muscle complexes were excised, embedded
in TissueTec (Sakura, USA) and snap frozen in -150◦C methylbutane. Frozen sections (5
nm) were placed on microscope slides, fixed with pre-cooled acetone, and stored at -80◦C
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before staining. To assess skeletal muscle vascularity, muscle samples were stained with an
endothelial cell-specific marker PE anti-mouse CD31 Antibody (Abcam, USA). All staining
procedures were performed according to the product-specific protocols (four for each slide).
The stains were quantified for extent (percentage area) of positive staining in randomly
chosen high-powered (200 ×) fields using algorithms validated by the group previously [123].
5.2.7 Transcriptomics
RNA extraction protocol Total gastrocnemius/soleus muscle RNAs (ligated and non-
ligated) from the saline and mMSCs treated mice were isolated using an RNeasy tissue
mini-kit (QIAGEN). RNA quality was measured using an Agilent Bioanalyzer and quantified
using a Qubit Fluorometer (Life Technologies) before microarray analysis.
Hybridization protocol Saline- or mMSCs- treated skeletal muscle (n = 4 each) were
paired with a non-ischemic sample on an array; samples came from the same mouse. I
employed a dye-balance design such that of the four replicates of each treated group, two
were in red (Cy5) and two were in green (Cy3). A total RNA of 200 ng was labeled using the
Agilent 2-color Low Input Quickamp Labeling kit (Agilent Technologies, Santa Clara, CA)
according to the manufacturer’s protocols. Labeled samples were hybridized to an Agilent
mouse 4x44K array and scanned on an Axon 4000B microarray scanner (Molecular Devices,
Sunnyvale, CA) at 5 µm resolution. Spotfinding was carried out using GenePix 6.1 image
analysis software (Molecular Devices, Sunnyvale, CA).
Microarray analysis description Microarray data pre-processing and statistical analyses
were done in R (v 3.3.2) [175] using the limma package (v3.30.6) [176]. Median foreground
and median background values from the eight arrays were read into R; no spots were manually
flagged as bad. The background was low and even across the arrays, and as such, it was
ignored. M-values (ln(2)(Cy5/Cy3)) for each array were normalized first with the traditional
loess within-array normalization, and then the scale between-array normalization [177].
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Agilent’s Mouse Gene Expression v2 4x44K Microarray interogates 23,254 genes using 39,030
probes spotted one time (1X), and 399 probes spotted ten times (10X) each based on current
annotation information. Correlations between the replicate spots for each probe were high,
and so the M-values for replicate spots were simply averaged for each sample. The positive
and negative control probes were used to assess what minimum expression level could be
considered ”detectable above background noise” (5.75 on the ln(2) scale) and then the control
probes were discarded. Further quality control investigations were done on individual Cy5 and
Cy3 values that were quantile normalized to assess variation among individual samples [177].
Because of the high correlations associated with the mouse/array pairings, and no observable
difference between the non-ischemic samples, all statistical analyses were done on the M-values
rather than the single-channel values. This is prefereable because the M-values implicitly
control for mouse/array pairings using limma’s empirical Bayes model that includes a term for
the dyes [178]. The equivalent of a one-way ANOVA test was pulled from the model to detect
any differences across the three groups (non-ischemic, ischemic saline-treated, and ischemic
mMSC-treated). These ANOVA values were used along with updated mappings of probes to
Entrez Gene IDs from Bioconductor’s MmAgilentDesign026655.db (v 3.4.0) [179] to reduce
the 39,429 unique probes down to a set of 11,885 representing expressed, unique genes: first,
probes without quantile-normalized expression values > 5.75 in at least 3 of the 16 samples
(21,752 probes) were removed; second, probes that did not map to any Entrez Gene ID (2,712
probes) were removed; and lastly for the 2,566 genes with more than one remaining probe, a
single probe based on the lowest ANOVA raw p-value was selected. Prior to the statistical
analysis, a literature search resulted in 149 genes known to be involved with angiogenesis or
peripheral arterial disease. An additional 234 genes (for a total of 383) were identified by
finding genes annotated to any of the 26 Gene Ontology terms with “angiogenesis” in the
name based on Bioconductor’s org.Mm.eg.db package (v 3.4.0). In addition to a one-way
ANOVA, three pairwise comparisons were also pulled from the model: saline vs. control,
stem cell vs. control and stem cell vs. saline. The False Discovery Rate (FDR) correction
135
was performed separately for the 383 “a priori” gene set and for the 11,522 additional genes
detected above background by the microarray, as well as globally for the one-way ANOVA +
3 pairwise comparisons. Heatmaps for specific genes were made from the quantile-normalized
separate channel values, after removing array and dye effects, then scaling each gene to have
a mean of zero and a standard deviation of one.
5.3 Results
5.3.1 mMSCs enhance angiogenic activity, perfusion, and muscle
function in DM mice
To non-invasively assess the angiogenic activity of mMSC-treated DM mice, I injected
and imaged the αV β3-targeted PET-CT probe,
64Cu-NOTA-PEG4-cRGD2, at a series of
timepoints after the onset of hindlimb ischemia (see Figure 5.2).
During image analysis, I determined the mean signal within volumes of interest corre-
sponding to both the ischemic and non-ischemic legs of each animal. Their ratio (mean
ischemic to non-ischemic) represents a measure of each animal’s response to mMSC (or
saline) treatment. I determined that angiogenic activity one week after mMSC treatment was
enhanced by approximately 80% relative to the saline control group (see Figure 5.3A). This
enhancement carried forward to week two in which I found a 40% relative increase. Weeks 3
and 4 were comparable in both groups.
Neovascularization is the first stage of angiogenic recovery. I investigated whether enhanced
αV β3 expression translated into blood perfusion recovery. A needle-like laser Doppler probe
was used to noninvasively determine the degree of blood perfusion in both the ischemic
nonischemic limbs of each animal in the immediate pre and postoperative periods as well as
one, two, and three weeks later. I did not find a significant difference between the mMSC-
and saline-treated animals one week after femoral artery ligation, however in weeks two and
four, blood perfusion increased in the mMSC group by almost 60% relative to the saline
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group (see Figure 5.4A).
The next step of this study was to determine if the enhanced angiogenesis and perfusion
impacted the muscle function of the diabetic ischemic hindlimb. The study was conducted
four weeks after surgery. I found a 1.7-fold increase in muscle strength in the mMSC group
relative to the saline group (see Figure 5.4B).
Finally, to assess organ specific uptake of 64Cu-NOTA-PEG4-cRGD2 probe in vivo, I
performed a biodistribution study at 90 minutes after intravascular injection into saline and
mMSC treated mice. As expected, the highest uptake was observed in the kidneys due to
renal filtration being the dominate excretion route (11.08 ± 0.98, 3.65 ± 0.44 %I.D./g for
cortex and medulla, respectively). Relatively high uptake was also observed in the intestines
(4.61± 0.30), lungs (2.95± 0.19), and the spleen (2.24± 0.19) (see Figure 5.3B).
5.3.2 In vitro Post mortem evaluation of mMSCs effect on the
ischemic microenviroment of PAD
To investigate the impact of mMSC treatment at the cellular level, at two weeks post trans-
plantation, a subset of animals was euthanized (n=4 for both the mMSC- and saline-treated
groups), sections of hindlimb muscle tissue were excised, and stained with a commercially avail-
able PE-labeled anti-CD31 (endothelial marker). Subsequent fluorescence imaging showed a
3.3-fold increase in the angiogenic activity of the ischemic stem cell treated hindlimb in com-
parison to the ischemic saline treated hindlimb (see Figure 5.5A). Whereas, the non-ischemic
saline and non-ischemic stem cell had no significant change in CD31 expression (see Figure
5.5B-D).
Additional sections of muscle tissue were used to investigate the mRNA expression of
several genes involved in the angiogenic process. Globally, I found that gene expression state
of the ischemic skeletal muscle of the mMSC-treated group was comparable with that of
non-ischemic control muscle, but it differed significantly from the saline treated animals. As
expected, samples from the same mouse/array were highly correlated and samples in the
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same dye had lower levels of correlation. However, after removing the effects of array and
dye, principal components analysis clustering showed that the non-ischemic samples from
mice administered with saline were not different from non-ischemic samples treated with
mMSCs, and there were no outlier samples (see Figure 5.6A,B).
Moreover, I found almost 2-fold increase in expression of the angiogenenic markers HIF1-α,
β3, and β5 in the mMSC-treated group relative to the saline-treated group (see Figure 5.7). I
also found that TNF-α and CD68 (both markers of inflammation) demonstrated a significant
(p < 0.05) 1.2-fold enhancement in the saline group, indicating an up-regulation of the
inflammatory response. I also noted a 1.2-fold increase in 2,6-phosphofructo-2-kinase, a key
enzyme involved in glycolysis, within the mMSC treated tissue.
Sections of ischemic saline- and mMSC-treated muscle tissues were also used to extract and
quantify protein expression levels. In accordance with the transcriptomics results, I found an
increase in expression of the pro-angiogenic proteins and a decrease in the pro-inflammatory
proteins in the stem cell-treated animals relative to the saline-treated animals (see Figure
5.6C)).
5.4 Discussion
Peripheral arterial disease (PAD) involves a broad range of vascular pathologies extending
from the cerebral vasculature to lower limb arteries. PAD patients experience insufficient
blood flow at rest and during the exercise, which can result in intermittent claudication.
Imaging techniques focused on PAD progression have the capability to improve the status
quo by facilitating earlier detection, guiding patient management decisions, and enabling
disease prevention and individualized therapies. The studies presented here utilize novel
imaging approaches developed to non-invasively assess the potency of muscle-derived MSCs
(mMSCs) as a regenerative therapy to repair and reverse diabetic vascular complications in
an established animal model of PAD. A variety of techniques and imaging strategies were
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applied to quantify angiogenesis, blood flow recovery, muscular function, and gene expression
profiles in mMSC-treated ischemic tissue.
I began the investigation by non-invasively assessing the expression of αV β3 in the two
experimental (mMSC) and control (saline) groups utilizing a cRGD-based PET tracer, 64Cu-
NOTA-PEG4-cRGD2. I observed an increase in the uptake of the probe in the ischemic
hindlimb as early as one week after femoral artery ligation and treatment with mMSC. This
was confirmed by an ischemic muscle co-stain of CD31 (a key marker for endothelium cell
proliferation). Importantly, as mMSCs do not express αV β3 (data not shown),the increased
signal I observed was attributable to the physiological effects of the mMSCs’ interactions
within the ischemic tissue, to wit the enhancement of angiogenic activity. Unfortunately,
many of the biochemical details of these interactions are complex, poorly understood, and
largely beyond the scope of this manuscript. By week four of the study, the enhancement I
observed had largely disappeared, indicating either a return to normalcy for the tissue or
a diminishment in the therapeutic effect of the mMSCs. Based on the results of the blood
perfusion, transcriptomics, and muscle recovery assays (see below), I believe it is more likely
the former rather than the later.
I next tested the hypothesis that the observed differences in αV β3 expression between
mMSC-treated and saline mice would translate into perfusion recovery. I evaluated blood
perfusion using a needle-like laser Doppler probe inserted at the gastrocnemius-soleus muscle
at one, two, and three weeks after surgery. I saw an increase in perfusion at weeks two and
three in mMSC-treated group where there was little or no change in the saline-treated group.
This indicates that the enhanced αV β3 activity was indeed associated with neovascularization
within the mMSC-treated ischemic tissue. The results are in agreement with several other
published studies that have found that stimulation of angiogenesis promotes the recovery
of tissue perfusion [180]. Moreover, these studies investigated the impact of several factors
such as age, sex, and genotype, and found an average time of approximately two weeks for
perfusion recovery (provided, of course, no essential genes are knocked out)—a timeframe in
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close agreement with the results.
After establishing non-invasively the therapeutic effects of mMSC transplantation into
ischemic limb, I wanted to confirm that the observed changes in peripheral angiogenesis and
perfusion were associated with a recovery in muscle function. After the four week imaging
session, an invasive contractile force measurement technique was employed to measure muscle
strength in the ischemic and nonischemic hindlimbs of a subset of the animals. I found a
1.7-fold increase in muscle strength in the mMSC-treated group relative to the saline-treated
control group. The mean ratio of ischemic to nonischemic muscle strength of mMSCs-treated
animals was approximately 0.89, indicating almost full recovery of muscle function. Due
to the invasive nature of the measurements, they were performed on only a small subset of
animals (n=2 for both the mMSC and saline groups). As such, statistical significance could
not be achieved. Instead, I investigated the expression levels of genes in the MyoD family
of muscle regulatory factors, which are known to be expressed on satellite cells (located
between the basal lamina and sarcolemma of myofibers) and stimulated by damage to the
muscle [181]. The mMSC-treated ischemic muscle showed a significant upregulation of the
key regulatory genes such as myogenic differentiation 1 (MYOD), and myogeneic factor 6
(MYF6) in comparison to the saline-treated ischemic muscle tissue, indicating increased
muscle regeneration and healing in mMSC-treated animals (see Figure 5.4C).
So far, this study has focused on the physiological effects of mMSC treatment at the animal
and tissue levels (neovascularizaton, blood flow recovery, muscle strength). Nevertheless, both
PAD and angiogenesis involve a number of cellular-level processes that are orchestrated by a
range of microenvironmental cues including those associated with ischemia and hypoxia [182],
nitric oxide [183], and inflammation [184]. Investigating how these factors influence the
behavior and gene expression state of the cells that make up skeletal muscle tissue, represents
an important final part of the study. I performed microarray transcriptomics experiments on
excised tissue samples, and attempted to quantify the differential expression of 5 important
categories of genes, namely those associated with hypoxia, inflammation, pro-angiogensis,
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anti-angiogensis, and metabolism (see Figure 5.7).
Several genes associated with the pro-angiogenic response (such as HIF-1α, β3 and β5,
Fgfr1, Tgfbr1, Vegfa, Flt1, and Itgav) were found to be enhanced in mMSC-treated muscles.
HIF-1α, a transcription factor that mediates the adaptive response to hypoxia and ischemia
by promoting angiogenesis, showed a significant increase in mMSC-treated mice compared to
the saline group. This confirms that the treatment with mMSCs upregulates the expression
of genes involved in initiation of the angiogenic pathway. Interestingly, the ischemic saline
treated group actually showed a down-regulation in HIF-1α compared to the nonischemic
tissues of the mice. This finding is consitent with other published data, and is attributed to
the hyperglycemic environment of the endothelium cells, which is unfavorable for induction
of angiogenesis [180].
Expression of these pro-angiogenic genes was found to correlate with metabolic genes such
as, fructose-2,6-biphosphatase 2 (Pfkfb2) and the solute carrier family 2 (Slc2a4) genes. It is
possible that the vascular remodeling itself may present energy or metabolite requirement, or
that the increase in blood flow and subsequent recovery of muscle function associated with
vascular repair may lead to increased metabolic activity.
In contrast, I found the expression of several genes associated with inflammation tended
to correlate with others known to inhibit angiogenesis. As examples, saline-treated ischemic
tissues demonstrated strong upregulation of the pro-inflammatory genes TNF-α and CD44
[185, 186] as well as the anti-angiogenic genes interleukin 18 (Il18), arrestin (Arrb1), and the
tissue inhibitor of metalloproteinase 2 (Timp2) [187–189] (among others). The mMSC-treated
mice showed no such upregulation. These results are in line with a pilot transcriptome
study of human patients with type-1 diabetes, in which a clear upregulation of TNF-α was
observed in functionally impared endothelial progenitor cells [190]. These results highlight the
importance of the tissue microenviroment in establishing the angiogenic response; inflamed
tissue inhibits angiogenesis and slows recovery from vascular occlusion. Additional proteomics
studies confirmed the up-regulation of the pro-angiogenic genes and relative down-regulation
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of the pro-inflammatory genes in the stem cell-treated ischemic tissue.
DM causes changes in the endothelial microenviroment that can make a single biomarker
therapy challenging to target PAD. Connective tissue growth factor expression (CTGF, an
inhibitor of angiogenesis), cysteine-rich protein 61 (Cyr61), metallothionein 1 (Mt1) and 2
(Mt2), and CD68 (expressed on monocytes/macrophages), as examples, have been shown
to be markedly increased in diabetic animals [191] (see Figure 5.6B). In general all animals
showed enhanced expression of these genes, however the ischemic mMSC-treated tissues
displayed a significant down regulation confirming, at the cellular level, the ability of mMSCs
to alter the tissue microenvironment in complex ways. Intriguingly, the same set of genes was
found to change after acute hindlimb ischemia within healthy mice in as soon as 6 hours and
return to homeostasis between 7 to 14 days later, again in accordance with these results [192].
Other DM-associated genes that have been shown to increase the risk of thrombosis
and vascular disease include Coagulation Factor III (F3) [193], which I found to be signif-
icanntly (p = 0.05) downregulated in the mMSC-treated group (see Figure 5.6B). Matrix
metalloproteinase-2 (Mmp2), which is implicated in angiogenesis, was upregulated in mMSC
group relative to saline animals, however other studies have found no change in its expres-
sion [194].
This study pieces together the changes that occur in diabetic mice after femoral artery
ligation and theraputic intervention with mMSCs. All told, This study paints a compelling
picture, in which mMSCs exert far-reaching effects, countering the anti-angiogenic effects of
DM and inflamation, and enhancing themprocess of neovascularization and healing. More
targeted experiments are needed to elucidate the biochemistry that underpin these responses,
but this work represents an important step to widen the knowledge on multifaceted actions
of mMSCs in the recovery of vascular complication associated with DM.
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5.5 Conclusion
Angiogenic tissue microenviroment is tightly controlled by multifactorial processes involving
both pro- and anti-angiogenic factors interacting with endothelial cells, smooth muscle cells,
and the extracellular matrix (ECM). The signalling pathways are complex, with many details
remaining unclear. To date, only a few studies have investigated the effects of diabetes on
angiogenesis within the skeletal muscle, and most of them focused almost entirely on a single
biomarker (VEGF-A) with ambiguous results [136,195,196].
Here I present findings that validate the potential for mMSCs to be used as a holistic
therapy for diabetes-associated PAD. Rather than targeting a single facet of the body’s
response to ischemia, mMSCs appear to exert far reaching effects on the ischemic tissue
microenvironment by enhancing angiogenesis, decreasing inflammation, and promoting muscle
recovery. This work focuses on the response to treatment at both the cellular and tissue
levels. To my knowledge this is the first study to utilize non-invasive targeted imaging
strategies to measure angiogenesis and blood flow in ischemic diabetic limbs after muscle-
derived mesenchymal stem cells therapy in combination with transcriptomics analysis. The
translational nature of this work is difficult to overstate; not only I find that mMSC-based
therapy can largely reverse vascular occlusion associated with PAD, but I also provide
effective molecular imaging approaches that one day may be used to help diagnose vascular
complications, as well as monitor their progression and treatment.
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Figure 5.1: Study overview. Streptozotocin was used to induce DM in 4 to 6 week old
C57BL/6 mice. The right femoral artery of the DM mice were then ligated to mimic PAD.
mMSCs were isolated from another group of mice and then injected into three different sites
in the ischemic gastrocnemius-soleus of DM group. A control group received saline injections.
Both experimental and control groups were serially evaluated for αV β3 expression (using
PET-CT), blood perfusion (using laser Doppler flow, LDF), and muscle function (denoted
FUNC). At week two, skeletal muscle tissue was extracted for immunohistochemistry and
microarray transcriptomics experiments (denoted TISSUE).
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Figure 5.2: Representative PET-CT images. Coronal, transverse, and sagittal views are
shown for both mMSC- and saline-treated mice at 1 week post surgery and implantation.
The mMSC-treated mice show significant αV β3-targeted probe accumulation in the ischemic
limb.
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Figure 5.3: Image based analysis of αV β3 expression and biodistribution. A)
64Cu-NOTA-
PEG4-cRGD2 was used to noninvasively assess αV β3 expression before femoral artery ligation
(week zero, baseline) and one, two, three, and four weeks after. mMSC-treated mice showed
significant enhancement relative to both the baseline and the saline-treated group at the
one and two week timepoints. B) The biodistribution assessed with gamma well counting of
radiolabeled 64Cu-NOTA-PEG4-cRGD2 targeted at αV β3 integrin demonstrated a favorable
biodistribution and optimal retention for targeted in vivo imaging of peripheral angiogenesis
in n=4 animals treated with mMSCs.
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Figure 5.4: Analysis of blood perfusion, muscle strength, and muscle function related gene
expression. A) Laser Doppler flow measurements were performed to assess blood perfusion
in the ischemic and non-ischemic tissue of the mMSC- and saline-treated mice. Perfusion
was significantly enhanced relative to baseline and saline-treated mice at the two and four
week timepoints. B) Muscle function was assessed using an invasive technique at the four
week timepoint. The mMSC-treated group showed a 1.7-fold increase over the saline-treated
mice. C) Key muscle function genes determined by microarray n=4 for each group show a
significant up-regulation in ischemic mMSCs treated mice in comparison to the saline and the
non-ischemic skeletal muscle. The asterisks indicates a p value of < 0.01 comparing ischemic
stem cell vs. ischemic saline treated mice.
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Figure 5.5: CD31 immunohistofluorescence. A) Quantification of CD31-positive area in
stained skeletal muscle tissue. The mMSC-treated ischemic tissue showed significant en-
hancement relative to non-ischemic tissue, and saline-treated tissues. B-E) representative
immunohistochemistry images with CD31 (red) and DAPI (blue).
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Figure 5.6: Analysis of transcriptomics and proteomics data. A) The gene expression states
of excised tissues projected onto the first two principal components. The mMSC-treated
ischemic tissue (blue) clusters with the non-ischemic tissues (red and black), indicating
similar gene expression profiles, while the saline-treated ischemic samples cluster separately
(green). B) Heatmap of the expression of several pro- and anti-angiogenic genes in the saline-
and mMSC-treated mice (n=4 in each group). Asterisks indicate the smallest FDR p-value
across the four comparisons (ischemic saline vs. non-ischemic saline, ischemic stem cell vs.
non-ischemic stem cell, ischemic stem cell vs. ischemic saline, overall ANOVA)). * FDR p
< 0.2, ** FDR p < 0.1, *** FDR p < 0.05. C) Heat map of cytokine expression (21 proteins)
comparing mMSC- and saline-treated ischemic tissue. For each protein on the cytokine
membrane, expression levels for both mMSC- and saline-treated tissues were averaged, and
the log2 ratio of each value relative to its respective average is shown.
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Figure 5.7: A representation of key regulatory genes. Pro-angiogenic and metabolic genes
are significantly increased in mMSC-treated ischemic tissue, where pro-inflammatory genes
are up-regulated in ischemic saline muscle tissue. There was no difference between the
non-ischemic saline vs non-ischemic stem cell treated samples. The asterisks indicates a p
value of < 0.05 comparing ischemic stem cell vs. ischemic saline treated mice.
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Chapter 6
Conclusions
Throughout this document I have attempted to walk the reader through the development
and application of a number of emerging imaging strategies designed to aid in the detection
and treatment of peripheral vascular complications. We began with the development of
two non-invasive molecular probes targeted at hypoxia and αV β3—important molecular
components involved in the angiogenic response. To investigate the physiological changes
associated with PAD we employed a sensitive new ultrasound technology that allows us to
detect slow-moving blood. This method is inexpensive, and can be performed using standard
ultrasound machines, which could help doctors diagnose PAD earlier and treat the disease
more effectively. After describing the imaging technologies we will use, our attention then
shifted to developing an appropriate animal model of diabetes-associated PAD. By evaluating
several markers associated with diabetes, we optimized an experimental protocols by which
the manifestation of DM in the animal model resembles that of human DM patients.
To date, a number of agents have shown promise inducing angiogenesis and arteriogenesis
in pre-clinical animal models of PAD, but none have proven successful in human randomized
control trials. One possible reason for this difficulty in translation could revolve around
the type of pre-clinical animal models used, and the functional outcomes being assessed.
Currently available animal models for PAD vary considerably in both the strains of rodents
used, and in the surgical procedures adopted in order to induce limb ischaemia. Moreover,
the ways in which the effectiveness of a given treatment is measured varies from study to
study, ranging from any one of a number of biomarkers (e.g. CD31, or VEGFR), to muscle
function or grip strength tests.
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In order to address these issues, I next pulled our imaging and animal model work
together into an unprecedentedly complete multimodal study of tissue neovascularization
following ischemia. This effort enables us to simultaneously track the dynamics of a number
of molecular and physiological changes as the animals recover from vascular occlusion. The
multimodal approach implemented in our study allows us to observe the immediate effects
of ligation, with perfusion and oxygenation levels dropping substantially just minutes after
the operation. From there, we note that in the deep tissue, the angiogenic response can
take approximately three days or more to be fully elicited, beginning with a rapid rise in
HIF-1α expression followed by a slower rise in αV β3 expression. The effects of angiogenesis,
viv-a-vis blood perfusion, do not manifest until approximately a week after ligation. We also
find that the surface tissue undergoes a very different mode of recovery than does the deep
tissue, beginning to reestablish normal blood perfusion within just two days, likely through
arteriogenesis rather than angiogenesis.
Finally, I begin to move from detection and diagnostics to treatment by developing a stem
cell-based therapy for PAD. I show that mMSCs mitigated several PAD-related complications
by countering the anti-angiogenic effects of DM and inflammation, and enhancing the process
of neovascularization and healing. This marks a milestone in the development of the next
generation of translatable treatment options for people suffering from the disease.
Looking toward the future, much work remains before us. Most of it is translational; our
multimodal imaging platform should be applied to large animals and eventually humans
in order to study PAD in actual patients. Clinical translation should also be the goal for
our stem cell work. While a number of additional experiments are needed to elucidate the
biochemistry, location, and survival of our therapeutic mMSCs, the existing results are very
promising, and I look forward to pursuing the approach in larger animals.
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